



Shenguan Holdings (Group) Limited

(incorporated in the Cayman Islands with limited liability)

Stock Code: 00829



ANNUAL REPORT

2016

CONTENTS

Corporate Information	2
Information for Investors	3
Financial Highlights	4
Chairman's Statement	5
Management Discussion and Analysis	7
Corporate Governance Report	16
Directors and Senior Management	26
Report of the Directors	30
Independent Auditor's Report	43
Audited Financial Statements	
Consolidated:	
Statement of Profit or Loss and Other Comprehensive Income	48
Statement of Financial Position	49
Statement of Changes in Equity	51
Statement of Cash Flows	53
Notes to Financial Statements	55
Five Year Financial Summary	122



CORPORATE INFORMATION

2 |

Executive Directors

Ms. Zhou Yaxian (*Chairman and President*)
Mr. Shi Guicheng
Mr. Ru Xiquan
Mr. Mo Yunxi

Non-executive Director

Dato' Sri Low Jee Keong

Independent Non-executive Directors

Mr. Tsui Yung Kwok
Mr. Meng Qinguo
Mr. Yang Xiaohu

Company Secretary

Mr. Ng Yuk Yeung *FCCA CPA CFA*

Legal Advisers as to Hong Kong Laws

Loong & Yeung
Room 1603, 16/F
China Building
29 Queen's Road Central
Hong Kong

Registered Office

Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman
KY1-1111
Cayman Islands

Hong Kong Office

Unit 2902, Sino Plaza
255-257 Gloucester Road
Causeway Bay
Hong Kong

Mainland Office

29 Fudian Shangchong
Xijiang Fourth Road
Wuzhou, Guangxi
PRC

Principal Bankers

Agricultural Bank of China
Citibank (Hong Kong)
Bank of China
Bank of Communications
China Construction Bank
The Hongkong and Shanghai Banking Corporation

Auditors

Ernst & Young
Certified Public Accountants
22/F CITIC Tower
1 Tim Mei Avenue
Central
Hong Kong

Listing Information

Listing: The Stock Exchange of Hong Kong Limited
Stock code: 829
Ticker Symbol
Reuters: 0829.HK
Bloomberg: 829: HK Equity

Index Constituent

Hang Seng Composite Index
Hang Seng Composite Industry Index – Consumer Goods
Hang Seng Composite SmallCap Index
MSCI AC Far East Ex Japan Small Cap Index

Key Dates

13 October 2009
Listed on Hong Kong Stock Exchange

17 March 2017
Announcement of 2016 Annual Results

17 May 2017 to 22 May 2017
(both days inclusive)
Closure of Register of Members
(for Annual General Meeting)

22 May 2017
Annual General Meeting

26 May 2017 to 1 June 2017
(both days inclusive)
Closure of Register of Members (for Final Dividend)

on or around 14 June 2017
Final Dividend Payment Date

Registrar & Transfer Offices

Principal:
Royal Bank of Canada Trust Company (Cayman) Limited
4th Floor, Royal Bank House
24 Shedden Road, George Town
Grand Cayman KY1-1110
Cayman Islands

Hong Kong Branch:
Tricor Investor Services Limited
Level 22, Hopewell Centre
183 Queen's Road East
Hong Kong

Shares Information

Board lot size: 2,000 shares

Shares issued as at 31 December 2016
3,259,276,000 shares

Market capitalization as at 31 December 2016
HK\$1,922,972,840

Basic earnings per share for 2016
Full year RMB4.7 cents

Dividend per share for 2016
Full year HK3.0 cents

Enquiries Contact

Y. Communications

Email: shenguan@ycom.hk

Website

www.shenguan.com.cn

FINANCIAL HIGHLIGHTS

4 |


Financial and Operating Highlights for the year ended 31 December

(RMB million, except where otherwise stated)	2016	2015	% change
Revenue	980.6	1,054.6	-7.0%
Profit attributable to Owners of the Company	154.2	291.4	-47.1%
Basic Earnings Per Share (RMB cents)	4.7	8.9	-47.2%
Dividend Per Share (HK cents)			
– Final	2.0	3.2	-37.5%
– Special (Final)	1.0	–	N/A
Cash Inflow from Operation	312.0	327.4	-4.7%
Total Assets	3,503.8	3,694.0	-5.1%
Inventory Turnover Day – Raw Materials (days)*	33.7	52.6	-18.9 days
Inventory Turnover Day – FG & WIP (days)*	422.0	495.7	-73.7 days
Trade Receivables Turnover Day (days)*	73.9	66.0	+7.9 days
Trade Payables Turnover Day (days)*	107.3	106.9	+0.4 days

* Calculated based on the average value between the beginning of the year and the end of the year


Turnover

RMB million



Profit attributable to Owners of the Company

RMB million





The Group made a breakthrough in the collagen technologies application and launched new products in October that adopted collagen technology as the core and focused on health industry for the first time. It is the first time ever for Shenguan to launch products other than sausage casings in a large scale over the three decades since its establishment, and is a major step of the Group to achieve product diversification.

Ms. Zhou Yaxian

Chairman of the Board and President of our Company

To all shareholders,

On behalf of the board (the "Board") of directors (the "Directors") of Shenguan Holdings (Group) Limited ("Shenguan Holdings" or the "Company"), I hereby present the audited annual results for the year ended 31 December 2016 (the "Year") of the Company and its subsidiaries (which are collectively referred to as "the Group").

In 2016, the Group made a breakthrough in the collagen technologies application and launched new products in October that adopted collagen technology as the core and focused on health industry for the first time. It is the first time ever for the Group to launch products other than sausage casings in a large scale over the three decades since its establishment, and is a major step of the Group to achieve product diversification. Collagen chips under

its own brand "Meday" and collagen piece facial masks under its own brand "COLL-FULL" were innovative products developed and manufactured by the Group and they were announced in a product launch ceremony at the end of 2016 in Guangzhou. Unlike sausage casing products which are only sold to the food manufacturers, these new products are sold directly to consumers, providing more room for development of the Group.

In respect of the sausage casing business, China's slowing economic growth and continued keen competition in the sausage casing market have led to a decrease in average selling price of collagen sausage casing products, which in turn affected the average selling price of the Group's products. However, the Group still recorded a double-digit growth in sales volume, which not only did it lower the inventories to a more desirable level, but also consolidated the leading position of the Group in the collagen sausage casing market.

During the Year, the Group focused on the mission of “de-stocking, lowering costs and maintaining quality” and enhanced operation efficiency by reducing energy consumption, reducing wastage, raising the level of mechanization, saving labour force and monitoring the credit of the customers closely.

In 2016, the Group's turnover decreased by approximately 7.0% to approximately RMB980.6 million; profit attributable to shareholders decreased by 47.1% to approximately RMB154.2 million. Earnings per share was RMB4.7 cent. The Board recommended the payment of a final dividend of HK2.0 cents per share and a special final dividend of HK1.0 cent per share. The total dividends for the year was approximate to that of the previous years.

Looking forward to 2017, the Group will continue to focus on the development of the core collagen technologies and strengthen development of the Group as the largest enterprise utilizing collagen technology in China.

The collagen sausage casing market will continue to experience consolidation but the downside risk of market price will be lower. The Group will continue to enhance product development and widen product range in order to cater to market demand and drive business growth, thus boosting the sales from collagen sausage casing.

In 2017, the Group will adhere to the mission of “de-stocking, adjusting structure, maintaining stable growth”, and strengthen the development of the Group's management model and the establishment of a marketing system, in order to maintain its competitive advantages. The Group will seek to enhance quality control, promote gradually automated and smart production, raise labor productivity per capita, reduce the costs of energy consumption and take into consideration of the effect of climate and sales seasonality in adjusting the production schedule, in a bid to improve efficiency and lower costs.

The Group will continue to foster its growth in the health industry in the next five to ten years and steadily facilitate the industry chain project development and proactively explore new projects of collagen technologies, as well as expanding to peripheral industries so as to broaden its development.

The Group is still at an early stage of developing new products. The management will spare no efforts but strengthen product research and development, manufacturing, marketing and sales in order to satisfy business development need in 2017. The Group strives to commence mass production and sales of “Meday” collagen chips and “COLL-FULL” collagen piece facial masks, and to strengthen their marketing and sales functions accordingly for a larger market share. We expect the new products will provide new growth impetus to the Group's revenue. We expect revenue from new product sales will account for about 10 per cent of the Group's total revenue and will become the new driver for the revenue growth.

The Group will obtain the province-level production permit of medical devices (class II) and state-level production permit of medical devices (class III) for the collagen medical products of Guangdong Victory as soon as possible, and it will invest more resources into research and development and establishment of sales network for a better sales performance.

The Group believes that the above measures will continue to promote sustainable development of the Group, drive growth of the collagen sausage casing business and further broaden the application of collagen technologies, so as to bring fruitful returns to the Shareholders in the long term.

Ms. Zhou Yaxian
Chairman and President

Hong Kong, 17 March 2017

MANAGEMENT DISCUSSION AND ANALYSIS

Market Review

The Brexit and the change of administration in the United States have brought about changes to the international political landscape in 2016 (the “Year”) which posed an effect on both international business activities and consumers’ confidence. Faced with the complicated domestic and overseas economic environment, China’s domestic economy continued to see downward pressure. During the Year, China’s gross domestic product (GDP) recorded a year-on-year increase of 6.7 per cent, or 0.2 percentage points lower as compared with the year ended 31 December 2015 (the “Prior Year”).

The meat market in China stayed weak. Meat production during the Year has seen negative growth as compared with the Prior Year. According to the National Bureau of Statistics, the output of fresh pork, beef, mutton and poultry decreased by 1.1 per cent year-on-year to 83.64 million tons in 2016, in which pork production was 52.99 million tons, representing a decline of 3.4 per cent.

Despite a steady growth in domestic industrial production, due to the slowing economic growth and the competition was still keen in the market of collagen sausage casing, overseas sausage casing manufacturers continued in growing their sales in China, small-scale domestic collagen sausage casing manufacturers kept selling products at low prices, leading to a decline of average selling price of collagen sausage casing products.

Business Reviews

To deal with the current economic situation and market environment, the Group has focused on the mission of “de-stocking, lowering costs and maintaining quality” during the Year, and proactively studied and established a management model for the Group, vigorously pushed ahead the establishment of a marketing system and tried to reduce finished goods inventories, reduce production costs and further stabilize and enhance collagen sausage casing product applicability. Meanwhile, the Group has embarked collagen-based product diversification. During the new products launch ceremony held in Guangzhou in October 2016, the Group officially launched its consumer products – “Meday” Collagen Chips and “COLL-FULL” Collagen Piece Facial Masks, which were officially available for sales since December 2016.

During the Year, the Group recorded a double-digit growth in the sales volume of collagen sausage casings, but it was insufficient to offset the decrease in price. Consumer products of collagen chips and collagen masks have commenced sales at the end of this Year, however their contributions to revenue are still insignificant. The Group’s revenue for the Year decreased by approximately 7.0% to approximately RMB980.6 million.



新生代
胶原蛋白膜贴面膜
全新之作 美丽膜范



The Group has seen progress in energy savings, wastage reduction, mechanization, labour force savings and strict customer credit monitoring, resulted in a decline in unit operating costs, which partially offset the decrease in average selling price, and successfully kept the Group's operation and financial condition stable.

During the Year, the Group has incurred an impairment loss of approximately RMB24.7 million on the goodwill recognized as a result of the acquisition of the 51% interest in Guangdong Victory Biotech Co., Ltd. ("Guangdong Victory") in the second half of 2015, which became one of the major causes of the decrease in the Group's net profit. Such impairment of goodwill was based on discounted cash flow method of income approach, as stated in the valuation report prepared by an independent valuer. The impairment of goodwill was mainly caused by the fact that the establishment of the sales network of medical-grade collagen raw materials of Guangdong Victory was slower than expected and the production permits of some new products which have already passed clinical trials have not been obtained, which resulted in a downward adjustment and delay in achieving the profit as set out in Guangdong Victory's financial forecast. The aforesaid factors also attributed to the fact that the revenue of Guangdong Victory was below the target of RMB20.0 million for the Year as set out in the original plan.



On the other hand, there was an increase in fair value of the put option related to Guangdong Victory which resulted in a gain of approximately RMB17.7 million recognized in other income and gains.

During the Year, profit attributable to shareholders decreased by 47.1% to RMB154.2 million and earnings per share was RMB4.7 cents. The Broad recommended the payment of a final dividend of HK2.0 cents per share and a special final dividend of HK1.0 cent per share. The total dividends for the Year is maintained at a similar level as that for the Prior Year.

Diversification

The Group have obtained production permit for its collagen chips in the fourth quarter of 2016 and the collagen chips were put into production and sales. The collagen wound dressing products developed by Guangdong Victory has completed the clinical trial in October 2016 and has formally applied for the province-level production permit of medical devices (class II) and is preparing for the application of the state production permit of medical devices (class III). As for Ferguson (Wuhan) Biotech Company Limited ("Ferguson Wuhan"), in which the Group owns 15% equity interests, the company increased efforts in boosting sales of nutrition package business and achieved better results. Sales of Ferguson Wuhan for the Year recorded a double-digit growth year-on-year.

The Group had completed the acquisition of a six-storey property in Singapore on 25 August 2016, which has a gross floor area of approximately 3,400 square meters on each floor. The Group plans to use it for the research and development, production and sale of various new products.

In addition, Wuzhou Zhongguan Testing Technology Services Co., Ltd (“Wuzhou Zhongguan”), a subsidiary of the Group, has commenced to accept external business.

Product Mix

The Group is principally engaged in the manufacture and sale of edible collagen sausage casings, most of which are used for the production of western sausages. Product innovation and diversification by sausage manufacturers continued to create demand for sausage casings of different sizes and fillings.

In order to keep pace with the new trend of the domestic meat product industry, the Group also launched new products that can be applied to more types of sausages fillings to cater for the market. These products are gradually marketed and adopted. At the same time, the Group also made great efforts in enhancing internal management, streamlining production processes and improving efficiency.

After the completion of acquisitions of equity interests in several companies during 2015, the Group has expanded the coverage of its products to the health industry, which include collagen food, collagen skincare products, medical-grade collagen materials and medical products.

Supply of Raw Materials

Cattle’s inner skin is a major raw material for collagen sausage casing production. The supply of cattle’s inner skin remained stable over the past few years and such situation is expected to remain unchanged in the coming years. During the Year, in response to the market situation, the Group used its bargaining power of bulk purchases to successfully reduce the purchase price of raw materials and effectively controlled the production cost, increasing the competitiveness of the Group’s products in the future.

Technological Research & Development

As the largest enterprise utilizing collagen technologies in China, the Group is committed to stepping up the development of collagen technologies, with an aim of establishing a base for the production of safe, reliable and standardized materials required by the health industry. The move will also upgrade and transform the collagen industry and proactively promote the application of collagen in the health industry.

Wuzhou Shenguan, a subsidiary of the Group, was titled as the national-grade “Post-doctoral Research and Development Work Station (博士後科研工作站)” and “Cluster of Collagen Technology Talents in Guangxi (廣西膠原蛋白技術人才小高地)”, for which seven professional talents, including three doctors and four postgraduates, were recruited during the Year to enhance the Group’s technological development and market expansion capabilities.

In respect of the sausage casing business, as at 31 December 2016, the Group had 47 valid patents granted by the State Intellectual Property Office of China, and 7 patents applications accepted by the relevant authorities were pending for approval.

Quality Control

The Group strictly controls each production step to ensure that its products are at the best quality and comply with all safety requirements.

Wuzhou Zhongguan, a subsidiary of the Group, is able to examine over 200 indicators, including physicochemical indicators such as heavy metals and microelements, pesticide residues, microorganisms and proteins. During the Year, Wuzhou Zhongguan has started to independently undertake third party inspection assignments. It could conduct direct inspection service of various food and relevant products in society and issue officially-recognized inspection reports. Such qualification is going to lay solid foundations for the Group’s development into a base of collagen material, thereby promoting the sound development of high-end foods, health care products and medications in the health industry.

The Group’s production of collagen sausage casings has passed the assessment of ISO9001:2008 Quality Management System and the certification of ISO22000:2005 Food Safety Management System, and has obtained the QS Food Production Permit. It has also registered with the Food and Drug Administration in the United States for export of sausage casing products to the United States. In addition, the production of all of the Group’s sausage casing products have strictly complied with China’s national standards (GB14967-94), sausage casing manufacturing industry standards (SB/T10373-2012) and the filed corporate standards (Q/WZSG0001S-2012). All these certifications are the recognition of the Group as a trustworthy product supplier to its customers.

On 23 June 2016, the design, production and sale of Guangdong Victory's medical collagen wound dressing has passed the vetting for its certification by European Union, and obtained the certification of ISO13485: 2003 and EN ISO22442: 2007, with the validity period until 28 February 2019.

Customer Relationship

The Group is committed to developing long-term cooperation relationships based on mutual trust with its business partners and has built a sophisticated customer network. The Group has established its closely-knit yet extensive network of leading manufacturers of processed meat products and sausages, not only for cooperation with enterprises in China, but also with those in various overseas markets, such as South America, Southeast Asia and the United States. During the Year, the Group continued to supply high-quality sausage casing products to a number of renowned food manufacturers in China. The number of domestic customers remained stable.

Financial Analysis

Revenue

Revenue decreased by approximately 7.0% to approximately RMB980.6 million for the Year from approximately RMB1,054.6 million for the Prior Year. Although the sales volume of collagen sausage casing increased by approximately 16.7%, the overall decrease in product price in the industry and the Group's commitment to reduce the inventory level led to the decline in the average selling price.

Cost of sales

Cost of sales increased by approximately 16.8% to approximately RMB687.5 million for the Year from approximately RMB588.7 million for the Prior Year, including provision and write-off of inventory by approximately RMB17.1 million. Had the provision and write-off of inventory excluded, the cost of sales increased by approximately 13.9% to approximately RMB670.4 million for the Year, which was less than the increase in sales volume of 16.7%. The Group has also taken various measures to control production costs per unit.

By taking advantage of the economic downturn of the environment, the Group based on the principle of high quality and low cost to purchase and lowered the cost of

supplies purchase. The costs of raw materials increased by approximately 11.0% to approximately RMB259.2 million. In addition, the Group continued to control energy consumption, as the charges for energy increased by approximately 10.9% to approximately RMB153.5 million. The increase in the both expenses above was lower than that of the sales volume. The direct labor cost increased by 18.0% to approximately RMB132.2 million.

Gross profit

Gross profit decreased by approximately 37.1% to approximately RMB293.1 million for the Year from approximately RMB465.9 million for the Prior Year. The gross profit margin decreased from 44.2% to 29.9% for the Year. Had the provision and write-off of inventory excluded, the gross profit decreased by approximately 33.4% to approximately RMB310.2 million, with a gross profit margin of 31.6%. The decrease in gross profit margin mainly because of the overall decrease in product price in the industry and reduction of the inventory level by the Group which led to the decline in the average selling price, however the cost saving was unable to fully offset the decline.

Other income and gains

Other income and gains increased by approximately 115.7% to approximately RMB88.5 million for the Year from approximately RMB41.0 million for the Prior Year.

In 2012, the Group entered into a land development investment contract (the "Development Contract") with an independent third party. The costs incurred by the Group in connection with the Development Contract comprised mainly the costs incurred in demolition and relocation and land acquisition compensation fees during the period of land development (the "Contract Costs"). Since the land's auction occurred later than expected, the Group had continuous negotiation with such independent third party on withdrawing from the Development Contract. On 2 March 2016, the Group entered into a settlement agreement with such independent third party, pursuant to which, such independent third party agreed to transfer the land development project from the Group back to such independent third party, and refund the Contract Costs together with the accrued return of 10 per cent per annum. The increase of other income and gains was mainly attributed to the return received from the Development Contract of approximately RMB25.6 million.

On the other hand, there was an increase in fair value of the put option related to Guangdong Victory of, which resulted in a gain of RMB17.7 million recognized in other income and gains.

In addition, a foreign exchange gain of approximately RMB14.3 million was recognized in other income for the Year, which was mainly contributed by the revaluation of an intercompany liability within the Group denominated in Renminbi recorded by a subsidiary in Hong Kong which functional currency is Hong Kong Dollar. According to current accounting standards, given the Group's presentation currency is in Renminbi, the corresponding exchange loss arose when the accounts of the subsidiary in Hong Kong translated into Renminbi was recognized in exchange reserves. In aggregate, there was no effect on the total comprehensive income of the Group relating to the exchange difference of the intercompany balance.

Selling and distribution expenses

Selling and distribution expenses increased by approximately 178.8% from approximately RMB11.7 million for the Prior Year to approximately RMB32.5 million for the Year, mainly due to the increase in marketing costs for the promotion of various new products including the "Meday" Collagen Chips and the "COLL-FULL" Collagen Piece Facial Mask, as well as the increase in wages due to the expansion in sales team. Selling and distribution expenses as a percentage of revenue increased to approximately 3.3% for the Year from approximately 1.1% for the Prior Year.

Administrative expenses

Administrative expenses increased by approximately 26.8% from approximately RMB140.4 million for the Prior Year to approximately RMB177.9 million for the Year.

For the technologies acquired by the Group through the acquisition of Guangdong Victory in August 2015, the intangible assets will be amortized over five years. The related amortization expense was approximately RMB50.8 million for the Year. After deducting the minority interest and deferred taxation of Guangdong Victory, the effect of the related amortization expense on the net profit of the Group was approximately RMB19.4 million.

During the Year, the Group has incurred an impairment loss of approximately RMB24.7 million on the goodwill recognized as a result of the acquisition of the 51% interest in Guangdong Victory Biotech Co., Ltd.

("Guangdong Victory") in the second half of 2015. The impairment loss of goodwill was mainly caused by the fact that the establishment of the sales network of medical-grade collagen raw materials of Guangdong Victory was slower than expected and the production permits of some new products which have already passed clinical trials have not been obtained, which resulted in a downward adjustment and delay in achieving the profit as set out in Guangdong Victory's financial forecast.

Both factors above which had a relatively material impact on the net profit for the Year were non-cash items and the cash flow of the Group was not affected.

During 2015, the Group disposed of certain non-efficient production lines and equipment, and demolished and reconstructed an old office building, incurred a loss of approximately RMB23.8 million from the disposal of fixed assets. The loss from disposal of fixed assets was approximately RMB13,000 during the Year.

Finance costs

Finance costs decreased by approximately 10.0% to approximately RMB15.9 million for the Year from approximately RMB17.7 million for the Prior Year.

Income tax expenses

Income tax expenses were approximately RMB21.6 million for the Year, as compared to approximately RMB51.6 million for the Prior Year. The Company's major operating subsidiaries, Wuzhou Shenguan Protein Casing Co., Ltd. ("Wuzhou Shenguan") and Wuzhou Shensheng Collagen Products Co., Ltd. ("Shensheng Collagen") enjoyed a preferential tax treatment because of their location in western China as well as their engagement in industries encouraged by the government policies. The applicable tax rate for Wuzhou Shenguan and Shensheng Collagen was 15%.

The effective tax rates applied to the Group was approximately 15.3% and approximately 13.9% of profit before tax, respectively for the Prior Year and the Year.

Profit attributable to owners of the Company

Due to the aforesaid reasons and adding back the loss attributable to the minority interests of approximately RMB20.5 million, profit attributable to owners of the Company decreased by approximately 47.1% to approximately RMB154.2 million for the Year from approximately RMB291.4 million for the Prior Year.

Liquidity and Capital Resources

Cash and bank borrowings

The Group generally finances its business operations and capital expenditure with internally generated cash flows as well as the bank borrowings provided by its principal banks.

As at 31 December 2016, the cash and cash equivalents together with the pledged deposits amounted to approximately RMB575.0 million, representing an increase of approximately RMB9.5 million from the end of 2015. Among these balances, approximately 96.0% was denominated in Renminbi, and the remaining 4.0% was denominated in Hong Kong dollars, Singapore dollars and U.S. dollars.

As at 31 December 2016, the total bank borrowings of the Group amounted to approximately RMB343.6 million, representing a decrease of approximately RMB201.0 million (as at 31 December 2015: approximately RMB544.5 million), and all the bank borrowings were wholly repayable within one year. Of which, the total bank borrowings denominated in Renminbi were approximately RMB300.0 million, while the total bank borrowings denominated in Hong Kong dollars were HK\$48.7 million (translated to approximately RMB43.6 million).

The Group was in a net cash position (cash and cash equivalents together with pledged deposits less total bank borrowings) of approximately RMB231.4 million as at 31 December 2016, representing an increase of approximately RMB210.5 million as compared to that at the end of 2015. The debt-to-equity ratio was 11.9% as at 31 December 2016 (as at 31 December 2015: 19.0%). The debt-to-equity ratio was calculated by dividing the total bank borrowings by the total equity.

Cash flows

During the Year, the net cash inflow of approximately RMB312.0 million and RMB4.6 million was generated from operating activities and investing activities, respectively, while financing activities utilized approximately RMB309.6 million. The net cash inflow in investment activities was mainly attributable to the cash inflow from the recovery of Contract Costs under the Development Contract and the return generated therefrom, and the cash outflow for the purchase of properties, plants and equipment.

The net cash outflow from financing activities was mainly attributable to the combined effects of the repayment of bank borrowing and the new bank borrowings, the payment of 2015 final dividend and the payment of interest.

Financial assets at fair value through profit or loss

Pursuant to an equity transfer agreement in respect of the acquisition of 51% equity interests in Guangdong Victory entered into between the Group and Enneford Industrial Limited ("Enneford Industrial") on 20 July 2015, the Group was granted with a put option, whereby the Group has the discretion to request Enneford to repurchase the 51% equity interest in Guangdong Victory owned by the Group at a consideration of RMB146,880,000 and the capital contribution made by the Group (if any), if the annual sales revenue of Guangdong Victory fails to reach RMB120,000,000 and fails to obtain the production permits of certain products for the year ending 31 December 2020. The put option is exercisable as at the date immediately after 31 December 2020.

The put option is measured at fair value of RMB18.1 million as at 31 December 2016 estimated by an independent valuer by using the binomial option pricing model. The increase in fair value of the put option of RMB17.7 million was recognized in other income and gains for the Year.

Prepayments, deposits and other receivables

As at 31 December 2016, prepayments, deposits and other receivables decreased by approximately RMB76.2 million as compared to that as at the end of 2015, which was mainly due to the recovery of the Contract Costs in the Development Contract of approximately RMB128.1 million during the Year.

Exposure to exchange risks

The Group mainly operates in Mainland China with most of its transactions settled in Renminbi. The assets and liabilities, and transactions arising from the operations are mainly denominated in Renminbi. Although the Group may be exposed to foreign currency exchange risks, the board of directors of the Company believes that the future currency fluctuations will not have any material impact on the Group's operations. The Group had not adopted formal hedging policies.

Capital expenditure

The capital expenditure of the Group during the Year amounted to approximately RMB144.9 million, which was mainly used for the acquisition of property, plant, and equipment, and the capital commitments as at 31 December 2016 amounted to approximately RMB114.8 million, which were mainly related to the improvement and upgrades of production facilities.

The estimated capital expenditure of the Group for 2017 amounted to approximately RMB140 million, which will be used for the upgrade and intellectualization of production facilities for sausage casing business, as well as expansion of production facilities of the newly-acquired corporations, and the renovation and addition of equipment for the research and development center in Singapore.

Pledge of assets

As at 31 December 2016, pledged bank deposits amounted to approximately RMB456.0 million in total.

Contingent liabilities

As at 31 December 2016 and up to the date of this annual report, the Group was not aware of any material contingent liabilities.

Significant investments, material acquisitions and disposals of subsidiaries, associated companies and joint ventures

The Group had no significant investments, material acquisitions or disposals of subsidiaries, associated companies or joint ventures during the Year.

Acquisition of Guangdong Victory and Revenue Guarantee

Pursuant to an equity transfer agreement in respect of the acquisition of 51% equity interests in Guangdong Victory entered into between the Group and Enneford Industrial on 20 July 2015, Enneford Industrial guaranteed that the audited revenue of Guangdong Victory for the year ended 31 December 2015 would reach RMB20 million (the "Revenue Guarantee") and the consideration for the acquisition of RMB20 million (the "Third Installment Consideration") shall be paid by the Group to Enneford Industrial within 10 business days upon the fulfillment of the Revenue Guarantee. Given that the Revenue Guarantee was not fulfilled, upon further negotiations, the Group and Enneford Industrial agreed that the Third

Installment Consideration shall only be payable by the Group when the accumulated total sales revenue of Guangdong Victory commencing from 1 January 2016 has reached RMB20 million. Up to the date of this annual report, the accumulated total sales revenue of Guangdong Victory commencing from 1 January 2016 has not reached RMB20 million, therefore the Third Installment Consideration has not yet been paid by the Group.

Human resources

As at 31 December 2016, the Group had a total of approximately 3,200 contract employees. During the Year, the total remuneration and employees' benefit expenses charged to profit or loss were approximately RMB174.0 million (2015: approximately RMB145.6 million). In order to attract and retain high quality talents to ensure smooth operation and to cope with the need of the Group's continuing expansion, the Group offers competitive remuneration packages with reference to the market conditions and individual qualifications and experience.

Subsequent Events

On 13 March 2017, Wuzhou Shenguan entered into an equity transfer agreement with Guangxi Shenguan Investment Limited ("Guangxi Shenguan"), pursuant to which Guangxi Shenguan agreed to dispose of and Wuzhou Shenguan agreed to acquire 5% equity interest of Ferguson Wuhan at a consideration of RMB13,380,000. Upon completion of the equity transfer, Ferguson Wuhan will be owned as to 40%, 20%, 20% and 20% by Guangxi Shenguan, Gobitech Limited, Guangxi Guan Yu Zhiye Limited ("Guangxi Guan Yu") and Wuzhou Shenguan, respectively.

On 13 March 2017, Wuzhou Shenguan entered into a capital increase agreement with Guangxi Shenguan, Gobitech Limited and Guangxi Guan Yu, pursuant to which Wuzhou Shenguan agreed to make a capital contribution of RMB17,843,900 to Ferguson Wuhan by cash, of which RMB5,611,300 will be contributed to the registered capital of Ferguson Wuhan and RMB12,232,600 will be contributed to the capital reserve of Ferguson Wuhan.

Upon completion of the capital increase, (i) the registered capital of Ferguson Wuhan will be increased by approximately 6.67% from RMB84,170,000 to RMB89,781,300; and (ii) Ferguson Wuhan will be held as to 37.5%, 18.75%, 18.75% and 25% by Guangxi Shenguan, Gobitech Limited, Guangxi Guan Yu and Wuzhou Shenguan, respectively.

As at 13 March 2017, (i) Guangxi Shenguan is owned as to 95% by Ms. Zhou Yaxian (“Ms. Zhou”); and (ii) Guangxi Guan Yu is owned as to 88%, 3%, 3% and 3% by Ms. Zhou, Mr. Ru Xiquan (“Mr. Ru”), Mr. Shi Guicheng (“Mr. Shi”) and Mr. Mo Yunxi (“Mr. Mo”), respectively. Since Ms. Zhou is an executive Director and a controlling shareholder of the Company, whereas each of Mr. Ru, Mr. Shi and Mr. Mo is an executive Director, each of Guangxi Shenguan and Guangxi Guan Yu is thus a connected person of the Company.

For further details, please refer to the announcement of the Company dated 13 March 2017.

Saved as disclosed above, there was no important events affecting the Group that have occurred since the year ended 31 December 2016.

Major Awards

The Group received various awards in 2016, including “Chairman Quality Award of Guangxi Zhuang Autonomous Region (廣西壯族自治區主席質量獎)”, “ILRA (Industry-Learning-Research-Application) Integrated Enterprise of Guangxi Zhuang Autonomous Region (廣西壯族自治區產學研用一體化企業)”, “Innovative Enterprise for Executing Performance Excellence Model in Guangxi (廣西實施卓越績效模式先進企業)”, “Top 50 Manufacturers of Guangxi (廣西製造企業50強)” and “Top 50 Private Enterprises of Guangxi (廣西民型企業50強)”. In addition, the Group maintained its title of a national-level “High-Tech Enterprise”, and was also titled as the national-grade “Post-doctoral Research and Development Work Station (博士後科研工作站)” and “Cluster of Collagen Technology Talents in Guangxi (廣西膠原蛋白技術人才小高地)”. In respect of the projects, the Group was awarded Third Prize of Guangxi Science and Technology Advancement for the “Development and Application of Heat Pump and Close-cycle Drying Technology to Collagen Casing (膠原蛋白腸衣熱泵及閉式迴圈乾燥技術開發與應用項目)” and Third Prize of Guangxi Science and Technology Advancement for the “Development and Application of Smart Production Information System (智慧製造資訊系統開發與應用項目)”. Besides, the Group received the “Innovative Industrial Product of Guangxi Zhuang Autonomous Region Award (廣西壯族自治區工業新產品獎)” for its thin collagen sausage casings.

Prospects and Strategies

Looking forward to 2017, the World Bank expects that the global economic growth will accelerate, but economic policies will remain uncertain. China’s economy will continue to face downward pressure, but with a more balanced economic structure. The Central Economic Work Conference stated that 2017 is an important year for implementing the Thirteenth Five-Year plan, and a year to strengthen the supply side structural reform, thus the country’s economic policy should follow the general principle of making progress on stable performance, and promote stable, healthy economic development and social harmony.

Recently, the Thirteenth Five-Year Plan promulgated by the government and the relevant departments, which includes the “Thirteenth Five Development Plan on the National Strategic Emerging Industry (「十三五」國家戰略性新興產業發展規劃)” issued by the State Council, the “Thirteenth Five plan on National Science and Technology Innovation (「十三五」國家科技創新規劃)” issued by the State Council, “the Catalogue of Key Products and Services in Strategic Emerging Industries (戰略性新興產業重點產品和服務指導目錄)” issued by The National Development and Reform Commission, and the “Pharmaceutical Industry Development Planning Guide (醫藥工業發展規劃指南)” issued by the Ministry of Industry and Information Technology, have added the collagen biotechnology industry into the list of strategic emerging industries with national support. This provides a favorable opportunity and room for development for the Group’s diversification strategy.

Better livelihood, continuously rising consumption and diversified consumer needs will create new market opportunities. The decline of pork consumption in these two years and the fact that China’s average pork consumption was still below the level of developed countries implies immense growth potential. It is reported that the number of slaughtered pigs in China has been on an upward trend recently, reversing the originally continuing downward trend, and providing a favorable backdrop for the Group’s development. However, labor costs, raw material costs, environmental costs and service costs, etc. will increase, imposing certain pressure on the business operations.

The Group will follow its Thirteenth Five-Year Plan and keep on using its collagen technologies as the core, using its collagen sausage casing business as the foundation, and set collagen-based products such as foods, healthcare products, cosmetic products, medical products and medical materials as the development direction, through automation and knowledge-based measures, to achieve product diversification and explore the health industry and emerging strategic industries, thereby developing Shenguan as a world-class collagen research and development and application base and the largest supplier of collagen raw materials.

For the first half of 2017, the Group will strive to commence the mass production and sale of collagen chips and collagen masks under the brands of “Meday” and “COLL-FULL”, respectively, and further enhance the marketing and sales accordingly for a larger market share. As to Guangdong Victory’s collagen medical products, the Group will obtain province-level production permit of medical devices (class II) and state production permit of medical devices (class III) as soon as possible, and invest more resources into research and development and sales network establishment for a better sales performance.

While adhering to the mission of “de-stocking, adjusting structure, maintaining stable growth” in 2017, the Group will enhance development in setting up the Group’s management model, and sales and marketing system so as to maintain its leading position in the collagen sausage casing market. The Group will also establish a quality control model and introduce stringent quality responsibility system to ensure the quality objectives are achieved. At the same time, the Group will innovate to improve labor productivity per capita, reduce the costs of energy consumption, improve the quality and lower the costs.

In addition, the Group will take into account the effect of climate and sales seasonality in the production management. Based on the evaluation results of the production experience in 2016, the Group will make full use of the abundant production capacity, to formulate annual, monthly and daily production plans. The Group will avoid production during the period with large energy consumption and low production efficiency in summer, and during the higher tariffs period of each day, in order to reduce the energy consumption and improve production efficiency.

The Group will also strengthen its marketing and sales team, especially in the establishment of the marketing team for non-casing new products. The Group will further expand the sales channels of its products, develop sales incentive programme, and enhance customer support, in order to accomplish sales targets.

The Group’s overall operation remained solid, and overall financial status remain sound and healthy. The Group is confident that the above measures will continue to foster its sustainable development, promote the development of collagen sausage casing business, and further widen the application of collagen technology, bringing fruitful return to shareholders in the long term.



CORPORATE GOVERNANCE REPORT

16 |

Corporate Governance Practices

The Company recognises the value and importance of achieving high corporate governance standards to enhance corporate performance, transparency and accountability, earning the confidence of shareholders and the public. The Board strives to adhere to the principles of corporate governance and adopt sound corporate governance practices to meet the legal and commercial standards by focusing on areas such as internal control, adequate disclosure and accountability to all shareholders.

The Company's corporate governance practices are based on the code provisions as set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

Save as disclosed in the section headed "Chairman and Chief Executive" in this Corporate Governance Report, the Board considered that the Company had complied with all the code provisions as set out in the Corporate Governance Code (the "Code") contained in Appendix 14 to the Listing Rules during the Year.

Details of the Company's corporate governance are summarized below.

Board of Directors

Composition

As at the date of this report, the Board comprised eight Directors including four executive Directors, one non-executive Director and three independent non-executive Directors:

Executive Directors:

Ms. Zhou Yaxian (*Chairman and President*)

Mr. Shi Guicheng

Mr. Ru Xiquan

Mr. Mo Yunxi

Non-Executive Director:

Dato' Sri Low Jee Keong

Independent Non-Executive Directors:

Mr. Tsui Yung Kwok

Mr. Meng Qinguo

Mr. Yang Xiaohu

The Board is responsible for the leadership and control of the Company and oversees the Group's businesses, strategic decisions and performance. The management was delegated with the authority and responsibility by the Board for the management and administration of the Group. In addition, the Board has also delegated various responsibilities to the board committees. All Board members have separate and independent access to the Company's management to fulfill their duties, and upon reasonable request, to seek independent professional advice under appropriate circumstances and at the Company's expenses. All Directors also have access to the company secretary who is responsible for ensuring that the Board procedures, and all applicable rules and regulations, are followed. Board meetings are structured so as to encourage open discussion, frank debate and active participation by Directors in meetings. The Company provides the Board with such information and explanations that are necessary to enable Directors to make an informed assessment of the financial and other information put before the Board. Queries raised by Directors are answered fully and promptly. Meeting agenda accompanied by relevant Board/committee papers are distributed to the Directors/committee members with reasonable notice in advance of a Board meeting. Minutes of board meetings and meetings of board committees, which recorded in sufficient detail the matters considered by the Board and decisions reached thereat, including any concerns raised or dissenting views expressed by any Director, are kept by the company secretary and open for inspection by the Directors.

Key information regarding the Directors' academic and professional qualifications and other appointments are set out in the section headed "Directors and Senior Management" of this report.

During the Year, the Board maintained a high level of independence, with one-third of the members of the Board comprised of independent non-executive Directors who had exercised independent judgments. The independent non-executive Directors are expressly identified in all corporate communications whenever the names of the Directors are disclosed. There is no relationship in respect of any financial, business, family or other material relevant aspects among members of the Board, the senior management or substantial or controlling shareholders.

Board Meetings and Attendance

Under code provision A.1.1 of the Code, the Board shall meet regularly and at least four times a year at approximately quarterly intervals. During the Year, the Board held eight meetings and the individual attendance of the Directors at the Board meetings is as follows:

	Attendance/ Meeting held
Ms. Zhou Yaxian (<i>Chairman and President</i>)*	6/8
Mr. Shi Guicheng	8/8
Mr. Ru Xiquan	8/8
Mr. Mo Yunxi	8/8
Dato' Sri Low Jee Keong	8/8
Mr. Tsui Yung Kwok	8/8
Mr. Meng Qinguo	8/8
Mr. Yang Xiaohu	7/8

* *During the Year, there were 2 out of 8 Board meetings relating to transactions of which Ms. Zhou Yaxian had or was deemed to have material interest and thus had abstained from attending and voting at these Board meetings.*

Independent Non-executive Directors

The Company has received from each of the independent non-executive Directors an annual confirmation of independence pursuant to Rule 3.13 of the Listing Rules. The Company considers that all the independent non-executive Directors meet the independence guidelines set out in Rule 3.13 of the Listing Rules and hence are independent to the Company.

Chairman and Chief Executive

Under code provision A.2.1 of the Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual.

Ms. Zhou Yaxian, who acts as the chairman (the "Chairman") and the president of the Company, is also responsible for overseeing the general operations of the Group. The Company has not appointed any chief executive officer and the daily operations of the Group are delegated to other executive Directors, the management and various department heads. The Board will meet regularly to consider major matters affecting the operations of the Group. The Board considers that this structure will not impair the balance of power and authority between the Board and the management of the Company. The roles of the respective executive Directors and senior management, who are in charge of different functions complement the role of the chairman and chief executive. The Board believes that this structure is conducive to strong and consistent leadership which enables the Group to operate efficiently.

The Company understands the importance to comply with code provision A.2.1 of the Code and will continue to consider the feasibility of appointing the chief executive. The Company will make timely announcement if the chief executive has been appointed.

The Chairman takes the lead to ensure that the Board acts in the best interests of the Company, that there is effective communication with the shareholders and that their views are communicated to the Board as a whole. The Chairman meets at least annually with the non-executive Directors without the executive Directors being present.

Appointment, Re-election and Removal of Directors

The Company has established the nomination committee (the "Nomination Committee") on 19 September 2009. The Nomination Committee has from time to time identified individuals suitably qualified to become Board members and make recommendations to the Board. The main consideration in selecting candidates for directorships is whether their characters, qualifications and experiences are appropriate for the businesses of the Group.

Save and except for Mr. Mo Yunxi, each of the executive Directors and non-executive Director has entered into a service contract with the Company for a term of three years commencing from 13 October 2015 and may be terminated by either party by giving not less than three months' prior written notice.

Mr. Mo Yunxi, an executive Director, has entered into a service contract with the Company for a term of three years commencing from 16 May 2015 and may be terminated by either party by giving not less than three months' prior written notice.

Each of the independent non-executive Directors has entered into a service contract with the Company for a term of two years commencing from 13 October 2015 and may be terminated by either party by giving at least three months' written notice.

In accordance with article 84 of the articles of association (the "Articles") of the Company, at each annual general meeting, at least one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting at least once every three years.

Mr. Tsui Yung Kwok, Mr. Meng Qinguo and Mr. Yang Xiaohu will retire from office as Directors at the forthcoming annual general meeting, and being eligible, offer themselves for re-election.

Board Diversity Policy

The Nomination Committee has adopted a board diversity policy (the "Board Diversity Policy") setting out the approach to diversity of members of the Board, which is summarised below:

The Company recognises and embraces the benefits of having a diverse Board to enhance the quality of its performance. The Nomination Committee works to ensure a balance of skills, experience and diversity of perspectives appropriate to the requirements of the Company's business and objectives. All Board appointments will be based on meritocracy, and candidates will be considered against selection criteria based on a range of diversity perspectives, which would include but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and length of service. The ultimate decision will be based on merit and contribution that the selected candidates will bring to the Board.

Model Code Set Out in Appendix 10 to the Listing Rules

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") set out in Appendix 10 to the Listing Rules as its own code of conduct regarding Directors' securities transactions. The Company has also adopted the Model Code for the members of senior management of the Group.

The Company has made specific enquiry of all Directors and all the Directors have confirmed that they have complied with the Model Code during the Year. Moreover, no incident of non-compliance of the Model Code by the senior management was noted by the Company.

Corporate Governance Duties

The Board is responsible for performing the corporate governance duties as set out in code provision D.3.1 of the Code. During the Year, the Board had reviewed and discussed the corporate governance policy of the Group and was satisfied with the effectiveness of the corporate governance policy of the Group.

Induction and Professional Development

All newly appointed Directors received comprehensive, formal training on the first occasion of their appointments to ensure they have a proper understanding of the businesses and development of the Group and that they were fully aware of their responsibilities under statute and common law, the Listing Rules, applicable legal requirements and other regulatory requirements and the business and governance policies of the Company.

To facilitate the Directors to discharge their responsibilities, they have been continuously updated with regulatory developments, business and market changes and the strategic development of the Group.

The Company is committed to arranging and funding suitable training to all Directors for their continuous professional development. Each Director is briefed and updated from time to time to ensure that he/she is fully aware of his/her responsibilities under the Listing Rules and applicable legal and regulatory requirements and the governance policies of the Group. All the Directors also understand the importance of continuous professional development and are committed to participating in any suitable training to develop and refresh their knowledge and skills. All Directors including Ms. Zhou Yaxian, Mr. Shi Guicheng, Mr. Ru Xiquan, Mr. Mo Yunxi, Dato' Sri Low Jee Keong, Mr. Tsui Yung Kwok, Mr. Meng Qinguo and Mr. Yang Xiaohu, have participated in continuous professional development to develop and refresh their knowledge and skills and provided their training records for the Year to the Company.

Supply of and Access to Information

In respect of regular Board meeting, and so far as practicable in all other cases, an agenda accompanied by the relevant Board papers are sent to all Directors in a timely manner and at least 3 days before the intended date of a Board meeting.

All Directors are entitled to have access to Board papers, minutes and related materials.

Audit Committee

The Company established an audit committee (the "Audit Committee") on 19 September 2009 with written terms of reference in compliance with the code provisions of the Code. The primary duties of the Audit Committee are to make recommendation to the Board on the appointment, reappointment and removal of external auditors, review and monitor the external auditors' independence and objectivity and the effectiveness of the audit process in accordance with applicable standards, develop and implement policy on the engagement of external auditors to supply non-audit services, monitor the integrity of financial statements of the Company and the Company's annual report and accounts, half-year report and significant financial reporting judgments contained therein and review of the risk management and internal control systems and the effectiveness of the issuer's internal audit function. The members of the Audit Committee consist of three independent non-executive Directors, namely Mr. Tsui Yung Kwok, Mr. Meng Qinguo and Mr. Yang Xiaohu. Mr. Tsui Yung Kwok who possesses a professional accounting qualification and relevant accounting experience, is the chairman of the Audit Committee. The Audit Committee shall meet at least twice a year.

The terms of reference of the Audit Committee is available on the website of the Stock Exchange and the Company as required by the Code.

During the Year, the Audit Committee had reviewed the final results for the year ended 31 December 2015, the interim results for the six months ended 30 June 2016 of the Group and the Group's internal controls for the year ended 31 December 2015. The Group's final results for the Year had been reviewed by the Audit Committee before submission to the Board for approval. The Audit Committee had also reviewed this annual report, and confirmed that this annual report is complete and accurate, and has complied with the Listing Rules. There is no disagreement between the Directors and the Audit Committee regarding the selection and appointment of the external auditors.

The Audit Committee held two meetings during the Year. Details of the attendance of the Audit Committee meetings are as follows:

	Attendance/ Meeting held
Mr. Tsui Yung Kwok (<i>Chairman</i>)	2/2
Mr. Meng Qinguo	2/2
Mr. Yang Xiaohu	2/2

Auditors' Remuneration

During the Year, the fees incurred for audit and non-audit services provided by the auditors to the Group are set out as follows.

Type of services	Fee paid/payable <i>RMB'000</i>
Non-audit services	533
Audit services	1,998
	2,531

Nomination Committee

The Company established the Nomination Committee pursuant to a resolution of the Directors passed on 19 September 2009. The primary duties of the Nomination Committee are to review the structure, size and composition (including gender, age, cultural and educational background, professional experience, length of service, skills, knowledge and experience) of the Board, identify individuals suitably qualified to become Board member, assess the independence of independent non-executive Directors and review the Board Diversity Policy and the progress on achieving the objectives set for implementing such policy. A summary of the Board Diversity Policy is set out in the section headed "Board Diversity Policy" in this Corporate Governance Report. The Nomination Committee consists of Ms. Zhou Yaxian, an executive Director and two independent non-executive Directors, namely Mr. Meng Qinguo and Mr. Yang Xiaohu. Ms. Zhou Yaxian is the chairman of the Nomination Committee.

The Nomination Committee shall meet at least once every year for reviewing the structure, size and composition (including the skills, knowledge and experience) of the Board, assessing the independence of the independent non-executive Directors, reviewing the Company's Board Diversity Policy and the progress on achieving the objectives set for implementing such policy, and other related matters.

The terms of reference of the Nomination Committee is available on the website of the Stock Exchange and the Company as required by the Code.

The Nomination Committee held one meeting during the Year. Details of the attendance of the Nomination Committee meetings are as follows:

	Attendance/ Meeting held
Ms. Zhou Yaxian (<i>Chairman</i>)	1/1
Mr. Meng Qinguo	1/1
Mr. Yang Xiaohu	1/1

At the meeting, the Nomination Committee had reviewed the structure, size and composition of the Board, assessing the independence of independent non-executive Directors, reviewed the Board Diversity Policy and other related matters of the Company.

Remuneration Committee

The Company established a remuneration committee (the "Remuneration Committee") pursuant to a resolution of the Directors passed on 19 September 2009 in compliance with the code provisions of the Code. The primary duties of the Remuneration Committee are to consult the chairman of the Board about their remuneration proposals for other executive Directors, make recommendation to the Board on the Company's remuneration policy and structure for all Directors' and senior management and make recommendation to the Board on the remuneration packages of individual Directors' and senior management. The Remuneration Committee comprises Ms. Zhou Yaxian, an executive Director and two independent non-executive Directors, namely Mr. Meng Qinguo and Mr. Yang Xiaohu. Mr. Meng Qinguo is the chairman of the Remuneration Committee.

The Remuneration Committee shall meet at least once every year to discuss the remuneration packages and related matters in relation to the Directors and the senior management. No Director is allowed to be involved in deciding his/her own remuneration.

The terms of reference of the Remuneration Committee is available on the website of the Stock Exchange and the Company as required by the Code.

The Remuneration Committee held one meeting during the Year. Details of the attendance of the Remuneration Committee meeting are as follows:

	Attendance/ Meeting held
Mr. Meng Qinguo (<i>Chairman</i>)	1/1
Ms. Zhou Yaxian	1/1
Mr. Yang Xiaohu	1/1

At the meeting, the Remuneration Committee had reviewed and made recommendations to the Board on the remuneration policies of the Directors and the senior management as well as the remuneration packages for the years of 2015 and 2016 and the performance of the Directors.

Remuneration of Directors and Senior Management

The Group has paid or accrued the amounts of approximately RMB4,068,000, RMB1,673,000, RMB1,673,000, RMB1,673,000, RMB68,000, RMB188,000, RMB188,000 and RMB188,000 to Ms. Zhou Yaxian, Mr. Shi Guicheng, Mr. Ru Xiquan, Mr. Mo Yunxi, Dato' Sri Low Jee Keong, Mr. Tsui Yung Kwok, Mr. Meng Qinguo and Mr. Yang Xiaohu respectively, as Directors' remuneration, for the Year.

Directors' remuneration is determined based on a variety of factors such as market conditions and responsibilities assumed by each Director. As at 31 December 2016, there was no arrangement in which the Directors waived their remuneration.

Senior management's remuneration payment of the Group in the Year falls within the following bands:

	Number of Individuals
HK\$1,000,001 to HK\$1,500,000	1
HK\$1,500,001 to HK\$2,000,000	2

Directors' and Auditors' Responsibility for the Financial Statements

All Directors acknowledge their responsibility for preparing the accounts and the financial statements for the Year. The auditors to the Company acknowledge their reporting responsibilities in the auditors' report on the financial statements for the Year. The Directors are not aware of any material uncertainties relating to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern, therefore the Directors continue to adopt the going concern approach in preparing the financial statements.

Financial Controller

The financial controller of the Company (the “Financial Controller”) is responsible for preparing interim and annual financial statements based on accounting principles generally accepted in Hong Kong and ensures that the financial statements truly reflect the Group’s results and financial position and are in compliance with the Companies Ordinance (Chapter 622, Laws of Hong Kong), the Listing Rules and other relevant laws and regulations. The Financial Controller reports directly to the Chairman of the Audit Committee and co-ordinates with external auditors on a regular basis. In addition, the Financial Controller will review the control of financial risks of the Group and provide advices thereon to the Board.

Company Secretary

Mr. Ng Yuk Yeung has been appointed as the company secretary of the Company (the “Company Secretary”) with effect from 19 September 2009. The Company Secretary reports directly to the Board. All the Directors have easy access to the Company Secretary and responsibility of the Company Secretary is to ensure the board meetings are properly held and are in compliance with the relevant laws and regulations. The Company Secretary is also responsible for giving advices with respect to the Directors’ obligations on securities interest disclosure, disclosure requirements of notifiable transactions, connected transactions and inside information.

The Company Secretary shall provide advices to the Board with respect to strict compliance with the laws, requirements and the Articles at appropriate times. As the Company’s principal channel of communication with the Stock Exchange, the Company Secretary assists the Board in implementing and strengthening the Company’s corporate governance code so as to bring the best long term value to shareholders. In addition, the Company Secretary also provides relevant information updates and continuous professional development to the Directors with respect to legal, supervisory and other continuous obligations for being a director of a listed company at appropriate times. The Company Secretary is also responsible for fostering and managing the Group’s investors relationship. The Company Secretary has complied with Rule 3.29 of the Listing Rules in relation to the professional training requirements.

Risk Management and Internal Control

The Group’s risk management and internal control systems provide a clear governance structure, policies and procedures, as well as reporting mechanism to facilitate the Group to manage its risks across business operations effectively.

The Group has established a risk management framework, which consists of the Board of Directors, the Audit Committee and the Risk Management Taskforce. The Board of Directors determines the nature and extent of risks that shall be taken in achieving the Group’s strategic objectives, and has the overall responsibility for monitoring the design, implementation and the overall effectiveness of risk management and internal control systems.

The Group has formulated and adopted Risk Management Policy in providing direction in identifying, evaluating and managing significant risks. At least on an annual basis, the Risk Management Taskforce identifies risks that would adversely affect the achievement of the Group’s objectives, and assesses and prioritizes the identified risks according to a set of standard criteria. Risk mitigation plans and risk owners are then established and assigned for those risks considered to be significant.

In addition, the Group has engaged an independent professional advisor to provide internal audit services, which assist the Board of Directors and the Audit Committee in ongoing monitoring of the risk management and internal control systems of the Group. Deficiencies in the design and implementation of internal controls are identified and recommendations are proposed for improvement. Significant internal control deficiencies are reported to the Audit Committee and the Board of Directors on a timely basis to ensure prompt remediation actions are taken.

Risk management report and internal control report are submitted to the Audit Committee and the Board of Directors at least once a year. The Board of Directors had performed annual review on the effectiveness of the Group's risk management and internal control systems, including but not limited to the Group's ability to cope with its business transformation and changing external environment; the scope and quality of management's review on risk management and internal control systems; result of internal audit work; the extent and frequency of communication with the Board of Directors in relation to result of risk and internal control review; significant failures or weaknesses identified and their related implications; and status of compliance with the Listing Rules. The Board of Directors considers the Group's risk management and internal control systems are effective and adequate.

The risk management and internal control systems are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable and not absolute assurance against material misstatement or loss.

Procedures and internal controls for the handling and dissemination of inside information

The Group complies with requirements of Securities & Futures Ordinance ("SFO") and the Listing Rules. The Group discloses inside information to the public as soon as reasonably practicable unless the information falls within any of the safe harbours as provided in the SFO. Before the information is fully disclosed to the public, the Group ensures the information is kept strictly confidential. If the Group believes that the necessary degree of confidentiality cannot be maintained or that confidentiality may have been breached, the Group would immediately disclose the information to the public. The Group is committed to ensure that information contained in announcements are not false or misleading as to a material fact, or false or misleading through the omission of a material fact in view of presenting information in a clear and balanced way, which requires equal disclosure of both positive and negative facts.

Investor Relations

The Company places great emphasis on its relationship and communication with investors. The Company has numerous communication channels such as seminars with the media, analysts and fund managers. Designated senior management holds regular dialogue with institutional investors and analysts which enables them to keep abreast of the Group's latest developments. In addition, the Group's website presents the most updated information and the status of the business development of the Group.

General Meetings with Shareholders

The 2016 annual general meeting ("2016 AGM") was held on 25 May 2016. The attendance record of the Directors at the 2016 AGM is as follows:

	Attendance/ General Meeting held
Ms. Zhou Yaxian (<i>Chairman and President</i>)	1/1
Mr. Shi Guicheng	1/1
Mr. Ru Xiquan	1/1
Mr. Mo Yunxi	1/1
Dato' Sri Low Jee Keong	1/1
Mr. Tsui Yung Kwok	1/1
Mr. Meng Qinguo	1/1
Mr. Yang Xiaohu	1/1

The Company's external auditors also attended the 2016 AGM.

Communication with Shareholders

The Company and the senior management recognise the responsibility to maintain an on-going dialogue with its shareholders and in particular, through annual general meetings or other general meetings to communicate with the shareholders and encourage their participation.

The forthcoming annual general meeting of the Company will be held on 22 May 2017.

The Company will continue to maintain an open and effective investor communication policy and to update investors on relevant information on the Group's business in a timely manner, subject to relevant regulatory requirement.

The Board and senior management also recognise the responsibility of safeguarding the interest of shareholders of the Company. The Company reports its financial and operating performance to shareholders through annual reports and interim reports. Shareholders of the Company can also obtain information of the Group in time through annual reports, interim reports, announcements, circulars, press releases and the Company's website (<http://www.shenguan.com.cn>).

Procedures for Directing Shareholders' Enquiries to the Board

Shareholders may at any time send their enquiries and concerns to the Board in writing to the following address of the Hong Kong Office of the Company:

Shenguan Holdings (Group) Limited
Unit 2902, Sino Plaza
255-257 Gloucester Road
Causeway Bay
Hong Kong
Attention: Mr. Ng Yuk Yeung

Procedures for Convening an Extraordinary General Meeting and Putting Forward Proposals at General Meetings by Shareholders

Pursuant to article 58 of the Articles, extraordinary general meetings shall be convened on the requisition of one or more shareholders of the Company holding, at the date of deposit of the requisition, not less than one tenth of the paid up capital of the Company having the right of voting at general meetings. Such requisition shall be made in writing to the Board or the Company Secretary for the purpose of requiring an extraordinary general meeting to be called by the Board for the transactions of any business specified in such requisition. If within 21 days of such deposit, the Board fails to proceed to convene such meeting, the requisition(s) may do so in the same manner.

Pursuant to article 85 of the Articles, no person (other than a retiring Director) shall be eligible for election to the office of Director at any general meeting unless a notice in writing of the intention to propose that person for election as a Director and notice in writing by that person of his willingness to be elected shall have been lodged at the Head Office or at the Registration Office no earlier than the day after the dispatch of the notice of the general meeting appointed for such election and end no later than 7 days prior to the date of such general meeting and the minimum length of the period during which such notices to the Company may be given will be at least 7 days.

The procedures for shareholders of the Company to propose a person for election as a Director is posted on the website of the Company. Shareholders may also contact the Company through the details as mentioned in the section headed "Procedures for Directing Shareholders' Enquiries to the Board" above for procedures for putting forward proposals at general meetings.

Constitutional Documents

There has been no material changes in the Company's constitutional documents during the Year.

DIRECTORS AND SENIOR MANAGEMENT

26 |



Ms. Zhou Yaxian

Chairman of the Board and
President of our Company



Aged 58, Ms. Zhou is a founder of the Group and a director of all the subsidiaries of the Company. She is primarily responsible for the Group's overall strategic planning, technology and business management. Ms. Zhou has nearly 37 years of experience in the collagen sausage casing industry. Before founding the Group, she had been involved in the trial production of collagen sausage casings in the Meat Products Factory of Wuzhou Food Products Corporation (梧州市食品總公司肉類制品廠) from 1979 to 1989 and was employed by Wuzhou Protein Casing Factory (梧州市蛋白腸衣廠) ("Wuzhou Protein Factory") in 1989, mainly responsible for technology development. She was appointed as the head of Wuzhou Protein Factory and the Deputy General Manager of Guangxi Wuzhou Zhongheng Group Co., Ltd. (廣西梧州中恒集團股份有限公司) in 1992 and 1997, respectively. Since 2004, Ms. Zhou has been the chairman of the board of directors and the general manager of Wuzhou Shenguan Protein Casing Co., Ltd. (梧州神冠蛋白腸衣有限公司) ("Wuzhou Shenguan").

Ms. Zhou completed the course of Economic Management held by The Central Party School (中共中央黨校) in December 2001. She was a member of the 10th National People's Congress from February 2003 to February 2008 and is a senior engineer in biotechnology. She is one of the inventors of four national patents in respect of production method and facilities for collagen sausage casings and has received special allowances granted by the State Council since 2008. Ms. Zhou was awarded the "The Third Class Prize in National Science

and Technology Advancement Award" (國家科學技術進步三等獎) by the National Science and Technology Committee of the PRC (中華人民共和國國家科學技術委員會) in 1995, the "Guangxi Outstanding Expert" (廣西優秀專家) by the Wuzhou Government in 2006, the "Influential Person in China Meat Industry" (中國肉類行業影響力人物) by the China Meat Association (中國肉類協會) in 2007, the "2007 Guangxi Outstanding Entrepreneur" (2007年度廣西優秀企業家) jointly by the Guangxi Enterprises Union (廣西企業聯合會) and the Guangxi Entrepreneurs Association (廣西企業家協會) in 2008, the "China Outstanding Female Entrepreneur" (中國傑出創業女性) by the China Female Entrepreneurs Association (中國女企業家協會) in 2008, the "Binshan Cup Technological Innovative Figure in China Meat Industry" (冰山杯—中國肉類產業科技創新人物) in 2009, the "Technological Leaders in China Meat Industry" (中國肉類產業科技領軍人物) by the China Meat Association (中國肉類協會) in 2012, and the "Influential Entrepreneur of China Meat Product Industry" (中國肉類食品行業影響力企業家) by the China Meat Association (中國肉類協會) in 2013. She was appointed as a Director on 24 February 2009 and redesignated as an executive Director, and appointed as the Chairman of the Board on 19 September 2009.

Ms. Zhou is also a director of Shenguan Biology Science & Technology Investment Company Limited ("Hong Kong Shenguan"), Glories Site Limited ("Glories Site"), Xian Sheng Limited ("Xian Sheng") and Rich Top Future Limited ("Rich Top Future"), all are companies having an interest in the shares of the Company.



Mr. Shi Guicheng
Vice President and
Executive Director

Aged 54, Mr. Shi's official Chinese name is 施貴成, he has previously used another Chinese name 施桂成. He is primarily responsible for the Group's machinery and equipment management. He is a mechanical engineer and has nearly 24 years of experience in the collagen sausage casing industry. Mr. Shi graduated from Guangxi Central Radio and TV University (廣西廣播電視大學) and attained the Professional Qualification Graduation Certificate in Mechanical Production in July 1987. Mr. Shi joined Wuzhou Protein Factory as the Head of Technology in 1993. He was appointed as the Deputy Head of Wuzhou Protein Factory in 2001 and has been the Deputy General Manager of Wuzhou Shenguan since 2004, responsible for machinery and equipment management, production safety and environmental protection. He was appointed as a Director on 19 September 2009.



Mr. Ru Xiquan
Vice President and
Executive Director

Aged 55, Mr. Ru is primarily responsible for matters relating to the Group's accounting, treasury and financial planning. He has nearly 26 years of experience in the collagen sausage casing industry. Mr. Ru graduated from Guangxi Central Radio and TV University (廣西廣播電視大學) and attained the Professional Qualification Graduation Certificate in Finance and Accounting in July 1989. He obtained the certificate of accounting professional issued by the Wuzhou Finance Bureau in November 2001. He also completed the course of Economic Management held by The Central Party School (中共中央黨校) in 2002. Mr. Ru is an accountant and joined Wuzhou Protein Factory as the Head of the Finance and Accounting Department in 1990. He has been the Chief Accountant of Wuzhou Shenguan since 2004, responsible for matters relating to accounting and finance. He was appointed as a Director on 19 September 2009.



Mr. Mo Yunxi
Vice President and
Executive Director

Aged 49, Mr. Mo is primarily responsible for the Group's product and technology developments. He has long been engaged in product development and has nearly 24 years of experience in the collagen sausage casing industry. Mr. Mo graduated from Tianjin College of Commerce (天津商學院), majoring in Food Engineering in July 1990. Mr. Mo joined Wuzhou Protein Factory in 1993 and he has been the Deputy General Manager of Wuzhou Shenguan since 2004. Mr. Mo is a senior engineer in food engineering. He was awarded the "First Prize in Wuzhou Science and Technology Advancement" (梧州市科學技術進步一等獎) and the "First Prize in Guangxi Outstanding Achievement on New Products" (廣西新產品優秀成果一等獎) by the Wuzhou Government and The People's Government of Guangxi, respectively, in 2008. He was appointed as a Director on 16 May 2012.

Non-executive Director

Dato' Sri Low Jee Keong

Aged 52, Dato' Sri Low's Chinese name 劉子強 is an unofficial name. He is primarily responsible for the Group's export business. Dato' Sri Low has nearly 24 years of experience in the collagen sausage casing industry. Before founding the Group, Dato' Sri Low, through LJK Frozen SDN. BHD. ("LJK") (formerly known as Exceltech Enterprise SDN. BHD.), started his business relationship with Wuzhou Protein Factory for the resale of edible collagen sausage casing products in Malaysia in 1993, and has maintained the relationship with Wuzhou Shenguan after the acquisition of the entire ownership rights of Wuzhou Protein Factory by Wuzhou Shenguan in November 2004. Dato' Sri Low is a founder of the Group and has been a director of Wuzhou Shenguan since 2004. Dato' Sri Low has not been involved in the Group's day-to-day operations as he resides in Malaysia. However, he has participated, and will continue to participate, in the strategic planning and decision-making processes in the business operations. He is also a director of Full Win Consultants Limited and Excel Gather Limited, both are subsidiaries of the Company. Dato' Sri Low was awarded a Datukship by Pahang State Government of Malaysia on 24 October 2012. He was appointed as a Director on 19 September 2009. Dato' Sri Low is a director of Rich Top Future which has an interest in the share of the Company.

Independent Non-executive Directors

Mr. Tsui Yung Kwok

Aged 49, Mr. Tsui was awarded a bachelor's degree in Business (Accounting) by Curtin University of Technology, Australia in August 1992 and a master degree in Corporate Governance by The Hong Kong Polytechnic University in December 2007. Mr. Tsui has nearly 23 years of experience in accounting and finance. He held a senior position in an international accounting firm in Hong Kong from 1994 to 2003 and was the Chief Financial Officer of SMI Culture Group Holdings Limited (formerly known as Qin Jia Yuan Media Services Company Limited) (Hong Kong Stock Code: 02366), the shares of which are listed on the Stock Exchange, from 2003-2004. Mr. Tsui has been the Chief Financial Officer and the Company Secretary of Ju Teng International Holdings Limited (Hong Kong Stock Code: 03336), the shares of which are listed on the Stock Exchange, since 2004. Mr. Tsui became an executive director of Ju Teng International Holdings Limited in June 2005. Mr. Tsui has also served as an independent non-executive director of SITC International Holdings Company Limited (Hong Kong Stock Code: 01308), 361 Degrees International Limited (Hong Kong Stock Code: 01361) and Cabbeen Fashion Limited (Hong Kong Stock Code: 02030) since September 2010, September 2012 and February 2013, respectively, the shares of which are all listed on the Stock Exchange. Mr. Tsui is a member of the Institute of Chartered Accountants in Australia, CPA Australia, the Hong Kong Institute of Certified Public Accountants and the Hong Kong Institute of Chartered Secretaries. He was appointed as a Director on 19 September 2009.

Mr. Meng Qinguo

Aged 60, Mr. Meng was awarded a master degree and a doctorate degree in Law by Wuhan University (武漢大學) in July 1985 and July 2001, respectively. He had been a Senior Visiting Scholar at the University of California, Berkeley, member of the Supervisory Division of Higher Education Institutions Legal Education of Ministry of Education of China (教育部高等學校法學學科教學指導委員會委員), director of China Law Society (中國法學會), the Vice-Chairperson of the Consumer Protection Law Research Centre of China Law Society (中國法學會消費者權益保護法研究會), standing director of China Civil Law Society (中國法學會民法學會), and the Vice-Chairperson of Guangxi Law Society (廣西法學會). Mr. Meng is currently a tutor to Ph.D students in civil and commercial law at Wuhan University (武漢大學) and has received special allowances granted by the State Council.

Mr. Meng was an independent director of Sealand Securities Co., Ltd. (國海證券股份有限公司) until December 2014, and he had been appointed as special legal consultant since January 2015, the shares of which are listed on the Shenzhen Stock Exchange. Mr. Meng was appointed as a Director on 19 September 2009.

Mr. Yang Xiaohu

Aged 43, Mr. Yang graduated from Peking University, majoring in Economics and minoring in Law in July 1997. Mr. Yang has nearly 18 years of experience in the financial industry. He joined Everbright Securities Company Limited (光大證券股份有限公司), focusing on investment banking in 1998 and is currently the General Manager of the Investment Banking Division of the Shenzhen Second Branch of Everbright Securities Company Limited. He was appointed as a Director on 19 September 2009.

Senior Management



Ms. Cai Yueqing
Vice President

Aged 62, Ms. Cai is primarily responsible for the Group's production management. She has nearly 24 years of experience in the collagen sausage casing industry. Ms. Cai graduated from Wuzhou Branch of Guangxi University (廣西大學梧州分校) and attained the Professional Qualification Certificate in Quality Management in January 1998. Ms. Cai joined Wuzhou Protein Factory as the Supervisor of the Quality Control Office in 1992. She was appointed as the Deputy Head of Wuzhou Protein Factory in 1994 and has been the Deputy General Manager of Wuzhou Shenguan since 2004, responsible for production management and quality control. She was appointed as a Director on 19 September 2009 and retired on 1 June 2014. After her retirement, she has remained as a vice president of the Company.



Mr. Wen Jinpei
Vice President

Aged 56, Mr. Wen is primarily responsible for the Group's human resources, logistics, tendering of projects, marketing and development plans. Mr. Wen graduated with a bachelor's degree in Engineering from Guangdong Ocean University in July 1982 and was named Senior Engineer in technological engineering in 1996. He was responsible for plan control, economy management, state-owned and collective assets management as well as technology management. Mr. Wen was the Deputy Officer of Wuzhou Planning Committee (梧州市計劃委員會), Deputy Officer of Wuzhou City Collective Industry Association (梧州市城鎮集體工業聯社), Deputy Chief of Wuzhou Medicinal Chemistry Bureau (梧州市醫藥化學工業局), Deputy Officer of Wuzhou Economic and Commerce Committee (梧州市經濟貿易委員會), Deputy Officer of Wuzhou People's Government Asset Management Committee (梧州市人民政府國有資產監督管理委員會) and Deputy Chief of Wuzhou Technology Bureau (梧州市科學技術局) from 1995 to 2010. He has been the Vice President of Wuzhou Shenguan since October 2010.



Mr. Ng Yuk Yeung
Financial Controller

Aged 44, Mr. Ng joined the Company in February 2009 and is responsible for supervising the financial reporting, corporate finance and investors relationship. Mr. Ng has nearly 21 years of experience in auditing and financial management, which was mostly gained from positions in one of the international firms of certified public accountants from 1996 to 1999 and from 2001 to 2002, and in China Resources Enterprise Limited (Hong Kong Stock Code: 00291), the shares of which are listed on the Stock Exchange, from 2002 to 2007. Mr. Ng attained his bachelor's degree in Computer Science from the University of Hong Kong in November 1995 and is a fellow member of the Association of Chartered Certified Accountants, a member of the Hong Kong Institute of Certified Public Accountants and a CFA Charter holder. Mr. Ng is also the Company Secretary.

REPORT OF THE DIRECTORS

30 |

The Directors present their report and the audited financial statements for the Year.

Principal Activities

The principal activity of the Company is investment holding. Details of the principal activities of the Group's major subsidiaries are set out in note 1 to the financial statements. The Group is principally engaged in the manufacture and sale of edible collagen sausage casing products, pharmaceutical products, food products, skin care and health care products and bioactive collagen products.

Business Review

Further discussion and analysis of the activities of the Group for the Year and an indication of likely future developments in the Group's business, can be found in the section headed "Management Discussion and Analysis" as set out on pages 7 to 15 of this annual report. These discussions form part of this directors' report.

Principal Risks and Uncertainties

A number of factors may affect the results and business operations of the Group, some of which are inherent to the industry and some are from external sources. Major risks are summarized below.

The Group's business depends on a stable and adequate supply of raw materials, which is subject to price volatility and other risks

The production volume and production costs of the Group are dependent on the Group's ability to source at acceptable prices and maintain a stable and sufficient supply of raw materials such as cattle's inner skins and packaging materials. If the Group is unable to obtain raw materials in the quantities and of a quality that the Group requires, the volume or quality of the production and the revenue of the Group may be adversely affected.

The Group may face competition from international competitors or competition from other substitutes for edible collagen sausage casing products which may affect the profits of the Group

Overseas competitors may take measures such as establishing production lines in the PRC or reducing price of their products to gain entry into the PRC market. This may cause the Group to experience downward pressure on the price and profit margins.

The Group may also face competition from other substitute products for edible collagen sausage casing products such as natural sausage casing. If the customers prefer any of the substitutes for edible collagen sausage casing products over the products of the Group, the business and profitability of the Group may be adversely affected.

Any substantial changes in the domestic demand of the Group's products in the PRC may adversely affect the performance and profitability of the Group

Sales in the PRC represent a significant proportion of the total revenue of the Group. Accordingly, the operating results and financial position of the Group are largely subject to the economic, political, social and legal developments in the PRC as well as changes in the domestic demand for the Group's products in the PRC. There is no assurance that such changes in the PRC will not adversely affect the performance and profitability of the Group.

Environmental Policies, Performance and Compliance with Laws and Regulations

The Group is committed to promoting clean production, enhancing the resources utilization, and strives to ensure that its business operations have minimal impact on the environment through recycling and conserving energy.

The Group and its activities are subject to requirements under various laws. The laws and regulations which have a significant impact on the Group include, among others, The Food Safety Law of the PRC (《中華人民共和國食品安全法》), The Regulations on the Implementation of the Food Safety Law of the PRC (《中華人民共和國食品安全法實施條例》), The Standardization Law of the PRC (《中華人民共和國標準化法》), The Provisional Detailed Rules for Administration and Supervision of the Quality and Safety in Food Production and Processing Enterprises (《食品生產加工企業質量安全監督管理實施細則(試行)》), The Law of Product Quality of the PRC (《中華人民共和國產品質量法》), Environment Protection Law of PRC (《中華人民共和國環境保護法》), Energy Conservation Law of the PRC (《中華人民共和國節約能源法》), The Metrology Law of People's Republic of China (《中華人民共和國計量法》) and The Regulation of the People's Republic of China on the Administration of Production License for Industrial Products (《中華人民共和國工業生產授權管理條例》). The Group is committed to maintaining legal compliance in business operations and has put in place in-house rules and work procedures to ensure that the Group's operation is in compliance with applicable laws and regulations in material respects.

Key Relationships with Employees, Customers and Suppliers

The Directors consider that human resources are essential to the business success and the development of the Group in the long run. The Group ensures that the remuneration of staff is commensurate with market level and on-the-job training and development are provided to staff members. The Directors also recognize that customers and suppliers are the keys to the sustainable development of the Group. The Group is committed to building a close and caring relationship with its suppliers and customers and has ongoing communication with the customers and suppliers through various channels to obtain their feedback and suggestions.

Results and Dividends

The Group's profit for the Year and the Group's financial position at that date are set out in the financial statements on pages 48 to 121 of this annual report.

The Directors recommended the payment of a final dividend of HK2.0 cents per ordinary share and a special final dividend of HK1.0 cent per ordinary share for the Year to shareholders whose names appear on the register of members of the Company on 1 June 2017 (Thursday) out of the share premium account of the Company. Subject to the approval of the shareholders at the forthcoming annual general meeting, it is expected that the final dividend and the special final dividend will be paid on or around 14 June 2017 (Wednesday).

Closure of Register of Members

For the purposes of determining the shareholders' eligibility to attend and vote at the forthcoming annual general meeting to be held on 22 May 2017 (Monday), the register of members of the Company will be closed from 17 May 2017 (Wednesday) to 22 May 2017 (Monday), both days inclusive. The latest time to lodge transfer documents for registration will be at 4:30 p.m. on 16 May 2017 (Tuesday). For determining entitlement to the final dividend and the special final dividend (if approved at the forthcoming annual general meeting), the register of members of the Company will be closed from 26 May 2017 (Friday) to 1 June 2017 (Thursday), both days inclusive. The record date will be 1 June 2017 (Thursday). The latest time to lodge transfer documents for registration will be at 4:30 p.m. on 25 May 2017 (Thursday). During the above closure periods, no transfer of shares will be registered. To be eligible to attend and vote at the forthcoming annual general meeting, and to qualify for the final and the special final dividends (if approved at the forthcoming annual general meeting), all transfer of shares accompanied by the relevant share certificates must be lodged with the Company's Hong Kong branch share registrar, Tricor Investor Services Limited, at Level 22, Hopewell Centre, 183 Queen's Road East, Hong Kong no later than the dates and times stated above respectively.

Summary Financial Information

A summary of the published results and assets, liabilities and non-controlling interests of the Group for the last five financial years, as extracted from the audited financial statements, is set out on page 122 of this annual report. This summary does not form part of the audited financial statements.

Share Capital and Share Options

Details of movements in the Company's authorised or issued share capital are set out in note 28 to the financial statements. There is no share option outstanding, granted, cancelled and lapsed under the share option scheme of the Company during the Year.

Pre-emptive Rights

There are no provisions for pre-emptive rights under the Articles or the laws of the Cayman Islands, the jurisdiction in which the Company was incorporated, which would oblige the Company to offer new shares on a pro rata basis to existing shareholders.

Purchase, Redemption or Sale of Listed Securities of the Company

During the Year, the Company purchased certain of its shares on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and these shares were subsequently cancelled by the Company. The summary details of the share repurchase during the Year are as follows:

Month	Number of shares repurchased	Number of shares cancelled	Price per share		Total price paid HK\$
			Highest HK\$	Lowest HK\$	
January 2016	2,000,000	2,000,000	0.97	0.93	1,917,200

7,000,000 shares repurchased during November and December 2015 and 2,000,000 shares repurchased in January 2016 were cancelled on 27 January 2016.

The purchase of the Company's shares during the Year was effected by the Directors, pursuant to the general mandate granted by the shareholders at the annual general meeting of the Company held in 2015, with a view to benefiting shareholders as a whole by enhancing the net asset value per share and earnings per share of the Company.

Save as disclosed above, neither the Company, nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities during the Year.

Distributable Reserves

For the Year, the profit attributable to owners of the Company amounted to approximately RMB154,163,000. The Company's reserves available for distribution comprise share premium and retained profits. Under the Companies Law of the Cayman Islands, the Company's share premium account may be applied by the Company in paying distributions or dividend to shareholders of the Company provided that immediately following the date on which the distribution or dividend is proposed to be paid, the Company shall be able to pay its debts as they fall due in the ordinary course of business.

As at 31 December 2016, the Company had distributable reserves amounting to approximately RMB580,310,000, of which approximately RMB86,766,000 has been proposed as a final dividend for the Year, calculated in accordance with statutory provisions applicable in the Cayman Islands.

Charitable Contributions

During the Year, the Group made charitable contributions totalling RMB2,071,000.

Major Customers and Suppliers

During the Year, sales to the Group's five largest customers accounted for approximately 54.3% of the total sales for the Year and sales to the largest customer included therein amounted to approximately 28.1%. Purchases from the Group's five largest suppliers accounted for approximately 69.2% of total purchases for the Year and purchases from the largest supplier included therein amounted to approximately 26.0%.

Wuzhou Junye Trademark Printing Material Co., Ltd ("Wuzhou Junye Printing Material") and Guangxi Zhiguan Industrial Development Co., Limited ("Guangxi Zhiguan") were one of the Group's five largest suppliers for the Year. As at the date of this report, the registered capital of Wuzhou Junye Printing Material was owned as to 99.2% by Mr. Sha Shuming ("Mr. Sha"), the spouse of Ms. Zhou Yaxian ("Ms. Zhou"), an executive Director and one of the controlling shareholders of the Company, and 0.8% by Mr. Sha Junqi, the son of Mr. Sha and Ms. Zhou.

On the other hand, Ms. Zhou, together with her associates and Mr. Ru Xiquan, Mr. Mo Yunxi and Mr. Shi Guicheng, each an executive Director, own more than 30% of the equity interest in Guangxi Zhiguan.

Save as disclosed above, none of the Directors or any of their close associates (as defined under the Listing Rules) or any shareholders (which, to the best knowledge of the Directors, own more than 5% of the Company's issued share capital) had any beneficial interest in the Group's five largest customers and suppliers.

Emolument Policy

The Remuneration Committee was established for reviewing the Group's emolument policy and structure for all remuneration of the Directors and senior management of the Group, having regard to the Group's operating results, individual performance and comparable market practices. The Company has adopted a share option scheme as incentive to Directors and eligible employees, details of which are set out in the paragraph headed "Share Option Scheme" below.

Directors

The Directors during the Year and as at the date of this annual report were as follows:

Executive Directors:

Ms. Zhou Yaxian (*Chairman and President*)

Mr. Shi Guicheng

Mr. Ru Xiquan

Mr. Mo Yunxi

Non-executive Director:

Dato' Sri Low Jee Keong

Independent Non-executive Directors:

Mr. Tsui Yung Kwok

Mr. Meng Qinguo

Mr. Yang Xiaohu

In accordance with article 84 of the Articles, at each annual general meeting one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not less than one-third) shall retire from office by rotation provided that every Director shall be subject to retirement at an annual general meeting at least once every three years. The non-executive Director and independent non-executive Directors are appointed for periods of three years and two years, respectively.

The Company has received annual confirmations of independence from Mr. Tsui Yung Kwok, Mr. Meng Qinguo and Mr. Yang Xiaohu, and as at the date of this annual report, the Company still considers them to be independent.

Directors' and Senior Management's Biographies

Biographical details of the Directors and the senior management of the Group are set out on pages 26 to 29 of this annual report.

Directors' Service Contracts

Save and except for Mr. Mo Yunxi, each of the executive Directors and non-executive Director has entered into a service contract with the Company for a term of three years commencing from 13 October 2015 and may be terminated by either party by giving not less than three months' prior written notice.

Mr. Mo Yunxi, an executive Director, has entered into a service contract with the Company for a term of three years commencing from 16 May 2015 and may be terminated by either party by giving not less than three months' prior written notice.

Each of the independent non-executive Directors has entered into a service contract with the Company for a term of two years commencing from 13 October 2015 and may be terminated by either party by giving at least three months' written notice.

Apart from the foregoing, no Director proposed for re-election at the forthcoming annual general meeting has a service contract with the Company which is not determinable by the Company within one year without payment of compensation, other than statutory compensation.

Directors' Remuneration

The Directors' emoluments are determined by the Board with reference to Directors' duties, responsibilities and performance and the results of the Group. Details of the remuneration of the Directors are set out in note 8 to the financial statements.

Directors' Interests in Transactions, Arrangements or Contracts

Save as disclosed in note 37 to the financial statements and in the section headed "Connected Transactions" in this annual report, no Director nor a connected entity of a Director had a material interest, either directly or indirectly, in any transactions, arrangements or contracts of significance to the business of the Group to which the holding company of the Company, or any of the Company's subsidiaries or fellow subsidiaries was a party during the Year.

Management Contracts

No contracts concerning the management and administration of the whole or any substantial part of the business of the Company were entered into or existed during the Year.

Directors' and Chief Executive's Interests and Short Positions in Shares and Underlying Shares and Debentures

As at 31 December 2016, the interests and short positions of the directors and chief executive in the share capital and underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance ("SFO")) which have been notified to the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which were taken or deemed to have under such provisions of the SFO) or have been entered in the register maintained by the Company pursuant to Section 352 of the SFO, or otherwise have been notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") were as follows:

1. Interests and Short Position in the Shares (the "Shares") of the Company

Name of Director	Capacity/Nature	No. of Shares held/interested in	Approximate percentage of issued share capital of the Company
Ms. Zhou Yaxian ("Ms. Zhou")	Interest of controlled corporation (<i>Note 2</i>)	2,215,742,000 (L)	67.98%
	Beneficial owner	200,000 (L)	0.01%
Dato' Sri Low Jee Keong ("Dato' Sri Low")	Interest of controlled corporation (<i>Note 3</i>)	78,936,000 (L)	2.42%
Mr. Shi Guicheng ("Mr. Shi")	Beneficial owner	800,000 (L)	0.02%
Mr. Ru Xiquan ("Mr. Ru")	Beneficial owner	800,000 (L)	0.02%
Mr. Mo Yunxi ("Mr. Mo")	Beneficial owner	800,000 (L)	0.02%

2. Long Position in the Ordinary Shares of Associated Corporations

Name of Director	Name of the associated corporation	Capacity/Nature	No. of shares held/ interested in	Approximate percentage of interest in the associated corporation
Ms. Zhou	Rich Top Future Limited ("Rich Top Future")	Interest of controlled Corporation (<i>Note 2</i>)	65,454	65.45%
Dato' Sri Low	Rich Top Future	Interest of controlled Corporation (<i>Note 3</i>)	20,835	20.84%

Notes:

1. The letters "L" denote a long position in the Shares.
2. Ms. Zhou holds 100% interest in Shenguan Biology Science & Technology Investment Company Limited ("Hong Kong Shenguan") which holds 100% interest in Glories Site Limited ("Glories Site"), which holds approximately 65.45% interest in Rich Top Future. Hong Kong Shenguan also holds 100% interest in Xian Sheng Limited ("Xian Sheng"). Therefore, Ms. Zhou is deemed or taken to be, interested in all the Shares which are beneficially owned by Hong Kong Shenguan, Rich Top Future and Xian Sheng for the purpose of the SFO. Ms. Zhou is a director of each of Hong Kong Shenguan, Glories Site, Xian Sheng and Rich Top Future.
3. Dato' Sri Low holds 100% interest in Wealthy Safe Management Limited ("Wealthy Safe"), which holds 78,936,000 Shares. Therefore, Dato' Sri Low is deemed or taken to be, interested in all the Shares held by Wealthy Safe for the purpose of the SFO. Dato' Sri Low holds 100% interest in Brighten Lane Limited, which holds approximately 20.84% interest in Rich Top Future.

Save as disclosed above, as at 31 December 2016, none of the Directors or chief executives of the Company had registered any interests or short position in the Shares, underlying Shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would be required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO, or which would be required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein, or otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

Interests and Short Positions of Substantial Shareholders in Shares and Underlying Shares of the Company

As at 31 December 2016, as far as is known to the Directors, the following persons (not being a Director or chief executive of the Company) had interests or short positions in the Shares or underlying Shares which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

Name of Shareholders	Capacity/Nature	No. of Shares held/ interested in	Approximate percentage of issued share capital of the Company
Rich Top Future	Beneficial owner	1,926,240,000 (L)	59.10%
Xian Sheng	Beneficial owner	248,040,000 (L)	7.61%
Glories Site	Interest of controlled corporation (<i>Note 2</i>)	1,926,240,000 (L)	59.10%
Hong Kong Shenguan	Interest of controlled corporation (<i>Note 3</i>)	2,174,280,000 (L)	66.71%
	Beneficial owner	41,462,000 (L)	1.27%
Mr. Sha Shuming ("Mr. Sha")	Interest of spouse (<i>Note 4</i>)	2,215,942,000 (L)	67.99%

Notes:

- The letters "L" denote a long position in the Shares.
- Glories Site holds approximately 65.45% interest in Rich Top Future. Therefore, Glories Site is deemed or taken to be, interested in all the Shares which are beneficially owned by Rich Top Future for the purpose of the SFO.
- Hong Kong Shenguan holds 100% interest in Glories Site, which holds approximately 65.45% interest in Rich Top Future. Hong Kong Shenguan also holds 100% interest in Xian Sheng. Therefore, Hong Kong Shenguan is deemed or taken to be, interested in all the Shares which are beneficially owned by Rich Top Future and Xian Sheng for the purpose of the SFO.
- Ms. Zhou holds 100% interest in Hong Kong Shenguan and Hong Kong Shenguan holds 100% interest in Glories Site, which holds approximately 65.45% interest in Rich Top Future. Hong Kong Shenguan also holds 100% interest in Xian Sheng. Therefore, Ms. Zhou is deemed or taken to be, interested in all the Shares which are beneficially owned by Hong Kong Shenguan, Rich Top Future and Xian Sheng for the purpose of the SFO. Ms. Zhou beneficially owns 200,000 Shares. Mr. Sha is the spouse of Ms. Zhou and therefore, Mr. Sha is deemed or taken to be, interested in all the Shares in which Ms. Zhou is interested for the purpose of the SFO.

Save as disclosed above, at 31 December 2016, the Directors were not aware of any persons (who were not Directors or chief executive of the Company) who had an interest or short position in the Shares or underlying Shares which would fall to be disclosed under Divisions 2 and 3 of Part XV of the SFO, or which would be required, pursuant to Section 336 of the SFO, to be entered in the register referred to therein.

Competing Interests

On 26 January 2015, Wuzhou Shenguan Protein Casing Co., Ltd. (梧州神冠蛋白腸衣有限公司) (“Wuzhou Shenguan”) (a wholly-owned subsidiary of the Company) entered into an equity transfer agreement with Mr. Sha, the spouse of Ms. Zhou, the Chairman of the Board and an executive Director, pursuant to which Mr. Sha agreed to sell and Wuzhou Shenguan agreed to purchase the entire equity interest in Guangxi Wuzhou Sanjian Pharmaceutical Company Limited (廣西梧州三箭製藥有限公司) (“Sanjian Pharmaceutical”) at a consideration of RMB4,810,000 (the “Acquisition”). Upon completion of the Acquisition, Sanjian Pharmaceutical has become a wholly-owned subsidiary of Wuzhou Shenguan.

Subsequent to the Acquisition, Guangxi Wuzhou Shennong Pharmaceutical co., Ltd (廣西梧州神農藥業有限公司) (“Shennong Pharmaceutical”), a joint venture which is owned as to 72% by Ms. Zhou and is principally engaged in the manufacture and sale of pharmaceutical products in the PRC, has become a competing business of Ms. Zhou with the Group.

As disclosed in the prospectus issued by the Company dated 30 September 2009, pursuant to the deed of non-competition dated 19 September 2009 entered into by Ms. Zhou in favour of the Company (the “Deed of Non-competition”), when business opportunities which may compete with the business of the Group arise, Ms. Zhou or any of her associates shall offer to the Company the right of first refusal (the “Right of First Refusal”) to take up such business opportunities.

As such, pursuant to the Deed of Non-competition, Ms. Zhou served a written notice to the Company on 8 January 2015 in respect of such matter and offered to the Company the Right of First Refusal to acquire 72% equity interest in Shennong Pharmaceutical for a consideration of RMB17,000,000 (the “Right of First Refusal”) and sought the Company’s decision as to whether it will exercise its Right of First Refusal to acquire the said 72% equity interests in Shennong Pharmaceutical.

The Directors (excluding Ms. Zhou who had abstained from voting) were of the opinion that it was not appropriate and was not in the best interests of the Company and its shareholders as a whole, for the Company to exercise the Right of First Refusal.

For details of the Acquisition and non-exercise of the Right of First Refusal, please refer to the announcement of the Company dated 26 January 2015.

Save as disclosed above, none of the Directors and their close associates (as defined under the Listing Rules), and the substantial shareholders of the Company had any interests in any business, which competed with or might compete with the business of the Group.

The Board has established a committee (the “Committee”) comprising all the independent non-executive Directors which was delegated with the authority to review on an annual basis the non-competition undertakings (the “Non-competition Undertakings”) given by Ms. Zhou, Dato’ Sri Low and Mr. Wei Cheng in three deeds of non-competition respectively entered into by Ms. Zhou, Dato’ Sri Low and Mr. Wei Cheng, all dated 19 September 2009. Ms. Zhou, Dato’ Sri Low and Mr. Wei Cheng confirmed that (a) they have provided all information necessary for the enforcement of the Non-competition Undertakings as requested by the Committee from time to time; and (b) from the effective date of the Non-competition Undertakings and up to 31 December 2016, they had complied with the Non-competition Undertakings. The Committee was not aware of any non-compliance with the Non-competition Undertakings given by Ms. Zhou, Dato’ Sri Low and Mr. Wei Cheng during the same period.

Share Option Scheme

In order to attract and retain the eligible persons, provide additional incentive to them and promote the success of the business of the Group, the Company conditionally adopted a share option scheme (the "Scheme") on 19 September 2009 whereby the Board are authorised, at their absolute discretion and subject to the terms of the Scheme, to grant options to subscribe the Shares to, inter alia, any employees (full-time or part-time), directors, consultants and advisors or any substantial shareholder, distributors, contractors, suppliers, agents, customers, business partners or service providers of the Group. The Scheme became unconditional on 13 October 2009 and shall be valid and effective for a period of ten years commencing on 19 September 2009, subject to the early termination provisions contained in the Scheme.

An offer for the grant of options must be accepted within seven days inclusive of the day on which such offer was made. The amount payable by the grantee of an option to the Company on acceptance of the offer for the grant of an option is HK\$1.00. The subscription price of a Share in respect of any particular option granted under the Scheme shall be a price solely determined by the Board and notified to a participant and shall be at least the highest of: (i) the closing price of the Shares as stated in the Stock Exchange's daily quotations sheet on the date of grant of the option; (ii) the average of the closing prices of the Shares as stated in the Stock Exchange's daily quotations sheets for the 5 trading days immediately preceding the date of grant of the option; and (iii) the nominal value of a Share on the date of grant of the option provided always that for the purpose of calculating the subscription price, where the Company has been listed on the Stock Exchange for less than 5 trading days, the issue price shall be used as the closing price for any trading day which fall within the period before the date of listing of the Company's shares (the "Listing Date").

The Company shall be entitled to issue options, provided that the total number of Shares which may be issued upon exercise of all options to be granted under the Scheme does not exceed 10% of the Shares in issue on the Listing Date. The Company may at any time refresh such limit, subject to the shareholders' approval and issue of a circular in compliance with the Listing Rules, provided that the total number of Shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under all the share option schemes of the Company does not exceed 30% of the Shares in issue at any time.

The total number of securities available for issue under the Scheme as at the date of this report was 314,520,000 Shares which represented approximately 9.65% of the issued share capital of the Company as at the date of this report. The total number of shares issued and to be issued upon exercise of options granted to any grantee (including both exercised and outstanding options) under the Scheme, in any 12-month period up to the date of grant shall not exceed 1% of the Shares in issue.

An option may be exercised in accordance with the terms of the Scheme at any time during a period as the Board may determine which shall not exceed ten years from the date of grant subject to the provisions of early termination thereof.

At no time during the Year were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any of the Directors or their respective spouses or minor children, or were any such rights exercised by them; nor was the Company, its holding company, or any of its subsidiaries or fellow subsidiaries a party to any arrangement to enable the Directors to acquire such rights in any other body corporate.

Further details of the Scheme are disclosed in note 29 to the financial statements.

Contract of Significance

Save as disclosed in the section headed "Connected Transactions" in this report, no contracts of significance in relation to the Group's business in which the Company, any of its subsidiaries or fellow subsidiaries, or its parent company was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted during or at the end of the Year.

Connected Transactions

During the Year, the Group had the following continuing connected transactions, certain details of which are disclosed in compliance with the requirements of Chapter 14A of the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules").

The Group carried out or entered into the following continuing connected transactions (other than continuing connected transactions that are exempted under Rule 14A.76 of the Listing Rules) during the Year:

(i) Transactions with Wuzhou Junye Trademark Printing Material Co., Ltd.

On 22 December 2014, the Company entered into a sale and purchase agreement with Wuzhou Junye Trademark Printing Material Co., Ltd.* (梧州駿業商標印刷有限公司) ("Wuzhou Junye Printing Material"), pursuant to which Wuzhou Junye Printing Material agreed to supply packaging materials to the Company (or any one or more of its subsidiaries) for a term of three years commencing from 1 January 2015 and ending on 31 December 2017. The purchases by the Group from Wuzhou Junye Printing Material under the said agreement for the Year amounted to RMB11,648,000 and the annual cap set in the said agreement for the Year is RMB28,266,000.

Wuzhou Junye Printing Material is owned by Mr. Sha Shuming ("Mr. Sha"), the spouse of Ms. Zhou Yaxian ("Ms. Zhou"), as to 99.2% and by Mr. Sha Junqi, the son of Mr. Sha and Ms. Zhou, as to 0.8%. Ms. Zhou is a Director and a controlling shareholder of the Company. Wuzhou Junye Printing Material is therefore a connected person of the Company under Chapter 14A of the Listing Rules.

(ii) Transactions with Wuzhou Zhongbo Packaging Co., Ltd.

On 22 December 2014, the Company entered into a sale and purchase agreement with Wuzhou Zhongbo Packaging Co., Ltd.* (梧州市中柏包裝有限公司) ("Wuzhou Zhongbo Packaging"), pursuant to which Wuzhou Zhongbo Packaging agreed to supply packaging materials to the Company (or any one or more of its subsidiaries) for a term of three years commencing from 1 January 2015 and ending on 31 December 2017. The purchases by the Group from Wuzhou Zhongbo Packaging under the said agreement for the Year amounted to RMB2,815,000 and the annual cap set in the said agreement for the Year is RMB8,999,000.

Wuzhou Zhongbo Packaging is owned by Mr. Sha, the spouse of Ms. Zhou, as to 86.67% and by Mr. Sha Junqi, the son of Mr. Sha and Ms. Zhou, as to 13.33%. Ms. Zhou is a Director and a controlling shareholder of the Company. Wuzhou Junye Printing Material is therefore a connected person of the Company under Chapter 14A of the Listing Rules.

(iii) Transactions with LJK Frozen SDN. BHD and Exceltech Global Investment Pte Limited

On 22 December 2014, the Company entered into a sale and purchase agreement with LJK Frozen SDN. BHD ("LJK") and Exceltech Global Investment Pte Limited (優良國際投資有限公司) ("Exceltech"), pursuant to which the Company (or any one or more of its subsidiaries) agreed to supply collagen sausage casing products to LJK and Exceltech for a term of three years commencing from 1 January 2015 and ending on 31 December 2017. The sales from the Group to LJK and Exceltech under the said agreement for the Year amounted to RMB2,626,000 and the annual cap set in the said agreement for the Year is RMB11,000,000.

LJK is owned by Dato' Sri Low Jee Keong ("Dato' Sri Low"), a Director, as to 80% and Exceltech is wholly owned by Dato' Sri Low. Therefore, each of LJK and Exceltech is a connected person of the Company under Chapter 14A of the Listing Rules.

* For identification purpose only

(iv) Transactions with Guangxi Zhiguan Industrial Development Co., Limited

On 30 October 2015, the Company entered into a long-term framework agreement with Guangxi Zhiguan Industrial Development Co., Limited* (廣西志冠實業開發有限公司) ("Guangxi Zhiguan"), pursuant to which Guangxi Zhiguan agreed to supply cattle inner skin to the Company (or any one or more of its subsidiaries) for a period commencing from 1 November 2015 and ending on 31 December 2017. The purchases by the Group from Guangxi Zhiguan under the said agreement for the Year amounted to RMB47,855,000 and the annual cap set in the said agreement for the Year is RMB90,000,000.

Ms. Zhou, together with her associates and Mr. Ru Xiquan, Mr. Mo Yunxi and Mr. Shi Guicheng, each an executive Director, own more than 30% of the equity interest in Guangxi Zhiguan and thus Guangxi Zhiguan is a connected person of the Company under Chapter 14A of the Listing Rules.

For further details of the transactions stated in (i), (ii) and (iii) above, please refer to the announcement issued by the Company on 22 December 2014. For further details of the transaction stated in (iv) above, please refer to the announcement issued by the Company on 30 October 2015.

The independent non-executive Directors have reviewed the continuing connected transactions set out above and have confirmed that these continuing connected transactions were entered into (i) in the ordinary and usual course of business of the Group; (ii) on normal commercial terms or on terms no less favourable to the Group than terms available to or from independent third parties; and (iii) in accordance with the relevant agreements governing them on terms that are fair and reasonable and in the interests of the shareholders of the Company as a whole.

Ernst & Young, the Company's auditors, were engaged to report on the Group's continuing connected transactions (other than continuing connected transactions that are exempted under Rule 14A.76 of the Listing Rules) in accordance with Hong Kong Standard on Assurance Engagements 3000 *Assurance Engagements Other Than Audits or Reviews of Historical Financial Information* and with reference to Practice Note 740 *Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules* issued by the Hong Kong Institute of Certified Public Accountants. Ernst & Young have issued their unqualified letter containing their findings and conclusions in respect of the continuing connected transactions disclosed above (other than continuing connected transactions that are exempted under Rule 14A.76 of the Listing Rules) by the Group in accordance with Rule 14A.56 of the Listing Rules. A copy of the auditor's letter has been provided by the Company to the Stock Exchange.

Related Party Transactions

Save as the transactions disclosed above, the Directors consider that those material related party transactions disclosed in note 37(a) to the financial statements are "continuing connected transactions" in Chapter 14A of the Listing Rules but are exempted from the reporting, announcement or independent shareholders' approval requirements under the Listing Rules, and the related party transactions disclosed in notes 37(b) and (c) to the financial statements are not regarded as connected transactions or continuing connected transactions under the Listing Rules.

Corporate Governance

The Company has applied the code provisions set out in the Code contained in Appendix 14 to the Listing Rules. The Company has complied with the code provisions of the Code for the year ended 31 December 2016, save for the exceptions explained in the Corporate Governance Report in this annual report.

Sufficiency of Public Float

Based on information that is publicly available to the Company and within the knowledge of the Directors, at least 25% of the Company's total issued share capital was held by the public as at the latest practicable date prior to the issue of this annual report.

Event after the Balance Sheet Date

Saved as disclosed in note 43 to the financial statements, there was no other important events affecting the Group that have occurred since the end of 31 December 2016.

Permitted Indemnity Provisions

Pursuant to article 164 of the articles of association of the Company, every Director is entitled to be indemnified out of the assets of the Company against all losses or liabilities which he may sustain or incur in or about the execution of the duties of his office or otherwise in relation thereto.

Auditors

The consolidated financial statements of the Company for the year ended 31 December 2016 have been audited by Ernst & Young. Ernst & Young will retire as auditors of the Company and a resolution for their reappointment as auditors of the Company will be proposed at the forthcoming annual general meeting.

ON BEHALF OF THE BOARD

Zhou Yaxian
Chairman

Hong Kong
17 March 2017



To the shareholders of Shenguan Holdings (Group) Limited

(Incorporated in the Cayman Islands with limited liability)

Opinion

We have audited the consolidated financial statements of Shenguan Holdings (Group) Limited (the "Company") and its subsidiaries (the "Group") set out on pages 48 to 121, which comprise the consolidated statement of financial position as at 31 December 2016, and the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2016, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

Basis for Opinion

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSA") issued by the HKICPA. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the HKICPA's *Code of Ethics for Professional Accountants* (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the consolidated financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying consolidated financial statements.

To the shareholders of Shenguan Holdings (Group) Limited

(Incorporated in the Cayman Islands with limited liability)

Key Audit Matters (Continued)**Key audit matter***Impairment assessment of goodwill and intangible assets*

As at 31 December 2016, the Group had goodwill (net of impairment) of RMB22.8 million and intangible assets of RMB188.3 million relating to bioactive collagen products cash-generating unit ("CGU"). In accordance with HKAS 36 *Impairment of Assets*, management is required to test goodwill for impairment annually. Management is also required to determine whether there is any impairment indicator for the intangible assets with reference to the recoverable amount of the CGU.

We focused on this area because this assessment is based on the recoverable amount of the CGU as determined in a value-in-use calculation, which required significant management judgement with respect to pre-tax cash flow projection based on financial budget approved by management covering a nine-year period. The projection is largely based on management expectations and estimates of future results of sale of bioactive collagen products.

RMB24.7 million was impaired on goodwill as at 31 December 2016.

Related disclosures are included in notes 3, 16 and 17 to the consolidated financial statements.

Provision for obsolete and slow-moving of inventories

As at 31 December 2016, the Group had inventories (net of provision) amounting to RMB794.8 million, which represented 22.7% of the total assets of the Group.

As at 31 December 2016, provision for inventories of approximately RMB4.1 million was recorded by the Group.

We focused on this area because the balance of inventories was material to the consolidated financial statements. Also, the determination of provision also involved significant estimates.

Related disclosures are included in notes 3 and 20 to the consolidated financial statements.

How our audit addressed the key audit matter

Our audit procedures included the assessment of the valuation methodology and the key assumptions, such as the sales growth rate, budgeted gross margin and the discount rate based on our knowledge of the business and industry.

We checked the input data to supporting evidence, such as the approved budgets and the recent historical results of the Group. We performed sensitivity analysis for the recoverable amount of the CGU. We also assessed the adequacy of the disclosures in the consolidated financial statements.

Our audit procedures included the assessment of controls over identifying and valuing obsolete, damaged, slow-moving, excess and other inventory items for which their costs may not be fully recoverable; checking the aging of inventories and sales and usage after the end of the reporting period; and evaluating the estimates and underlying data used by the Group in calculating the net realisable values of inventories.

To the shareholders of Shenguan Holdings (Group) Limited

(Incorporated in the Cayman Islands with limited liability)

Key Audit Matters (Continued)**Key audit matter**

Recoverability of trade and bills receivables and prepayment, deposits and other receivables

As at 31 December 2016, the Group had trade and bills receivables (net of provision) of RMB215.2 million, and prepayment, deposits and other receivables of RMB115.8 million. As at 31 December 2016, impairment of trade and bills receivables of RMB29.9 million was recorded by the Group.

We focused on this area because significant judgement is required in determining the provision, with reference to management's assessments on debtors based on their repayment history, financial position, reputation and business relationship with the Group.

Related disclosures are included in notes 3, 21 and 22 to the consolidated financial statements.

How our audit addressed the key audit matter

We assessed the Group's processes and controls relating to the monitoring of receivables to identify objective evidence of impairment.

Our procedures included obtaining direct confirmations on a sampling basis, checking the aging of receivable balances, the debtor's historical payment patterns and the bank receipts for the payment received subsequent to the end of the reporting period. We also checked the evidence including correspondence between the parties involved for the latest progress of the outstanding balances and credit status of these debtors.

Other Information Included in the Annual Report

The directors of the Company are responsible for the other information. The other information comprises the information included in the Annual Report, other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

To the shareholders of Shenguan Holdings (Group) Limited

(Incorporated in the Cayman Islands with limited liability)

Responsibilities of the Directors for the Consolidated Financial Statements

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors of the Company are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors of the Company either intend to liquidate the Group or to cease operations or have no realistic alternative but to do so.

The directors of the Company are assisted by the Audit Committee in discharging their responsibilities for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Our report is made solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

To the shareholders of Shenguan Holdings (Group) Limited

(Incorporated in the Cayman Islands with limited liability)

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements (Continued)

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the Audit Committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is CHIU, Caroline Su Yuen.

Ernst & Young

Certified Public Accountants

22/F, CITIC Tower

1 Tim Mei Avenue

Central, Hong Kong

17 March 2017

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Year ended 31 December 2016

	<i>Notes</i>	2016 <i>RMB'000</i>	2015 <i>RMB'000</i>
REVENUE	5	980,617	1,054,565
Cost of sales		(687,542)	(588,713)
Gross profit		293,075	465,852
Other income and gains, net	5	88,473	41,016
Selling and distribution expenses		(32,506)	(11,660)
Administrative expenses		(177,898)	(140,372)
Finance costs, net	7	(15,927)	(17,700)
PROFIT BEFORE TAX	6	155,217	337,136
Income tax expense	10	(21,565)	(51,558)
PROFIT FOR THE YEAR		133,652	285,578
OTHER COMPREHENSIVE INCOME			
Other comprehensive income may be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of foreign operations		(21,401)	(12,493)
NET OTHER COMPREHENSIVE INCOME MAY BE RECLASSIFIED TO PROFIT OR LOSS IN SUBSEQUENT PERIODS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX		(21,401)	(12,493)
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		112,251	273,085
Profit attributable to:			
Owners of the Company		154,163	291,390
Non-controlling interests		(20,511)	(5,812)
		133,652	285,578
Total comprehensive income attributable to:			
Owners of the Company		132,762	278,897
Non-controlling interests		(20,511)	(5,812)
		112,251	273,085
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY OWNERS OF THE COMPANY	12		
Basic (RMB cents per share)		4.7	8.9
Diluted (RMB cents per share)		4.7	8.9

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

31 December 2016

| 49

	<i>Notes</i>	2016 <i>RMB'000</i>	2015 <i>RMB'000</i>
NON-CURRENT ASSETS			
Property, plant and equipment	13	1,351,345	1,310,261
Investment properties	14	7,342	–
Prepaid land lease payments	15	118,863	122,619
Goodwill	16	22,760	47,486
Other intangible assets	17	191,219	242,924
Available-for-sale investment	18	37,100	37,100
Deferred tax assets	27	42,973	56,326
Long term prepayments		13,318	15,642
Total non-current assets		1,784,920	1,832,358
CURRENT ASSETS			
Financial asset at fair value through profit or loss	19	18,078	353
Inventories	20	794,845	921,958
Trade and bills receivables	21	215,220	181,904
Prepayments, deposits and other receivables	22	115,766	191,920
Pledged deposits	23	456,000	354,727
Cash and cash equivalents	23	119,016	210,784
Total current assets		1,718,925	1,861,646
CURRENT LIABILITIES			
Trade and bills payables	24	65,335	42,726
Other payables and accruals	25	104,108	114,067
Interest-bearing bank and other borrowings	26	343,563	544,545
Tax payable		3,928	9,985
Total current liabilities		516,934	711,323
NET CURRENT ASSETS		1,201,991	1,150,323
TOTAL ASSETS LESS CURRENT LIABILITIES		2,986,911	2,982,681
NON-CURRENT LIABILITIES			
Deferred income		29,980	32,663
Deferred tax liabilities	27	61,655	79,523
Total non-current liabilities		91,635	112,186
Net assets		2,895,276	2,870,495

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
31 December 2016

50 |

	<i>Notes</i>	2016 <i>RMB'000</i>	2015 <i>RMB'000</i>
EQUITY			
Equity attributable to owners of the Company			
Issued capital	28	28,060	28,135
Reserves	30	2,795,637	2,752,614
		2,823,697	2,780,749
Non-controlling interests		71,579	89,746
Total equity		2,895,276	2,870,495

Ms. Zhou Yaxian
Director

Mr. Ru Xiquan
Director

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Year ended 31 December 2016

| 51

	Attributable to owners of the Company												Total equity	
	Notes	Issued capital	Share premium	Treasury shares	Contributed surplus	Reserve funds	Capital reserve	Employee share-based compensation reserve	Exchange fluctuation reserve	Other reserves	Retained profits	Non-controlling interests		
		RMB'000	RMB'000	RMB'000 (note 30(iv))	RMB'000 (note 30(i))	RMB'000 (note 30(ii))	RMB'000	RMB'000	RMB'000	RMB'000 (note 30(iii))	RMB'000	RMB'000		RMB'000
At 1 January 2015		28,425	635,828	(20,403)	59	350,681	4,758	5,444	(73,958)	(264,343)	1,969,114	2,635,605	-	2,635,605
Profit for the year		-	-	-	-	-	-	-	-	-	291,390	291,390	(5,812)	285,578
Other comprehensive income for the year:														
Exchange differences related to foreign operations		-	-	-	-	-	-	-	(12,493)	-	-	(12,493)	-	(12,493)
Total comprehensive income for the year		-	-	-	-	-	-	-	(12,493)	-	291,390	278,897	(5,812)	273,085
Acquisition of a subsidiary	32	-	-	-	-	-	-	-	-	-	-	-	95,158	95,158
Capital contribution to a subsidiary		-	-	-	-	-	-	-	-	-	-	-	400	400
Share repurchase	30(iv)	-	-	(29,770)	-	-	-	-	-	-	-	(29,770)	-	(29,770)
Cancellation of shares repurchased	30(iv)	(301)	(43,732)	44,033	-	-	-	-	-	-	-	-	-	-
Share option exercised	29	11	3,210	-	-	-	-	(897)	-	-	-	2,324	-	2,324
Transfer of share option reserve upon the expiry of share options	29	-	-	-	-	-	-	(4,547)	-	-	4,547	-	-	-
Final 2014 dividend		-	(106,307)	-	-	-	-	-	-	-	-	(106,307)	-	(106,307)
Transfer from retained profits		-	-	-	-	19,042	-	-	-	-	(19,042)	-	-	-
At 31 December 2015		28,135	488,999*	(6,140)*	59*	369,723*	4,758*	-*	(86,451)*	(264,343)*	2,246,009*	2,780,749	89,746	2,870,495

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Year ended 31 December 2016

52 |

	Attributable to owners of the Company														
	Notes	Issued	Share	Treasury	Contributed	Reserve	Capital	Employee	Exchange	Other	Retained	Total	Non-	Total	
		capital	premium	shares	surplus	funds	reserve	share-based	fluctuation	reserves	profits		controlling		equity
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000		RMB'000		interests
			(note 30(iv))	(note 30(i))	(note 30(ii))				(note 30(iii))						
At 1 January 2016	28,135	488,999	(6,140)	59	369,723	4,758	-	(86,451)	(264,343)	2,246,009	2,780,749	89,746	2,870,495		
Profit for the year	-	-	-	-	-	-	-	-	-	154,163	154,163	(20,511)	133,652		
Other comprehensive income for the year:															
Exchange differences related to foreign operations	-	-	-	-	-	-	-	(21,401)	-	-	(21,401)	-	(21,401)		
Total comprehensive income for the year	-	-	-	-	-	-	-	(21,401)	-	154,163	132,762	(20,511)	112,251		
Capital contribution to a subsidiary	-	-	-	-	-	-	-	-	-	-	-	2,344	2,344		
Share repurchase 30(iv)	-	-	(1,624)	-	-	-	-	-	-	-	(1,624)	-	(1,624)		
Cancellation of shares repurchased 30(iv)	(75)	(7,668)	7,764	-	-	-	-	-	-	-	21	-	21		
Final 2015 dividend	-	(88,211)	-	-	-	-	-	-	-	-	(88,211)	-	(88,211)		
At 31 December 2016	28,060	393,120*	-*	59*	369,723*	4,758*	-*	(107,852)*	(264,343)*	2,400,172*	2,823,697	71,579	2,895,276		

* These reserve accounts comprise the consolidated reserves of RMB2,795,637,000 (2015: RMB2,752,614,000) in the consolidated statement of financial position.

CONSOLIDATED STATEMENT OF CASH FLOWS

Year ended 31 December 2016

| 53

	<i>Notes</i>	2016 <i>RMB'000</i>	2015 <i>RMB'000</i>
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		155,217	337,136
Adjustments for:			
Interest on bank loans	7	17,826	20,299
Bank interest income	5	(22,556)	(22,326)
Fair value gain on a financial asset at fair value through profit or loss	5	(17,725)	–
Gain on disposal of financial assets at fair value through profit or loss	5	(856)	(10,033)
Gain on disposal of a prepaid land lease	5	(302)	–
Loss on disposal of items of property, plant and equipment, net	6	13	23,797
Depreciation	6	94,843	96,257
Amortisation of prepaid land lease payments	6	3,004	2,984
Amortisation of other intangible assets	6	51,705	15,604
Impairment of goodwill	6	24,726	1,804
Government grants released		(7,328)	(9,988)
Write-off of inventories	6	13,026	–
Provision against obsolete and slow-moving inventories	6	4,098	–
Return received from contract in progress	5	(25,643)	–
Exchange (gain)/loss on intercompany loans		(13,451)	13,021
		276,597	468,555
Decrease/(increase) in inventories		109,989	(66,825)
(Increase)/decrease in trade and bills receivables		(32,494)	25,059
(Increase)/decrease in prepayments, deposits and other receivables		(30,893)	30,950
Increase/(decrease) in trade and bills payables		22,609	(60,866)
Decrease in other payables and accruals		(7,842)	(7,668)
Receipt of government grants		4,645	7,304
Cash generated from operations		342,611	396,509
Interest received		1,522	3,665
Hong Kong profits tax paid		(3,303)	(280)
PRC corporate income tax paid		(28,834)	(72,459)
Net cash flows from operating activities		311,996	327,435

CONSOLIDATED STATEMENT OF CASH FLOWS
Year ended 31 December 2016

54 |

	<i>Notes</i>	2016 <i>RMB'000</i>	2015 <i>RMB'000</i>
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchases of items of property, plant and equipment		(149,755)	(122,125)
Proceeds from disposal of a prepaid land lease		1,072	–
Acquisition of subsidiaries	32	–	(116,136)
Increase in contract in progress		–	(96)
Prepayments of land lease payments		–	(6,700)
Net increase in financial assets at fair value through profit or loss		856	10,033
Purchase of an available-for-sale investment		–	(37,100)
Decrease/(increase) in non-pledged time deposits with original maturity of more than three months when acquired		100,000	(100,000)
(Increase)/decrease in pledged deposits		(101,273)	191,317
Receipt refund on contract in progress		153,707	–
Net cash flows from/(used in) investing activities		4,607	(180,807)
CASH FLOWS FROM FINANCING ACTIVITIES			
Capital contribution from exercise of share option		–	2,324
New bank loans		530,000	453,464
Repayment of bank loans		(735,021)	(737,789)
Interest paid		(17,096)	(20,039)
Share repurchase	30(iv)	(1,624)	(29,770)
Capital contribution by a non-controlling shareholder		2,344	400
Dividends paid		(88,211)	(106,307)
Net cash flows used in financing activities		(309,608)	(437,717)
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS			
Cash and cash equivalents at beginning of year		110,784	399,585
Effect of foreign exchange rate changes, net		1,237	2,288
CASH AND CASH EQUIVALENTS AT END OF YEAR		119,016	110,784
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
Cash and bank balances	23	119,016	97,281
Non-pledged time deposits with original maturity of less than three months when acquired		–	13,503
Cash and cash equivalents as stated in the consolidated statement of cash flows		119,016	110,784
Non-pledged time deposits with original maturity of over three months when acquired		–	100,000
Cash and cash equivalents as stated in the consolidated statement of financial position	23	119,016	210,784

NOTES TO FINANCIAL STATEMENTS

31 December 2016

| 55

1. Corporate and Group Information

Shenguan Holdings (Group) Limited (the "Company") was incorporated in the Cayman Islands on 24 February 2009 as an exempted company with limited liability under the Companies Law, Cap 22 of the Cayman Islands. The registered address of the Company is P.O. Box 2681, Cricket Square, Hutchins Drive, Grand Cayman, KY1-1111, Cayman Islands. The Company's principal place of business in Hong Kong is located at Unit 2902, Sino Plaza, 255-257 Gloucester Road, Causeway Bay, Hong Kong.

The Group is principally engaged in the manufacture and sale of edible collagen sausage casing products, pharmaceutical products, food products, skin care and health care products and bioactive collagen products.

In the opinion of the directors, the immediate holding company of the Company is Rich Top Future Limited, which was incorporated in the British Virgin Islands ("BVI"), and the ultimate holding company of the Company is Shenguan Biology Science & Technology Investment Company Limited, a Hong Kong incorporated company.

Information about subsidiaries

Particulars of the Company's principal subsidiaries are as follows:

Name	Place of incorporation/ registration and business	Issued ordinary share capital/ registered and paid-up capital	Percentage of equity attributable to the Company		Principal activities
			Direct	Indirect	
Forever Gather Limited	Hong Kong	HK\$1	–	100%	Sale of collagen sausage casing
梧州神冠蛋白腸衣有限公司 ("Wuzhou Shenguan Protein Casing Co., Ltd.") ("Wuzhou Shenguan")*/^	The People's Republic of China (the "PRC")/ Mainland China	RMB460,000,000	–	100%	Manufacture and sale of collagen sausage casing
梧州市神生膠原製品有限公司 ("Wuzhou Shensheng Collagen Products Co., Ltd.") ("Wuzhou Shensheng")**/^	PRC/Mainland China	RMB200,000,000	–	100%	Manufacture and sale of collagen and collagen sausage casing
廣東勝馳生物科技有限公司 ("Guangdong Victory Biological Company Limited") ("Guangdong Victory")*/^	PRC/Mainland China	RMB18,430,331	–	51%	Manufacture and sale of bioactive collagen products
廣西梧州三箭制藥有限公司 ("Wuzhou Sanjian Pharmaceutical Co., Ltd") ("Sanjian Pharmaceutical")**/^	PRC/Mainland China	RMB25,000,000	–	100%	Manufacture and sale of pharmaceutical products

1. Corporate and Group Information (Continued)

Information about subsidiaries (Continued)

Name	Place of incorporation/ registration and business	Issued ordinary share capital/ registered and paid-up capital	Percentage of equity attributable to the Company		Principal activities
			Direct	Indirect	
南宁尚冠食品有限公司 ("Nanning Shangguan Food Co., Ltd") ("Nanning Shangguan")**/^	PRC/Mainland China	RMB2,000,000	-	100%	Manufacture and sale of food products
Singapore Shenguan Pte. Ltd.	Singapore	S\$18,189,168	-	100%	Manufacture of pharmaceutical intermediates and fine chemicals for human use

* These entities are registered as Sino-foreign joint ventures under PRC law

** These entities are registered as domestic limited liability companies under PRC law

^ The English names of these entities represent the best effort made by management of the Company to directly translate their Chinese names as no official English names have been registered

The above table lists the subsidiaries of the Company which, in the opinion of the directors, principally affected the results for the year or formed a substantial portion of the net assets of the Group. To give details of the other subsidiaries would, in the opinion of the directors, result in particulars of excessive length.

2.1 Basis of Presentation

These financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for a financial asset at fair value through profit or loss which has been measured in fair value. These financial statements are presented in Renminbi ("RMB") and all values are rounded to the nearest thousand except when otherwise indicated.

Basis of consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries (collectively referred to as the "Group") for the year ended 31 December 2016. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

2.1 Basis of Presentation (Continued)

Basis of consolidation (Continued)

When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee including:

- (a) the contractual arrangement with the other vote holders of the investee;
- (b) rights arising from other contractual arrangements; and
- (c) the Group's voting rights and potential voting rights.

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income are attributed to the owners of the company of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described above. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it derecognises (i) the assets (including goodwill) and liabilities of the subsidiary, (ii) the carrying amount of any non-controlling interest and (iii) the cumulative translation differences recorded in equity; and recognises (i) the fair value of the consideration received, (ii) the fair value of any investment retained and (iii) any resulting surplus or deficit in profit or loss. The Group's share of components previously recognised in other comprehensive income is reclassified to profit or loss or retained profits, as appropriate, on the same basis as would be required if the Group had directly disposed of the related assets or liabilities.

2.2 Changes in Accounting Policies and Disclosures

The Group has adopted the following new and revised HKFRSs for the first time for the current year's financial statements.

Amendments to HKFRS 10, HKFRS 12 and HKAS 28 (2011)	<i>Investment Entities: Applying the Consolidation Exception</i>
Amendments to HKFRS 11 HKFRS 14	<i>Accounting for Acquisitions of Interests in Joint Operations Regulatory Deferral Accounts</i>
Amendments to HKAS 1	<i>Disclosure Initiative</i>
Amendments to HKAS 16 and HKAS 38	<i>Clarification of Acceptable Methods of Depreciation and Amortisation</i>
Amendments to HKAS 16 and HKAS 41	<i>Agriculture: Bearer Plants</i>
Amendments to HKAS 27 (2011)	<i>Equity Method in Separate Financial Statements</i>
<i>Annual Improvements 2012-2014 Cycle</i>	Amendments to a number of HKFRSs

2.2 Changes in Accounting Policies and Disclosures (continued)

Except for the amendments to HKFRS 10, HKFRS 12 and HKAS 28 (2011), amendments to HKFRS 11, HKFRS 14, amendments to HKAS 16 and HKAS 41, amendments to HKAS 27 (2011), and certain amendments included in the *Annual Improvements 2012-2014 Cycle*, which are not relevant to the preparation of the Group's financial statements, the nature and the impact of the amendments are described below:

- (a) Amendments to HKAS 1 include narrow-focus improvements in respect of the presentation and disclosure in financial statements. The amendments clarify:
 - (i) the materiality requirements in HKAS 1;
 - (ii) that specific line items in the statement of profit or loss and the statement of financial position may be disaggregated;
 - (iii) that entities have flexibility as to the order in which they present the notes to financial statements; and
 - (iv) that the share of other comprehensive income of associates and joint ventures accounted for using the equity method must be presented in aggregate as a single line item, and classified between those items that will or will not be subsequently reclassified to profit or loss.

Furthermore, the amendments clarify the requirements that apply when additional subtotals are presented in the statement of financial position and the statement of profit or loss. The amendments have had no significant impact on the Group's financial statements.

- (b) Amendments to HKAS 16 and HKAS 38 clarify the principle in HKAS 16 and HKAS 38 that revenue reflects a pattern of economic benefits that are generated from operating a business (of which the asset is part) rather than the economic benefits that are consumed through the use of the asset. As a result, a revenue-based method cannot be used to depreciate property, plant and equipment and may only be used in very limited circumstances to amortise intangible assets. The amendments are applied prospectively. The amendments have had no impact on the financial position or performance of the Group as the Group has not used a revenue-based method for the calculation of depreciation of its non-current assets.
- (c) *Annual Improvements to HKFRSs 2012-2014 Cycle* issued in October 2014 sets out amendments to a number of HKFRSs. Details of the amendments are as follows:

HKFRS 5 Non-current Assets Held for Sale and Discontinued Operations: Clarifies that changes to a plan of sale or a plan of distribution to owners should not be considered to be a new plan of disposal, rather it is a continuation of the original plan. Accordingly, there is no change in the application of the requirements in HKFRS 5. The amendments also clarify that changing the disposal method does not change the date of classification of the non-current assets or disposal group held for sale. The amendments are applied prospectively. The amendments have had no impact on the Group as the Group did not have any change in the plan of sale or disposal method in respect of the disposal group held for sale during the year.

2.3 Issued but not Yet Effective Hong Kong Financial Reporting Standards

The Group has not applied the following new and revised HKFRSs, that have been issued but are not yet effective, in these financial statements.

Amendments to HKFRS 2	<i>Classification and Measurement of Share-based Payment Transactions²</i>
Amendments to HKFRS 4	<i>Applying HKFRS 9 Financial Instruments with HKFRS 4 Insurance Contracts²</i>
HKFRS 9	<i>Financial Instruments²</i>
Amendments to HKFRS 10 and HKAS 28 (2011)	<i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture⁴</i>
HKFRS 15	<i>Revenue from Contracts with Customers²</i>
Amendments to HKFRS 15	<i>Clarifications to HKFRS 15 Revenue from Contracts with Customers²</i>
HKFRS 16	<i>Leases³</i>
Amendments to HKAS 7	<i>Disclosure Initiative¹</i>
Amendments to HKAS 12	<i>Recognition of Deferred Tax Assets for Unrealised Losses¹</i>

¹ Effective for annual periods beginning on or after 1 January 2017

² Effective for annual periods beginning on or after 1 January 2018

³ Effective for annual periods beginning on or after 1 January 2019

⁴ No mandatory effective date is determined but is available for adoption

Further information about those HKFRSs that are expected to be applicable to the Group is as follows:

The HKICPA issued amendments to HKFRS 2 in August 2016 that address three main areas: the effects of vesting conditions on the measurement of a cash-settled share-based payment transaction; the classification of a share-based payment transaction with net settlement features for withholding a certain amount in order to meet the employee's tax obligation associated with the share-based payment; and accounting where a modification to the terms and conditions of a share-based payment transaction changes its classification from cash-settled to equity-settled. The amendments clarify that the approach used to account for vesting conditions when measuring equity-settled share-based payments also applies to cash-settled share-based payments. The amendments introduce an exception so that a share-based payment transaction with net share settlement features for withholding a certain amount in order to meet the employee's tax obligation is classified in its entirety as an equity-settled share-based payment transaction when certain conditions are met. Furthermore, the amendments clarify that if the terms and conditions of a cash-settled share-based payment transaction are modified, with the result that it becomes an equity-settled share-based payment transaction, the transaction is accounted for as an equity-settled transaction from the date of the modification. The Group expects to adopt the amendments from 1 January 2018. The amendments are not expected to have any significant impact on the Group's financial statements.

In September 2014, the HKICPA issued the final version of HKFRS 9, bringing together all phases of the financial instruments project to replace HKAS 39 and all previous versions of HKFRS 9. The standard introduces new requirements for classification and measurement, impairment and hedge accounting. The Group expects to adopt HKFRS 9 from 1 January 2018. During 2016, the Group performed a high-level assessment of the impact of the adoption of HKFRS 9. This preliminary assessment is based on currently available information and may be subject to changes arising from further detailed analyses or additional reasonable and supportable information being made available to the Group in the future. The expected impacts arising from the adoption of HKFRS 9 are summarised as follows:

2.3 Issued but not Yet Effective Hong Kong Financial Reporting Standards (Continued)

(a) Classification and measurement

The Group does not expect that the adoption of HKFRS 9 will have a significant impact on the classification and measurement of its financial assets. It expects to continue measuring at fair value all financial assets currently held at fair value. Equity investments currently held as available for sale will be measured at fair value through other comprehensive income as the investments are intended to be held for the foreseeable future and the Group expects to apply the option to present fair value changes in other comprehensive income. Gains and losses recorded in other comprehensive income for the equity investments cannot be recycled to profit or loss when the investments are derecognised.

(b) Impairment

HKFRS 9 requires an impairment on debt instruments recorded at amortised cost or at fair value through other comprehensive income, lease receivables, loan commitments and financial guarantee contracts that are not accounted for at fair value through profit or loss under HKFRS 9, to be recorded based on an expected credit loss model either on a twelve-month basis or a lifetime basis. The Group expects to apply the simplified approach and record lifetime expected losses that are estimated based on the present value of all cash shortfalls over the remaining life of all of its trade and other receivables. The Group will perform a more detailed analysis which considers all reasonable and supportable information, including forward-looking elements, for estimation of expected credit losses on its trade and other receivables upon the adoption of HKFRS 9.

Amendments to HKFRS 10 and HKAS 28 (2011) address an inconsistency between the requirements in HKFRS 10 and in HKAS 28 (2011) in dealing with the sale or contribution of assets between an investor and its associate or joint venture. The amendments require a full recognition of a gain or loss when the sale or contribution of assets between an investor and its associate or joint venture constitutes a business. For a transaction involving assets that do not constitute a business, a gain or loss resulting from the transaction is recognised in the investor's profit or loss only to the extent of the unrelated investor's interest in that associate or joint venture. The amendments are to be applied prospectively. The previous mandatory effective date of amendments to HKFRS 10 and HKAS 28 (2011) was removed by the HKICPA in January 2016 and a new mandatory effective date will be determined after the completion of a broader review of accounting for associates and joint ventures. However, the amendments are available for application now.

HKFRS 15 establishes a new five-step model to account for revenue arising from contracts with customers. Under HKFRS 15, revenue is recognised at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The principles in HKFRS 15 provide a more structured approach for measuring and recognising revenue. The standard also introduces extensive qualitative and quantitative disclosure requirements, including disaggregation of total revenue, information about performance obligations, changes in contract asset and liability account balances between periods and key judgements and estimates. The standard will supersede all current revenue recognition requirements under HKFRSs. In June 2016, the HKICPA issued amendments to HKFRS 15 to address the implement issues on identifying performance obligations, application guidance on principal versus agent and licences of intellectual property, and transition. The amendments are also intended to help ensure a more consistent application when entities adopt HKFRS 15 and decrease the cost and complexity of applying the standard. The Group expects to adopt HKFRS 15 on 1 January 2018 and is currently assessing the impact of HKFRS 15 upon adoption.

2.3 Issued but not Yet Effective Hong Kong Financial Reporting Standards (Continued)

HKFRS 16 replaces HKAS 17 *Leases*, HK(IFRIC)-Int 4 *Determining whether an Arrangement contains a Lease*, HK(SIC)-Int 15 *Operating Leases – Incentives* and HK(SIC)-Int 27 *Evaluating the Substance of Transactions Involving the Legal Form of a Lease*. The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise assets and liabilities for most leases. The standard includes two recognition exemptions for lessees – leases of low-value assets and short-term leases. At the commencement date of a lease, a lessee will recognise a liability to make lease payments (i.e., the lease liability) and an asset representing the right to use the underlying asset during the lease term (i.e., the right-of-use asset). The right-of-use asset is subsequently measured at cost less accumulated depreciation and any impairment losses unless the right-of-use asset meets the definition of investment property in HKAS 40. The lease liability is subsequently increased to reflect the interest on the lease liability and reduced for the lease payments. Lessees will be required to separately recognise the interest expense on the lease liability and the depreciation expense on the right-of-use asset. Lessees will also be required to remeasure the lease liability upon the occurrence of certain events, such as change in the lease term and change in future lease payments resulting from a change in an index or rate used to determine those payments. Lessees will generally recognise the amount of the remeasurement of the lease liability as an adjustment to the right-of-use asset. Lessor accounting under HKFRS 16 is substantially unchanged from the accounting under HKAS 17. Lessors will continue to classify all leases using the same classification principle as in HKAS 17 and distinguish between operating leases and finance leases. The Group expects to adopt HKFRS 16 on 1 January 2019 and is currently assessing the impact of HKFRS 16 upon adoption.

Amendments to HKAS 7 require an entity to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes. The amendments will result in additional disclosure to be provided in the financial statements. The Group expects to adopt the amendments from 1 January 2017.

Amendments to HKAS 12 were issued with the purpose of addressing the recognition of deferred tax assets for unrealised losses related to debt instruments measured at fair value, although they also have a broader application for other situations. The amendments clarify that an entity, when assessing whether taxable profits will be available against which it can utilise a deductible temporary difference, needs to consider whether tax law restricts the sources of taxable profits against which it may make deductions on the reversal of that deductible temporary difference. Furthermore, the amendments provide guidance on how an entity should determine future taxable profits and explain the circumstances in which taxable profit may include the recovery of some assets for more than their carrying amount. The Group expects to adopt the amendments from 1 January 2017.

2.4 Summary of Significant Accounting Policies

Business combinations and goodwill

Business combinations are accounted for using the acquisition method. The consideration transferred is measured at the acquisition date fair value which is the sum of the acquisition date fair values of assets transferred by the Group, liabilities assumed by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange for control of the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree that are present ownership interests and entitle their holders to a proportionate share of net assets in the event of liquidation at fair value or at the proportionate share of the acquiree's identifiable net assets. All other components of non-controlling interests are measured at fair value. Acquisition-related costs are expensed as incurred.

2.4 Summary of Significant Accounting Policies (continued)

Business combinations and goodwill (Continued)

When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in host contracts of the acquiree.

If the business combination is achieved in stages, the previously held equity interest is remeasured at its acquisition date fair value and any resulting gain or loss is recognised in profit or loss.

Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability is measured at fair value with changes in fair value recognised in profit or loss. Contingent consideration that is classified as equity is not remeasured and subsequent settlement is accounted for within equity.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred, the amount recognised for non-controlling interests and any fair value of the Group's previously held equity interests in the acquiree over the identifiable net assets acquired and liabilities assumed. If the sum of this consideration and other items is lower than the fair value of the net assets acquired, the difference is, after reassessment, recognised in profit or loss as a gain on bargain purchase.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. The Group performs its annual impairment test of goodwill as at 31 December. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units, or groups of cash-generating units, that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the Group are assigned to those units or groups of units.

Impairment is determined by assessing the recoverable amount of the cash-generating unit (group of cash-generating units) to which the goodwill relates. Where the recoverable amount of the cash-generating unit (group of cash-generating units) is less than the carrying amount, an impairment loss is recognised. An impairment loss recognised for goodwill is not reversed in a subsequent period.

Where goodwill has been allocated to a cash-generating unit (or group of cash-generating units) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on the disposal. Goodwill disposed of in these circumstances is measured based on the relative value of the operation disposed of and the portion of the cash-generating unit retained.

2.4 Summary of Significant Accounting Policies (Continued)

Fair value measurement

The Group measures its investment properties, derivative financial instruments and equity investments at fair value at the end of each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 – based on quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly
- Level 3 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Impairment of non-financial assets

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than inventories and financial assets), the asset's recoverable amount is estimated. An asset's recoverable amount is the higher of the asset's or cash-generating unit's value in use and its fair value less costs of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs.

An impairment loss is recognised only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

2.4 Summary of Significant Accounting Policies (continued)

Impairment of non-financial assets (Continued)

An assessment is made at the end of each reporting period as to whether there is an indication that previously recognised impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognised impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortisation) had no impairment loss been recognised for the asset in prior years. A reversal of such an impairment loss is credited to profit or loss in the period in which it arises, (only if there are revalued assets in the financial statements) unless the asset is carried at a revalued amount, in which case the reversal of the impairment loss is accounted for in accordance with the relevant accounting policy for that revalued asset.

Related parties

A party is considered to be related to the Group if:

- (a) the party is a person or a close member of that person's family and that person
 - (i) has control or joint control over the Group;
 - (ii) has significant influence over the Group; or
 - (iii) is a member of the key management personnel of the Group or of a parent of the Group;

or

- (b) the party is an entity where any of the following conditions applies:
 - (i) the entity and the Group are members of the same group;
 - (ii) one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);
 - (iii) the entity and the Group are joint ventures of the same third party;
 - (iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity;
 - (v) the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group;
 - (vi) the entity is controlled or jointly controlled by a person identified in (a);
 - (vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and
 - (viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

2.4 Summary of Significant Accounting Policies (Continued)

Property, plant and equipment and depreciation

Property, plant and equipment, other than construction in progress, are stated at cost (or valuation) less accumulated depreciation and any impairment losses. When an item of property, plant and equipment is classified as held for sale or when it is part of a disposal group classified as held for sale, it is not depreciated and is accounted for in accordance with HKFRS 5, as further explained in the accounting policy for “Non-current assets and disposal groups held for sale”. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalised in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognises such parts as individual assets with specific useful lives and depreciates them accordingly.

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

	Annual depreciation rate	Residual value
Freehold Land	Not depreciated	N/A
Buildings	3% to 11%	3% to 10%
Plant and machinery	6.4% to 19%	3% to 10%
Motor vehicles	7.5% to 33%	3% to 10%

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each financial year end.

An item of property, plant and equipment including any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognised in profit or loss in the year the asset is derecognised is the difference between the net sales proceeds and the carrying amount of the relevant asset.

Construction in progress represents a building under construction, which is stated at cost less any impairment losses, and is not depreciated. Cost comprises the direct costs of construction and capitalised borrowing costs on related borrowed funds during the period of construction. Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

2.4 Summary of Significant Accounting Policies (continued)

Investment properties

Investment properties are interests in land and buildings (including the leasehold interest under an operating lease for a property which would otherwise meet the definition of an investment property) held to earn rental income and/or for capital appreciation, rather than for use in the production or supply of goods or services or for administrative purposes; or for sale in the ordinary course of business. Such properties are measured initially at cost, including transaction costs. Subsequent to initial recognition, investment properties are stated at fair value, which reflects market conditions at the end of the reporting period.

Gains or losses arising from changes in the fair values of investment properties are included in profit or loss in the year in which they arise.

If a property occupied by the Group as an owner-occupied property becomes an investment property, the Group accounts for such property in accordance with the policy stated under "Property, plant and equipment and depreciation" up to the date of change in use, and any difference at that date between the carrying amount and the fair value of the property is accounted for as a revaluation in accordance with the policy stated under "Property, plant and equipment and depreciation" above.

Intangible assets (other than goodwill)

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible assets may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year end.

The Group's intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation of trademarks and technology knowhow is calculated using the straight-line method to allocate the cost over their estimated useful lives, as follows:

Trademarks	5 years
Technology knowhow	5 years

Operating leases

Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Where the Group is the lessor, assets leased by the Group under operating leases are included in non-current assets, and rentals receivable under the operating leases are credited to profit or loss on the straight-line basis over the lease terms. Where the Group is the lessee, rentals payable under operating leases net of any incentives received from the lessor are charged to profit or loss on the straight-line basis over the lease terms.

Prepaid land lease payments under operating leases are initially stated at cost and subsequently recognised on the straight-line basis over the lease terms.

2.4 Summary of Significant Accounting Policies (Continued)

Investments and other financial assets

Initial recognition and measurement

Financial assets are classified, at initial recognition, as financial assets at fair value through profit or loss, loans and receivables, available-for-sale financial investments and held-to-maturity investments, as appropriate. When financial assets are recognised initially, they are measured at fair value plus transaction costs that are attributable to the acquisition of the financial assets, except in the case of financial assets recorded at fair value through profit or loss.

All regular way purchases and sales of financial assets are recognised on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

Subsequent measurement

The subsequent measurement of financial assets depends on their classification as follows:

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss include financial assets held for trading and financial assets designated upon initial recognition as at fair value through profit or loss. Financial assets are classified as held for trading if they are acquired for the purpose of sale in the near term.

Financial assets at fair value through profit or loss are carried in the statement of financial position at fair value with positive net changes in fair value presented as other income and gains and negative net changes in fair value presented as finance costs in profit or loss. These net fair value changes do not include any dividends or interest earned on these financial assets, which are recognised in accordance with the policies set out for "Revenue recognition" below.

Financial assets designated upon initial recognition as at fair value through profit or loss are designated at the date of initial recognition and only if the criteria in HKAS 39 are satisfied.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. After initial measurement, such assets are subsequently measured at amortised cost using the effective interest rate method less any allowance for impairment. Amortised cost is calculated by taking into account any discount or premium on acquisition and includes fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included in other income and gains in profit or loss. The loss arising from impairment is recognised in profit or loss in finance costs for loans and in other expenses for receivables.

Available-for-sale financial investments

Available-for-sale financial investments are non-derivative financial assets in listed and unlisted equity investments and debt securities. Equity investments classified as available for sale are those which are neither classified as held for trading nor designated as at fair value through profit or loss. Debt securities in this category are those which are intended to be held for an indefinite period of time and which may be sold in response to needs for liquidity or in response to changes in market conditions.

2.4 Summary of Significant Accounting Policies (continued)

Investments and other financial assets (Continued)

Subsequent measurement (Continued)

Available-for-sale financial investments (Continued)

After initial recognition, available-for-sale financial investments are subsequently measured at fair value, with unrealised gains or losses recognised as other comprehensive income in the available-for-sale investment revaluation reserve until the investment is derecognised, at which time the cumulative gain or loss is recognised in profit or loss in other income, or until the investment is determined to be impaired, when the cumulative gain or loss is reclassified from the available-for-sale investment revaluation reserve to profit or loss in other gains or losses. Interest earned whilst holding the available-for-sale financial investments are reported as interest income and are recognised in profit or loss as other income in accordance with the policies set out for "Revenue recognition" below.

When the fair value of unlisted equity investments cannot be reliably measured because (a) the variability in the range of reasonable fair value estimates is significant for that investment or (b) the probabilities of the various estimates within the range cannot be reasonably assessed and used in estimating fair value, such investments are stated at cost less any impairment losses.

The Group evaluates whether the ability and intention to sell its available-for-sale financial assets in the near term are still appropriate. When, in rare circumstances, the Group is unable to trade these financial assets due to inactive markets, the Group may elect to reclassify these financial assets if management has the ability and intention to hold the assets for the foreseeable future or until maturity.

For a financial asset reclassified from the available-for-sale category, the fair value carrying amount at the date of reclassification becomes its new amortised cost and any previous gain or loss on that asset that has been recognised in equity is amortised to profit or loss over the remaining life of the investment using the effective interest rate. Any difference between the new amortised cost and the maturity amount is also amortised over the remaining life of the asset using the effective interest rate. If the asset is subsequently determined to be impaired, then the amount recorded in equity is reclassified to profit or loss.

Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e., removed from the Group's consolidated statement of financial position) when:

- the rights to receive cash flows from the asset have expired; or
- the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects rights and obligations that the Group has retained.

2.4 Summary of Significant Accounting Policies (Continued)

Impairment of financial assets

The Group assesses at the end of each reporting period whether there is objective evidence that a financial asset or a group of financial assets is impaired. An impairment exists if one or more events that occurred after the initial recognition of the asset have an impact on the estimated future cash flows of the financial asset or the group of financial assets that can be reliably estimated. Evidence of impairment may include indications that a debtor or a group of debtors is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganisation and observable data indicating that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults.

Financial assets carried at amortised cost

For financial assets carried at amortised cost, the Group first assesses whether impairment exists individually for financial assets that are individually significant, or collectively for financial assets that are not individually significant. If the Group determines that no objective evidence of impairment exists for an individually assessed financial asset, whether significant or not, it includes the asset in a group of financial assets with similar credit risk characteristics and collectively assesses them for impairment. Assets that are individually assessed for impairment and for which an impairment loss is, or continues to be, recognised are not included in a collective assessment of impairment.

The amount of any impairment loss identified is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred). The present value of the estimated future cash flows is discounted at the financial asset's original effective interest rate (i.e., the effective interest rate computed at initial recognition).

The carrying amount of the asset is reduced through the use of an allowance account and the loss is recognised in profit or loss. Interest income continues to be accrued on the reduced carrying amount using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. Loans and receivables together with any associated allowance are written off when there is no realistic prospect of future recovery and all collateral has been realised or has been transferred to the Group.

If, in a subsequent period, the amount of the estimated impairment loss increases or decreases because of an event occurring after the impairment was recognised, the previously recognised impairment loss is increased or reduced by adjusting the allowance account. If a write-off is later recovered, the recovery is credited to other expenses in profit or loss.

Available-for-sale financial investments

For available-for-sale financial investments, the Group assesses at the end of each reporting period whether there is objective evidence that an investment or a group of investments is impaired.

If an available-for-sale asset is impaired, an amount comprising the difference between its cost (net of any principal payment and amortisation) and its current fair value, less any impairment loss previously recognised in profit or loss, is removed from other comprehensive income and recognised in profit or loss.

2.4 Summary of Significant Accounting Policies (continued)

Impairment of financial assets (Continued)

Available-for-sale financial investments (Continued)

In the case of equity investments classified as available-for-sale, objective evidence would include a significant or prolonged decline in the fair value of an investment below its cost. "Significant" is evaluated against the original cost of the investment and "prolonged" against the period in which the fair value has been below its original cost. Where there is evidence of impairment, the cumulative loss – measured as the difference between the acquisition cost and the current fair value, less any impairment loss on that investment previously recognised in profit or loss – is removed from other comprehensive income and recognised in profit or loss. Impairment losses on equity instruments classified as available-for-sale are not reversed through profit or loss. Increases in their fair value after impairment are recognised directly in other comprehensive income.

The determination of what is "significant" or "prolonged" requires judgement. In making this judgement, the Group evaluates, among other factors, the duration or extent to which the fair value of an investment is less than its cost.

Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, or loans and borrowings, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings, net of directly attributable transaction costs.

The Group's financial liabilities include trade payables, other payables and accruals and interest-bearing bank borrowings.

Subsequent measurement of loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the effective interest rate amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortisation is included in finance costs in profit or loss.

Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognised in profit or loss.

2.4 Summary of Significant Accounting Policies (Continued)

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the statement of financial position if there is currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

Treasury shares

Own equity instruments which are reacquired and held by the Company or the Group (treasury shares) are recognised directly in equity at cost. No gain or loss is recognised in profit or loss on the purchase, sale, issue or cancellation of the Group's own equity instruments.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined on the weighted average basis and, in the case of work in progress and finished goods, comprises direct materials, direct labour and an appropriate proportion of overheads. Net realisable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal.

Cash and cash equivalents

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have a short maturity of generally within three months when acquired, less bank overdrafts which are repayable on demand and form an integral part of the Group's cash management.

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including term deposits, which are not restricted as to use.

Provisions

A provision is recognised when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

When the effect of discounting is material, the amount recognised for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in profit or loss.

Income tax

Income tax comprises current and deferred tax. Income tax relating to items recognised outside profit or loss is recognised outside profit or loss, either in other comprehensive income or directly in equity.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the country in which the Group operates.

2.4 Summary of Significant Accounting Policies (continued)

Income tax (Continued)

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- when the deferred tax liability arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognised for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses can be utilised, except:

- when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are reassessed at the end of each reporting period and are recognised to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

2.4 Summary of Significant Accounting Policies (Continued)

Government grants

Government grants are recognised at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the costs, which it is intended to compensate, are expensed.

Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual instalments.

Revenue recognition

Revenue is recognised when it is probable that the economic benefits will flow to the Group and when the revenue can be measured reliably, on the following bases:

- (a) from the sale of goods, when the significant risks and rewards of ownership have been transferred to the buyer, provided that the Group maintains neither managerial involvement to the degree usually associated with ownership, nor effective control over the goods sold;
- (b) from the rendering of services, when the services have been rendered;
- (c) interest income, on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a short period, when appropriate, to the net carrying amount of the financial asset; and
- (d) rental income, on a time proportion basis over the lease terms.

Share-based payments

The Company operates a share option scheme for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. Employees (including directors) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments ("equity-settled transactions").

The cost of equity-settled transactions with employees for grants is measured by reference to the fair value at the date at which they are granted. The fair value is determined by an external valuer using a binomial model, further details of which are given in note 29 to the financial statements.

The cost of equity-settled transactions is recognised in employee benefit expense, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled. The cumulative expense recognised for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The charge or credit to profit or loss for a period represents the movement in the cumulative expense recognised as at the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

2.4 Summary of Significant Accounting Policies (continued)

Share-based payments (Continued)

For awards that do not ultimately vest because non-market performance and/or service conditions have not been met, no expense is recognised. Where awards include a market or non-vesting condition, the transactions are treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

Where the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified, if the original terms of the award are met. In addition, an expense is recognised for any modification that increases the total fair value of the share-based payments, or is otherwise beneficial to the employee as measured at the date of modification.

Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. This includes any award where non-vesting conditions within the control of either the Group or the employee are not met. However, if a new award is substituted for the cancelled award, and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.

The dilution effect of outstanding options is reflected as additional share dilution in the computation of earnings per share.

Other employee benefits

Pension Schemes

The Group operates a defined contribution Mandatory Provident Fund retirement benefit scheme (the "MPF Scheme") under the Mandatory Provident Fund Schemes Ordinance for those employees who are eligible to participate in the MPF Scheme. Contributions are made based on a percentage of the employees' basic salaries and are charged to profit or loss as they become payable in accordance with the rules of the MPF Scheme. The assets of the MPF Scheme are held separately from those of the Group in an independently administered fund. The Group's employer contributions vest fully with the employees when contributed into the MPF Scheme.

As stipulated by the rules and regulations of the PRC, the Company's subsidiaries registered in the PRC are required to contribute to a state-sponsored retirement plan for all its PRC employees at certain percentages of the basic salaries predetermined by the local governments. The state-sponsored retirement plan is responsible for the entire retirement benefit obligations payable to retired employees and the Group has no further obligations for the actual retirement benefit payments or other post-retirement benefits beyond the annual contributions.

The costs of employee retirement benefits are recognised as cost of sales and administrative expenses in profit or loss in the period in which they are incurred.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets. The capitalisation of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalised. All other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

2.4 Summary of Significant Accounting Policies (Continued)

Dividends

Final dividends are recognised as a liability when they are approved by the shareholders in a general meeting.

Interim dividends are simultaneously proposed and declared, because the Company's memorandum and articles of association grant the directors the authority to declare interim dividends. Consequently, interim dividends are recognised immediately as a liability when they are proposed and declared.

Foreign currencies

The functional currency of the Company is the Hong Kong dollar while the presentation currency of the Company for the financial statements is RMB. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency rates of exchange ruling at the end of reporting period. Differences arising on settlement or translation of monetary items are recognised in profit or loss.

Differences arising on settlement or translation of monetary items are recognised in profit or loss with the exception of monetary items that are designated as part of the hedge of the Group's net investment of a foreign operation. These are recognised in other comprehensive income until the net investment is disposed of, at which time the cumulative amount is reclassified to profit or loss. Tax charges and credits attributable to exchange differences on those monetary items are also recorded in other comprehensive income.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognised in other comprehensive income or profit or loss is also recognised in other comprehensive income or profit or loss, respectively).

The functional currencies of certain group companies are currencies other than the presentation currency of the Company. As at the end of the reporting period, the assets and liabilities of these entities are translated into the presentation currency of the Company at the exchange rates prevailing at the end of the reporting period and their profit or loss are translated into RMB at the weighted average exchange rates for the year.

The resulting exchange differences are recognised in other comprehensive income and accumulated in the exchange fluctuation reserve. On disposal of a operation with functional currency other than RMB, the component of other comprehensive income relating to that particular operation is recognised in profit or loss.

For the purpose of the consolidated statement of cash flows, the cash flows of certain group companies with functional currency other than RMB are translated into RMB at the exchange rates ruling at the dates of the cash flows. Frequently recurring cash flows of these group companies which arise throughout the year are translated into RMB at the weighted average exchange rates for the year.

3. Significant Accounting Estimates

The preparation of the Group's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenue, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

Judgements

In the process of applying the Group's accounting policies, management has made the following judgements, apart from those involving estimations, which have the most significant effect on the amounts recognised in the financial statements:

Classification between investment properties and owner-occupied properties

The Group determines whether a property qualifies as an investment property, and has developed criteria in making that judgement. Investment property is a property held to earn rentals or for capital appreciation or both. Therefore, the Group considers whether a property generates cash flows largely independently of the other assets held by the Group. Some properties comprise a portion that is held to earn rentals or for capital appreciation and another portion that is held for use in the production or supply of goods or services or for administrative purposes. If these portions could be sold separately or leased out separately under a finance lease, the Group accounts for the portions separately. If the portions could not be sold separately, the property is an investment property only if an insignificant portion is held for use in the production or supply of goods or services or for administrative purposes. Judgement is made on an individual property basis to determine whether ancillary services are so significant that a property does not qualify as an investment property.

Estimation uncertainty

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.

Impairment of goodwill

The Group determines whether goodwill is impaired at least on an annual basis. This requires an estimation of the value in use of the cash-generating units to which the goodwill is allocated. Estimating the value in use requires the Group to make an estimate of the expected future cash flows from the cash-generating units and also to choose a suitable discount rate in order to calculate the present value of those cash flows.

Impairment of receivables

The Group records impairment of receivables based on an assessment of the recoverability of trade and bills receivables, and other receivables. The identification of doubtful debts requires directors' estimates. Where the expectation is different from the original estimate, the difference will impact on the carrying values of the trade and bills receivables and other receivables and doubtful debt expenses in the period in which the estimate has been changed.

Write-down of inventories to net realisable value

Write-down of inventories to net realisable value is made based on the estimated net realisable value of the inventories. The assessment of the write-down involves management's judgements and estimates. Where the actual outcome or expectation in future is different from the original estimate, the differences will have impact on the carrying amounts of inventories and the write-down/write-back of inventories in the period in which the estimate has been changed.

3. Significant Accounting Estimates (Continued)

Estimation uncertainty (Continued)

Impairment of non-financial assets

The Group assesses whether there are any indicators of impairment for all non-financial assets at the end of each reporting period. Non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm's length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value in use calculations are undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows.

Impairment of available-for-sale financial investment

The Group follows the guidance of HKAS 39 to determine when an available-for-sale financial investment is impaired. The Group records impairment loss on available-for-sale financial investment where there has been a significant or prolonged decline in the fair value below its cost. The determination of what is "significant" or "prolonged" requires significant judgement. Management monitors the Group's investments for impairment by considering factors including, but not limited to, current economic, market conditions and the operating performance of the investee.

Income tax

The Group is subject to income taxes in the PRC and Hong Kong. As a result of the fact that certain matters relating to income taxes have not been confirmed by the local tax bureau, objective estimate and judgement based on currently enacted tax laws, regulations and other related policies are required in determining the provision for income taxes. Where the final tax outcome of these matters is different from the amounts originally recorded, the differences will impact on the income tax and tax provisions in the period in which the differences realise.

Withholding taxes

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises in Mainland China. The requirement is effective from 1 January 2018 and applies to earnings after 31 December 2007. The Group is therefore liable for withholding taxes on dividends distributed by those subsidiaries established in Mainland China in respect of earnings generated from 1 January 2018.

As at 31 December 2016, the Group had unremitted earning that were subject to withholding taxes amounted to approximately RMB2,159,009,000 (2015: RMB1,916,186,000). In the opinion of the directors, the Company is able to control the timing of the reversal of the temporary difference and it is not probable that these subsidiaries established in Mainland China will distribute such earnings in the foreseeable future. Accordingly, no deferred tax has been recognised for withholding taxes that would be payable on distribution of unremitted earnings by the Group's subsidiaries established in Mainland China in respect of earnings generated.

Useful lives and residual values of property, plant and equipment and intangible assets

The Group's management determines the estimated useful lives, residual values and related depreciation or amortisation charges for its property, plant and equipment and intangible asset. This estimate is based on the historical experience of the actual useful lives of property, plant and equipment and intangible asset of similar nature and functions. Management will increase the depreciation or amortisation charges where useful lives are less than previously estimated lives or it will write off or write down technically obsolete or non-strategic assets that have been abandoned or sold. Actual economic lives may differ from estimated useful lives and actual residual values may differ from estimated residual values. Periodic review could result in a change in depreciable lives and residual values and therefore depreciation expenses in the future periods.

3. Significant Accounting Estimates (Continued)

Estimation uncertainty (Continued)

Contingent consideration of arising from business combinations

One of the Group's business acquisitions has involved post-acquisition performance-based contingent consideration. The Group follows the requirement of HKFRS 3 (Revised) to recognise the fair value of the contingent consideration for acquisition, as of its acquisition date as part of the consideration transferred in exchange for the acquired business/subsidiary. The fair value measurements require, among other things, significant estimation of post-acquisition performance of the acquired subsidiary/business and significant judgement on time value of money. Contingent consideration shall be remeasured at their fair value resulting from events or factors emerging after the acquisition date, with any resulting gain or loss recognised in profit or loss in accordance with HKFRS 3 (Revised).

4. Operating Segment Information

The Group is engaged in the principal business of the manufacture and sale of edible collagen sausage casing products. The Group also involves in the manufacture and sale of pharmaceutical products, food products, skin care and health care products and bioactive collagen products.

Since over 90% of the Group's revenue is generated by its edible collagen sausage casing products, no operating segments have been aggregated to form the above reportable operating segment.

Information about geographical areas

Geographical information is not presented since over 90% of the Group's revenue is derived from external customers based in the PRC and over 90% of the Group's non-current assets are located in the PRC. Accordingly, in the opinion of directors of the Company, the presentation of geographical information would provide no additional useful information to the users of these financial statements.

Information about a major customer

For the year ended 31 December 2016, revenue generated from a customer of the Group, excluding value added tax, amounting to RMB275,805,000 (2015: RMB343,616,000) has individually accounted for over 10% of the Group's total revenue.

5. Revenue, Other Income and Gains

Revenue represents the net invoiced value of goods sold, after allowances for returns and trade discounts; and the value of service rendered during the year.

An analysis of revenue, other income and gains is as follows:

	2016 RMB'000	2015 RMB'000
Revenue		
Sale of goods	980,326	1,054,366
Service income	291	199
	980,617	1,054,565
Other income		
Bank interest income	22,556	22,326
Sale of dried meat products	630	972
Government grants*	5,429	5,912
Return received from contract in progress	25,643	–
Others	1,057	1,773
	55,315	30,983
Gains		
Foreign exchange gain, net	14,275	–
Gain on disposal of financial assets at fair value through profit or loss	856	10,033
Gain on disposal of prepaid land lease	302	–
Change in fair value of a financial asset at fair value through profit or loss	17,725	–
	33,158	10,033
Total other income and gains	88,473	41,016

* Various government grants have been received in respect of significant tax contribution, improvements made to plant and machinery and the acquisition of certain land leases, and plant and equipment. The government grants received relating to assets were recognised as deferred income when conditions of these government grants were fulfilled, and released to other income over the expected useful lives of the relevant assets. There were no unfulfilled conditions or contingencies relating to these grants as at 31 December 2016 (2015: Nil).

6. Profit Before Tax

The Group's profit before tax is arrived at after charging/(crediting):

	Notes	2016 RMB'000	2015 RMB'000
Employee benefit expense (including directors' remuneration (note 8)):			
Wages and salaries		143,279	104,603
Retirement benefit contributions		30,739	40,960
		174,018	145,563
Auditor's remuneration		2,100	2,187
Cost of inventories sold**		670,418	588,713
Depreciation	13	94,843	96,257
Amortisation of prepaid land lease payments*	15	3,004	2,984
Impairment of goodwill*	16	24,726	1,804
Amortisation of other intangible assets*	17	51,705	15,604
Minimum lease payments under operating leases		1,348	1,168
Loss on disposal of items of property, plant and equipment, net*		13	23,797
Impairment of trade and bills receivables*	21	6,596	4,847
Write-off of inventories**		13,026	–
Provision against obsolete and slow-moving inventories**		4,098	–
Foreign exchange differences, net		(14,275)	12,049
Direct operating expenses (including repairs and maintenance) arising from rental-earning investment properties		7	–

* The above items are included in "Administrative expenses" in the consolidated statements of profit or loss and other comprehensive income.

** The above items are included in "Cost of sales" in the consolidated statements of profit or loss and other comprehensive income.

7. Finance Costs, Net

	2016 RMB'000	2015 RMB'000
Interest on bank loans	17,826	20,299
Arrangement fee	–	2,684
Less: Government grants*	(1,899)	(5,283)
	15,927	17,700

* Various government grants have been received in respect of interest expenses incurred for the purchase of certain raw materials in 2016 and 2015. The government grants received were deducted against related interest expenses when the conditions of the government grants were fulfilled. There were no unfulfilled conditions or contingencies relating to these grants as at 31 December 2016 and 2015.

8. Directors' Remuneration

Directors' remuneration for the year, disclosed pursuant to the Listing Rules, section 383(1)(a), (b), (c) and (f) of the Hong Kong Companies Ordinance and Part 2 of the Companies (Disclosure of Information about Benefits of Directors) Regulation, is as follows:

	Group	
	2016 RMB'000	2015 RMB'000
Fees	904	851
Other emoluments:		
Salaries, allowances and benefits in kind	6,606	2,326
Discretionary performance-related bonuses*	2,200	3,300
Retirement benefit contributions	9	9
	8,815	5,635
	9,719	6,486

* Executive directors of the Company are entitled to bonus payments which are determined as a percentage of the profit before tax of Wuzhou Shenguan and its subsidiaries.

(a) Independent non-executive directors

The fees paid to independent non-executive directors during the year were as follows:

	2016 RMB'000	2015 RMB'000
Mr. Tsui Yung Kwok	188	177
Mr. Meng Qinguo	188	177
Mr. Yang Xiaohu	188	177
	564	531

There were no other emoluments payable to the independent non-executive directors during the year (2015: Nil).

8. Directors' Remuneration (Continued)

(b) Executive directors and a non-executive director

	Fees <i>RMB'000</i>	Salaries, allowances and benefits in kind <i>RMB'000</i>	Discretionary performance- related bonuses <i>RMB'000</i>	Retirement benefit contributions <i>RMB'000</i>	Total remuneration <i>RMB'000</i>
2016					
Executive directors:					
Ms. Zhou Yaxian	68	3,000	1,000	–	4,068
Mr. Shi Guicheng	68	1,202	400	3	1,673
Mr. Ru Xiquan	68	1,202	400	3	1,673
Mr. Mo Yunxi	68	1,202	400	3	1,673
	272	6,606	2,200	9	9,087
Non-executive director:					
Mr. Low Jee Keong	68	–	–	–	68
	340	6,606	2,200	9	9,155
2015					
Executive directors:					
Ms. Zhou Yaxian	64	1,120	1,500	–	2,684
Mr. Shi Guicheng	64	402	600	3	1,069
Mr. Ru Xiquan	64	402	600	3	1,069
Mr. Mo Yunxi	64	402	600	3	1,069
	256	2,326	3,300	9	5,891
Non-executive director:					
Mr. Low Jee Keong	64	–	–	–	64
	320	2,326	3,300	9	5,955

There was no arrangement under which a director waived or agreed to waive any remuneration during the year (2015: Nil).

9. Five Highest Paid Employees

The five highest paid employees during the year included four directors (2015: three directors), details of whose remuneration are set out in note 8 above. Details of the remuneration for the year of the remaining one (2015: two) highest paid employee who is neither a director nor chief executive of the Company is as follows:

	2016 RMB'000	2015 RMB'000
Salaries, allowances and benefits in kind	1,262	2,131
Discretionary performance related bonuses	400	445
Retirement benefit contributions	3	36
	1,665	2,612

The non-director and non-chief executive highest paid employees whose remuneration fell within the following bands are as follows:

	Number of employees	
	2016	2015
HK\$1,000,001 to HK\$1,500,000	–	1
HK\$1,500,001 to HK\$2,000,000	1	1
	1	2

10. Income Tax

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Hong Kong profits tax has been provided at the rate of 16.5% on the estimated assessable profits arising in Hong Kong during the year.

Wuzhou Shenguan and Wuzhou Shensheng, being the Company's wholly-owned subsidiaries, are located in Wuzhou, Guangxi in the Western Region of China and are subject to the region's preferential corporate income tax ("CIT") rate of 15% as set out in the Notice of the Ministry of Finance and the General Administration of Custom and the State Administration of Taxation on Tax Policy Issues Concerning Further Implementing the Western China Development Strategy (Cai Shui [2011] No. 58).

Taxes on profits assessable in elsewhere have been calculated at the rate of tax prevailing in the jurisdictions in which the Group operates.

	2016 RMB'000	2015 RMB'000
Current – PRC	24,781	69,488
Current – Hong Kong		
Charge for the year	1,319	1,612
Overprovision in prior years	–	(16)
Deferred tax (note 27)	(4,535)	(19,526)
Total tax charge for the year	21,565	51,558

10. Income Tax (Continued)

A reconciliation of the tax expense applicable to profit before tax at the statutory income tax rates of the jurisdictions in which the Company and the majority of its subsidiaries are domiciled to the tax expense at the Group's effective tax rate is as follows:

2016

	Mainland China		Hong Kong		Total	
	RMB'000	%	RMB'000	%	RMB'000	%
Profit before tax	140,231		14,986		155,217	
Tax at the statutory tax rates	35,058	25.0	2,472	16.5	37,530	24.2
Lower tax rate for specific province or enacted by local authority	(19,689)		–		(19,689)	
Expenses not deductible for tax	5,075		1,012		6,087	
Income not subject to tax	(198)		(2,713)		(2,911)	
Tax losses utilised from previous years	–		(2)		(2)	
Tax losses not recognised	–		550		550	
Tax charge at the Group's effective rate	20,246	14.4	1,319	8.8	21,565	13.9

2015

	Mainland China		Hong Kong		Total	
	RMB'000	%	RMB'000	%	RMB'000	%
Profit before tax	334,201		2,935		337,136	
Tax at the statutory tax rates	83,550	25.0	484	16.5	84,034	24.9
Lower tax rate for specific province or enacted by local authority	(35,230)		–		(35,230)	
Overprovision in prior years	–		(16)		(16)	
Expenses not deductible for tax	2,718		1,159		3,877	
Income not subject to tax	(1,352)		(308)		(1,660)	
Tax losses utilised from previous years	–		(2)		(2)	
Tax losses not recognised	–		555		555	
Tax charge at the Group's effective rate	49,686	14.9	1,872	63.8	51,558	15.3

11. Dividends

	2016 RMB'000	2015 RMB'000
Final dividend proposed subsequent to the reporting period – HK2.0 cents (2015: HK3.2 cents) per ordinary share	57,844	87,151
Final special dividend proposed subsequent to the reporting period – HK1.0 cent (2015: Nil) per ordinary share	28,922	–
	86,766	87,151

The final dividend and special dividend for the year ended 31 December 2016 proposed subsequent to the reporting period have not been recognised as a liability at the end of the reporting period and are subject to the approval of the Company's shareholders at the forthcoming annual general meeting.

12. Earnings Per Share Attributable to Owner of the Company

The calculation of the basic earnings per share amount is based on the profit for the year attributable to owners of the Company of RMB154,163,000 (2015: RMB291,390,000) and the weighted average number of 3,259,850,000 ordinary shares (2015: 3,283,494,000) in issue during the year.

The calculation of diluted earnings per share amount for the year ended 31 December 2015 is based on the profit for the year attributable to owners of the Company of RMB291,390,000. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the year, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares of 274,000 assumed to have been issued at no consideration on the deemed exercise of all dilutive potential ordinary shares into ordinary shares.

The Group had no potentially dilutive ordinary shares in issue during the year ended 31 December 2016.

13. Property, Plant and Equipment

	Freehold land RMB'000	Buildings RMB'000	Plant and machinery RMB'000	Motor vehicles RMB'000	Construction in progress RMB'000	Total RMB'000
31 December 2016						
At 31 December 2015 and 1 January 2016:						
Cost	–	550,333	1,019,165	19,050	136,973	1,725,521
Accumulated depreciation	–	(82,823)	(323,810)	(8,627)	–	(415,260)
Net carrying amount	–	467,510	695,355	10,423	136,973	1,310,261
At 1 January 2016, net of accumulated depreciation	–	467,510	695,355	10,423	136,973	1,310,261
Additions	72,250	42,422	10,683	195	19,329	144,879
Disposals	–	(10)	(3)	–	–	(13)
Depreciation provided during the year	–	(18,966)	(73,550)	(2,327)	–	(94,843)
Transfers	–	18,710	–	–	(18,710)	–
Transfer to investment properties (<i>note 14</i>)	–	(7,342)	–	–	–	(7,342)
Exchange realignment	(1,569)	(173)	–	145	–	(1,597)
At 31 December 2016, net of accumulated depreciation	70,681	502,151	632,485	8,436	137,592	1,351,345
At 31 December 2016:						
Cost	70,681	603,637	1,029,727	19,390	137,592	1,861,027
Accumulated depreciation	–	(101,486)	(397,242)	(10,954)	–	(509,682)
Net carrying amount	70,681	502,151	632,485	8,436	137,592	1,351,345

13. Property, Plant and Equipment (Continued)

	Freehold land <i>RMB'000</i>	Buildings <i>RMB'000</i>	Plant and machinery <i>RMB'000</i>	Motor vehicles <i>RMB'000</i>	Construction in progress <i>RMB'000</i>	Total <i>RMB'000</i>
31 December 2015						
At 1 January 2015:						
Cost	–	514,823	1,042,966	18,038	117,290	1,693,117
Accumulated depreciation	–	(68,104)	(278,188)	(8,555)	–	(354,847)
Net carrying amount	–	446,719	764,778	9,483	117,290	1,338,270
At 1 January 2015, net of accumulated depreciation	–	446,719	764,778	9,483	117,290	1,338,270
Additions	–	16,576	12,873	2,919	48,512	80,880
Acquisition of subsidiaries (<i>note 32</i>)	–	4,292	5,688	79	1,106	11,165
Disposals	–	(3,760)	(19,558)	(479)	–	(23,797)
Depreciation provided during the year	–	(17,717)	(76,961)	(1,579)	–	(96,257)
Transfers	–	21,400	8,535	–	(29,935)	–
At 31 December 2015, net of accumulated depreciation	–	467,510	695,355	10,423	136,973	1,310,261
At 31 December 2015:						
Cost	–	550,333	1,019,165	19,050	136,973	1,725,521
Accumulated depreciation	–	(82,823)	(323,810)	(8,627)	–	(415,260)
Net carrying amount	–	467,510	695,355	10,423	136,973	1,310,261

14. Investment Properties

	2016 RMB'000	2015 RMB'000
Carrying amount at 1 January	–	–
Transfer from owner-occupied properties (note 13)	7,342	–
Carrying amount at 31 December	7,342	–

The Group's investment properties consist of three commercial properties in Wuzhou, Guangxi Province, the PRC. The Group's investment properties were revalued on 31 December 2016 based on valuations performed by 广西鑫诚资产评估有限公司 (Guangxi Guixincheng Asset Valuation Services Limited), independent professionally qualified valuers, at RMB7.3 million. Each year, the Company's directors decide to appoint which external valuer to be responsible for the external valuations of the Group's properties. Selection criteria include market knowledge, reputation, independence and whether professional standards are maintained. The Company's directors have discussions with the valuers on the valuation assumptions and valuation results once a year when the valuation is performed for annual financial reporting.

The investment properties are leased to a third party under operating leases, further summary details of which are included in note 35(a) to the financial statements.

Fair value hierarchy

The following table illustrates the fair value measurement hierarchy of the Group's investment properties:

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Recurring fair value measurement for commercial properties				
As at 31 December 2016	–	–	7,342	7,342
As at 31 December 2015	–	–	–	–

During the year, there were no transfer of fair value measurements between Level 1 and Level 2 and no transfer into or out of Level 3 (2015: Nil).

14. Investment Properties (Continued)

Reconciliation of fair value measurements categorised within Level 3 of the fair value hierarchy:

	<i>RMB'000</i>
Carrying amount at 1 January 2015, 31 December 2015 and 1 January 2016	–
Transfer from owner-occupied properties (<i>note 13</i>)	7,342
Carrying amount at 31 December 2016	7,342

Below is a summary of the valuation technique used and the key input to the valuation of investment properties:

	Valuation technique	Significant observable input	Value/rate
Commercial properties	Discount cash flow method	Estimated rental value (per sq.m per month) Discount rate	RMB145 8%

Under the discounted cash flow method, fair value is estimated using assumptions regarding the benefits and liabilities of ownership over the asset's life including an exit or terminal value. This method involves the projection of a series of cash flows on a property interest. A market-derived discount rate is applied to the projected cash flow in order to establish the present value of the income stream associated with the asset. The exit yield is normally separately determined and differs from the discount rate.

The duration of the cash flows and the specific timing of inflows and outflows are determined by events such as rent reviews, lease renewal and related reletting, redevelopment or refurbishment. The appropriate duration is driven by market behaviour that is a characteristic of the class of property. The periodic cash flow is estimated as gross income less vacancy, non-recoverable expenses, collection losses, lease incentives, maintenance costs, agent and commission costs and other operating and management expenses. The series of periodic net operating income, along with an estimate of the terminal value anticipated at the end of the projection period, is then discounted.

A significant increase (decrease) in the estimated rental value and the discount rate per annum in isolation would result in a significant increase (decrease) in the fair value of the investment properties. Generally, a change in the assumption made for the estimated rental value is accompanied by a directionally similar change in the rent growth per annum and the discount rate.

15. Prepaid Land Lease Payments

	2016 RMB'000	2015 RMB'000
Carrying amount at 1 January	125,621	124,911
Acquisition of a subsidiary (note 32)	–	3,694
Disposal	(770)	–
Recognised during the year (note 6)	(3,004)	(2,984)
Carrying amount at 31 December	121,847	125,621
Current portion included in prepayments, deposits and other receivables	(2,984)	(3,002)
Non-current portion	118,863	122,619

16. Goodwill

	2016 RMB'000	2015 RMB'000
At 1 January:		
Cost	49,290	–
Accumulated impairment	(1,804)	–
Net carrying amount	47,486	–
Net carrying amount at 1 January	47,486	–
Acquisition of subsidiaries (note 32)	–	49,290
Impairment during the year (note 6)	(24,726)	(1,804)
At 31 December	22,760	47,486
At 31 December:		
Cost	49,290	49,290
Accumulated impairment	(26,530)	(1,804)
Net carrying amount	22,760	47,486

Impairment test of goodwill

Goodwill acquired through business combinations is allocated to the following cash-generating units for impairment testing:

- Skin care and health care products cash-generating unit; and
- Bioactive collagen products cash-generating unit.

16. Goodwill (Continued)

Skin care and health care products cash-generating unit

In 2015, The recoverable amount of the skin care and health care products cash-generating unit has been determined based on a value in use calculation using pre-tax cash flow based on financial budgets covering a five-year period approved by senior management. The pre-tax discount rate applied to cash flow projections is 9.32%. Due to uncertainties, no growth rate was used to extrapolate the cash flows of the skin care and health care products cash-generating unit beyond the five-year period.

Assumptions were used in the value in use calculations of the skin care and health care products cash-generating unit for the year ended 31 December 2015. The following describes each key assumption on which management has based its cash flow projections to undertake impairment testing of goodwill:

Budgeted gross margins – The basis used to determine the value assigned to the budgeted gross margins is the past performance and management's expectations for market development.

Discount rate – The discount rate used is before tax and reflects specific risks relating to the relevant unit.

Based on the annual impairment test performed, an impairment loss of RMB1,804,000 has been provided in relation to the skin care and health care products business for the year ended 31 December 2015 as the cash-generating unit has recoverable amount of nil. The impairment loss arose as a result of the less than satisfactory expected performance of the cash-generating unit of the skin care and health care products business.

Bioactive collagen products cash-generating unit

The recoverable amount of the bioactive collagen products cash-generating unit has been determined based on a value in use calculation using pre-tax cash flow based on financial budgets covering a nine-year period approved by senior management which is extrapolated using declining growth rates from sixth to ninth year and adopted a terminal growth rate of 2.8% beyond the ninth year. Management believes that this forecast period is justified due to the long-term nature of the sale of bioactive collagen products business. The pre-tax discount rate applied to cash flow projections is 26.2%.

Assumptions were used in the value in use calculations of the bioactive collagen products cash-generating unit for the year ended 31 December 2016 and 31 December 2015. The following describes each key assumption on which management has based its cash flow projections to undertake impairment testing of goodwill:

Sales growth rates – The sales growth rates on certain product types are based on expected market share after obtaining the production permits of certain medicinal products and management experience in the industry.

Budgeted gross margins – The basis used to determine the value assigned to the budgeted gross margins is the management's expectations for market development.

Discount rate – The discount rate used is before tax and reflects specific risks relating to the relevant unit.

Based on the annual impairment test performed, an impairment loss of RMB24,726,000 has been provided in relation to the bioactive collagen products cash-generating unit as the recoverable amount has been reduced to RMB187,081,000 at the end of the reporting period. The impairment loss arose as a result of the less than satisfactory past and expected performance of the bioactive collagen products cash-generating unit.

16. Goodwill (Continued)

Bioactive collagen products cash-generating unit (Continued)

The determination of the recoverable amount of the bioactive collagen products cash-generating unit is particularly sensitive to changes in the following key assumptions:

- An increase of 1.4% in the discount rate adopted would result in the reduction of recoverable amount of (i.e. additional impairment loss of) RMB22,760,000.
- A reduction of 1.9% in the annual growth rates would result in the reduction of recoverable amount of (i.e. additional impairment loss of) RMB22,760,000.

17. Other Intangible Assets

	Technology RMB'000	Trademarks knowhow RMB'000	Total RMB'000
31 December 2016			
At 31 December 2015 and 1 January 2016:			
Cost	4,542	253,986	258,528
Accumulated amortisation	(680)	(14,924)	(15,604)
Net carrying amount	3,862	239,062	242,924
At 1 January 2016, net of accumulated amortisation			
Amortisation provided during the year (note 6)	(908)	(50,797)	(51,705)
At 31 December 2016	2,954	188,265	191,219
At 31 December 2016:			
Cost	4,542	253,986	258,528
Accumulated amortisation	(1,588)	(65,721)	(67,309)
Net carrying amount	2,954	188,265	191,219
31 December 2015			
At 1 January 2015	–	–	–
Acquisition of subsidiaries (note 32)	4,542	253,986	258,528
Amortisation provided during the year (note 6)	(680)	(14,924)	(15,604)
At 31 December 2015	3,862	239,062	242,924
At 31 December 2015:			
Cost	4,542	253,986	258,528
Accumulated amortisation	(680)	(14,924)	(15,604)
Net carrying amount	3,862	239,062	242,924

18. Available-For-Sale Investment

	2016 RMB'000	2015 RMB'000
Unlisted equity investment, at cost	37,100	37,100

As at 31 December 2016, the unlisted equity investment with a carrying amount of RMB37,100,000 (2015: RMB37,100,000) was stated at cost less impairment because the range of reasonable fair value estimates is so significant that the directors are of the opinion that its fair value cannot be measured reliably. The Group does not intend to dispose of the investment in the near future.

19. Financial Asset at Fair Value Through Profit or Loss

	2016 RMB'000	2015 RMB'000
Put option	18,078	353

Pursuant to the Guangdong Victory Agreement (as defined in note 32(iii)), the Group was granted with a put option, whereby the Group has the discretion to request Ennerford (as defined in note 32(iii)) to repurchase the 51% equity interest in Guangdong Victory owned by the Group at a consideration of RMB146,800,000 and the capital contribution made by the Group (if any), if the annual sales revenue of Guangdong Victory fails to reach RMB120,000,000 and Guangdong Victory fails to obtain the production permits of certain medical products for the year ending 31 December 2020.

The option is exercisable as at the date immediately after 31 December 2020. The option is measured at fair value estimated by an independent valuer by using the Binomial Option Pricing Model. The key inputs into the model for the value of the option are as follows:

	2016 Put option	2015 Put option
Strike (RMB'000)	188,740	199,560
Maturity (year)	4	5
Risk free rate (%)	40.60	2.35
Volatility (%)	37.8	41.9

In assessing the fair value of the put option, the Binomial Option Pricing Model was used. This model is one of the generally accepted methodologies used to calculate the fair value of the put option. It requires the input of subjective assumptions. Any changes in these assumptions can significantly affect the estimate of the fair value of the put option.

19. Financial Asset at Fair Value Through Profit or Loss (Continued)

The summary of significant unobservable inputs to the valuation of financial instruments and a quantitative sensitivity analysis are as follows:

As at 31 December 2016

	Valuation technique	Significant unobservable input	Range	Sensitivity of fair value to the input
Put option	Binomial Option Pricing Model	Risk free rate	-2% to 2%	2% increase/decrease in growth rate would result in decrease in fair value by RMB2,188,000/increase in fair value by RMB1,975,000
		Long term operating margin	-10% to 10%	10% increase/decrease in operating margin would result in increase in fair value by RMB1,820,000/decrease in fair value by RMB1,676,000

As at 31 December 2015

	Valuation technique	Significant unobservable input	Range	Sensitivity of fair value to the input
Put option	Binomial Option Pricing Model	Risk free rate	-1% to 1%	1% increase/(decrease) in growth rate would result in decrease/(increase) in fair value by RMB15,000
		Long term operating margin	-10% to 10%	10% increase/(decrease) in operating margin would result in increase/(decrease) in fair value by RMB31,000

20. Inventories

	2016 RMB'000	2015 RMB'000
Raw materials	60,926	65,935
Work in progress	254,111	130,854
Finished goods	479,808	725,169
	794,845	921,958

21. Trade and Bills Receivables

	2016 RMB'000	2015 RMB'000
Trade receivables	197,328	185,575
Bills receivable	45,094	17,309
Due from a related company	2,730	2,356
	245,152	205,240
Impairment	(29,932)	(23,336)
	215,220	181,904

The Group's trading terms with its customers are mainly on credit. The credit period is generally for a period of one month, extending up to three months for certain customers. The Group seeks to maintain strict control over its outstanding receivables and has a credit policy to minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group has provided impairment loss on trade and bills receivables based on past experience of collecting payments. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade and bills receivables are non-interest-bearing.

An ageing analysis of the trade and bills receivables as at the end of the reporting period, based on the invoice date and net of provision, is as follows:

	2016 RMB'000	2015 RMB'000
Within 3 months	160,296	170,640
3 to 4 months	40,054	3,744
Over 4 months	14,870	7,520
	215,220	181,904

The movements in provision for impairment of trade and bills receivables are as follows:

	2016 RMB'000	2015 RMB'000
At 1 January	23,336	18,489
Impairment losses recognised (note 6)	6,596	4,847
At 31 December	29,932	23,336

21. Trade and Bills Receivables (continued)

Included in the above provision for impairment of trade and bills receivables is a provision for individually impaired trade and bills receivables of RMB29,932,000 (2015: RMB23,336,000) with a carrying amount before provision of RMB33,719,000 (2015: RMB31,077,000).

The individually impaired trade and bills receivables relate to customers that were in financial difficulties or were in default in principal payments and only a portion of the receivables is expected to be recovered.

The ageing analysis of the trade and bills receivables that are not considered to be impaired is as follows:

	2016 RMB'000	2015 RMB'000
Neither past due nor impaired	125,081	161,789
Less than 1 month past due	35,336	4,486
1 to 2 months past due	40,055	3,375
2 to 4 months past due	10,961	4,513
	211,433	174,163

Receivables that were neither past due nor impaired relate to a large number of diversified customers for whom there was no recent history of default.

Receivables that were past due but not impaired relate to a number of independent customers that have a good track record with the Group. Based on past experience, the directors of the Company are of the opinion that no provision for impairment is necessary in respect of these balances as there has not been a significant change in credit quality and the balances are still considered fully recoverable.

Due from a related company:

	At 31 December 2016 RMB'000	Maximum amount outstanding during 2016 RMB'000	At 31 December 2015 and 1 January 2016 RMB'000	Maximum amount outstanding during 2015 RMB'000	At 1 January 2015 RMB'000
LJK Frozen SDN. BHD. ("LJK") (note)	2,730	2,730	2,356	5,371	5,371

Note:

LJK is controlled by Dato' Sri Low Jee Keong, a director of the Company. The amount due from LJK is unsecured, non-interest-bearing and has a repayment term of 45 days, which is on terms similar to those offered to other major customers of the Group.

22. Prepayments, Deposits and Other Receivables

	2016 RMB'000	2015 RMB'000
Prepayments	18,251	20,720
Deposits and other receivables	97,515	171,200
	115,766	191,920

None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default.

23. Cash and Cash Equivalents and Pledged Deposits

	2016 RMB'000	2015 RMB'000
Cash and bank balances	119,016	97,281
Time deposits	456,000	468,230
	575,016	565,511
Less: Pledged time deposits for short term bank loans (<i>note 26(b)</i>)	(456,000)	(354,727)
Cash and cash equivalents	119,016	210,784

At the end of the reporting period, the cash and bank balances (including time deposits) of the Group denominated in RMB amounted to RMB552,089,000 (2015: RMB531,592,000). The RMB is not freely convertible into other currencies, however, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Short term time deposits are made for varying periods of between one day and three months depending on the immediate cash requirements of the Group, and earn interest at the respective short term time deposit rates. The bank balances and time deposits are deposited with creditworthy banks with no recent history of default.

24. Trade and Bills Payables

An ageing analysis of the trade and bills payables as at the end of the reporting period, based on the invoice date, is as follows:

	2016 RMB'000	2015 RMB'000
Within 1 month	29,575	32,411
1 to 2 months	4,886	2,090
2 to 3 months	9,642	1,016
Over 3 months	21,232	7,209
	65,335	42,726

The trade and bills payables are non-interest-bearing and are normally settled on terms of range from 60 days to 180 days.

25. Other Payables and Accruals

	2016 RMB'000	2015 RMB'000
Advances from customers	4,389	9,341
Accruals	15,273	14,766
Other payables	84,446	89,960
	104,108	114,067

Other payables are non-trade, unsecured and non-interest-bearing and are normally settled on terms of 60 days.

26. Interest-Bearing Bank and Other Borrowings

	2016			2015		
	Effective interest rate (%)	Maturity	RMB'000	Effective interest rate (%)	Maturity	RMB'000
Current						
Bank loan - secured	HIBOR + 1	On demand	43,563	HIBOR + 1	On demand	322,545
Bank loan - secured	4.75	On demand	90,000	-	-	-
Bank loans - unsecured	3.97-4.35	2017	130,000	4.60-5.60	2016	222,000
Discounted bills with recourse	2.95-3.10	2017	80,000	-	-	-
			343,563			544,545

26. Interest-Bearing Bank and Other Borrowings (Continued)

	2016 RMB'000	2015 RMB'000
Analysed into:		
Within one year or on demand	343,563	544,545

Notes:

- (a) Except for the secured bank loan amounting to RMB43,563,000 (2015: RMB322,545,000) which was denominated in HK\$, all of the Group's bank borrowings were denominated in RMB as at 31 December 2016.
- (b) As at 31 December 2016, time deposits of RMB456,000,000 (2015: RMB354,727,000) were pledged to secure bank borrowings of RMB133,563,000 (2015: RMB322,545,000) and discounted bills with recourse of RMB80,000,000 (2015: Nil).
- (c) As at 31 December 2016, a discounted bill with recourse amounting to RMB60,000,000 is secured by personal guarantees provided by Ms. Zhou Yaxian, controlling shareholders of the Company, and Mr. Sha Shuming, the spouse of Ms. Zhou Yaxian.
- (d) As at 31 December 2016, the Group's bank loans of RMB300,000,000 (2015: RMB222,000,000) were at fixed rates.

27. Deferred Tax

The movements in deferred tax assets and liabilities during the year are as follows:

Deferred tax assets

	Deferred government grants RMB'000	Depreciation in excess of related depreciation allowance RMB'000	Accrued salary RMB'000	Impairment provision against trade receivables RMB'000	Impairment provision against inventories RMB'000	Unrealised profits arising from intra-group transactions RMB'000	Total RMB'000
At 1 January 2015	5,302	1,292	3,487	2,774	–	39,271	52,126
Acquisition of subsidiaries (note 32)	–	–	–	997	–	–	997
Deferred tax credited/ (charged) to profit or loss during the year (note 10)	(402)	104	(1,329)	916	–	3,914	3,203
At 31 December 2015 and 1 January 2016	4,900	1,396	2,158	4,687	–	43,185	56,326
Deferred tax credited/(charged) to profit or loss during the year (note 10)	(403)	(179)	(247)	2,091	616	(15,231)	(13,353)
At 31 December 2016	4,497	1,217	1,911	6,778	616	27,954	42,973

27. Deferred Tax (continued)

Deferred tax liabilities

	Depreciation in excess of related depreciation allowance <i>RMB'000</i>	Fair value adjustments arising from acquisition of subsidiaries <i>RMB'000</i>	Withholding tax <i>RMB'000</i>	Total <i>RMB'000</i>
At 1 January 2015	–	–	29,571	29,571
Acquisition of subsidiaries (<i>note 32</i>)	–	66,264	–	66,264
Deferred tax charged/(credited) to profit or loss during the year (<i>note 10</i>)	275	(3,984)	(12,614)	(16,323)
Exchange difference	11	–	–	11
At 31 December 2015 and 1 January 2016	286	62,280	16,957	79,523
Deferred tax credited to profit or loss during the year (<i>note 10</i>)	–	(13,037)	(4,851)	(17,888)
Exchange difference	20	–	–	20
At 31 December 2016	306	49,243	12,106	61,655

The Group has tax losses arising in Hong Kong of HK\$22,043,000 (2015: HK\$17,673,000), which was equivalent to RMB18,864,000 (2015: RMB14,199,000) and subject to the confirmation of tax losses from the Hong Kong Inland Revenue Department, that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose. Deferred tax assets have not been recognised in respect of these losses as it is not considered probable that taxable profits will be available against which the tax losses can be utilised.

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Mainland China. The requirement became effective from 1 January 2008 and applies to earnings after 31 December 2007. A lower withholding tax rate may be applied if there is a tax treaty between Mainland China and the jurisdiction of the foreign investors. For the Group, the applicable rate is 10%. The Group is therefore liable for withholding taxes on dividends distributed by those subsidiaries established in Mainland China in respect of earnings generated from 1 January 2008.

The aggregate amount of temporary differences associated with investments in subsidiaries in Mainland China for which deferred tax liabilities have not been recognised totalled approximately RMB2,159,009,000 (2015: RMB1,916,186,000) at 31 December 2016. In the opinion of the directors, it is not probable that these subsidiaries will distribute these unremitted earnings that are subject to withholding taxes in the foreseeable future.

There are no income tax consequences attaching to the payment of dividends by the Company to its shareholders.

28. Share Capital

	2016 HK\$'000	2015 HK\$'000
Authorised: 20,000,000,000 ordinary shares of HK\$0.01 each	200,000	200,000
Issued and fully paid: 3,259,276,000 (2015: 3,268,276,000) ordinary shares of HK\$0.01 each	32,593	32,683
Equivalent to RMB'000	28,060	28,135

A summary of movements in the Company's issued share capital is as follows:

	Number of issued and fully paid ordinary shares	Nominal value of ordinary shares HK\$'000	Share premium HK\$'000	Equivalent nominal value of ordinary shares RMB'000	Equivalent share premium RMB'000	Equivalent total RMB'000
1 January 2015	3,304,016,000	33,041	652,227	28,425	635,828	664,253
Cancellation of share repurchased (note 30(iv))	(37,100,000)	(371)	(54,364)	(301)	(43,732)	(44,033)
Share options exercised (note 29)	1,360,000	13	4,017	11	3,210	3,221
Final 2014 dividend	-	-	(134,904)	-	(106,307)	(106,307)
At 31 December 2015 and 1 January 2016	3,268,276,000	32,683	466,976	28,135	488,999	517,134
Cancellation of share repurchased (note 30(iv))	(9,000,000)	(90)	(9,193)	(75)	(7,668)	(7,743)
Final 2015 dividend	-	-	(104,297)	-	(88,211)	(88,211)
At 31 December 2016	3,259,276,000	32,593	353,486	28,060	393,120	421,180

29. Share Option Scheme

In order to attract and retain the eligible persons, to provide additional incentive to them and to promote the success of the business of the Group, the Company conditionally adopted a share option scheme (the "Scheme") on 19 September 2009 whereby the board of directors (the "Board") is authorised, at its absolute discretion and subject to the terms of the Scheme, to grant options to subscribe the shares of the Company (the "Shares") to, inter alia, any employees (full-time or part-time), directors, consultants and advisors or any substantial shareholder, distributors, contractors, suppliers, agents, customers, business partners or service providers of the Group. The Scheme became unconditional on 13 October 2009 and shall be valid and effective for a period of ten years commencing on 19 September 2009, subject to the early termination provisions contained in the Scheme.

The Company shall be entitled to issue options, provided that the total number of shares which may be issued upon exercise of all options to be granted under the Scheme does not exceed 10% of the Shares in issue on the Listing Date. The Company may at any time refresh this limit, subject to the shareholders' approval and issue of a circular in compliance with the Listing Rules, provided that the total number of shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under all the share option schemes of the Company does not exceed 30% of the shares in issue at the time.

The total number of shares issued and to be issued upon exercise of options granted to any grantee (including both exercised and outstanding options) under the Scheme, in any 12-month period up to the date of grant shall not exceed 1% of the Shares in issue.

Share options granted to a director, chief executive or substantial shareholder of the Company, or to any of their associates, are subject to approval in advance by the independent non-executive directors. In addition, any share options granted to a substantial shareholder or an independent non-executive director of the Company, or to any of their associates, in excess of 0.1% of the shares of the Company in issue at any time or with an aggregate value (based on the price of the Company's shares at the date of grant) in excess of HK\$5 million, within any 12-month period, are subject to shareholders' approval in advance in a general meeting.

The offer of a grant of share options may be accepted within seven days from the date of offer, upon payment of a nominal consideration of HK\$1 in total by the grantee. An option may be exercised in accordance with the terms of the Scheme at any time during a period as the Board may determine which shall not exceed ten years from the date of grant subject to the provisions of early termination thereof.

The exercise price of share options is determinable by the directors, but may not be less than the higher of (i) the closing price of the Shares as stated in The Stock Exchange's daily quotation sheet on the date of grant of the option; (ii) the average of the closing prices of the Shares as stated in The Stock Exchange's daily quotation sheets for the five business days immediately preceding the date of grant of the option; and (iii) the nominal value of a Share on the date of grant of the option provided always that for the purpose of calculating the subscription price, where the Company has been listed on The Stock Exchange for less than five business days, the issue price shall be used as the closing price for any trading day fall within the period before the date of listing of the Company's Shares.

29. Share Option Scheme (Continued)

Share options do not confer rights on the holders to dividends or to vote at shareholders' meetings.

The following share options were outstanding under the Scheme for the year ended in 31 December 2015:

	2015 Weighted average exercise price <i>HK\$ per share</i>	Number of options <i>'000</i>
At 1 January	2.165	7,880
Exercised during the year	2.165	(1,360)
Expired during the year	2.165	(6,520)
At 31 December	–	–

The weighted average share price at the date of exercise for share options exercised during the year ended 31 December 2015 was HK\$2.46 per share.

The exercise price and exercise period of the share options outstanding as at the end of the prior reporting period are as follows:

2015	Number of options <i>'000</i>	Exercise price* <i>HK\$ per share</i>	Exercise period
	–	2.165	13 October 2010–12 October 2015

* *The exercise price of the share options was subject to adjustment in the case of rights or bonus issues, or other similar changes in the Company's share capital.*

The fair value of equity-settled share options granted in 2009 was estimated as at the date of grant, using a binomial model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs to the model used:

Dividend yield (%)	–
Expected volatility (%)	36.955
Risk-free interest rate (%)	1.911
Expected life of options (year)	5.14–5.90
Weighted average share price (HK\$ per share)	2.165

The expected life of the options was based on management's expectation and was not necessarily indicative of the exercise patterns that may occur. The expected volatility which was based on the volatility computed from comparable companies reflected the assumption that the volatility of comparable companies was indicative of future trends, which may also not necessarily be the actual outcome.

29. Share Option Scheme (Continued)

No other feature of the options granted was incorporated into the measurement of fair value.

The 1,360,000 share options exercised during the year ended 31 December 2015 resulted in the issue of 1,360,000 ordinary shares of the Company and new share capital of HK\$13,000 (RMB11,000) and share premium of HK\$4,017,000 (RMB3,210,000) (before issue expenses).

At the date of approval of these financial statements, the Company had no share options outstanding under the Scheme.

30. Reserves

The amounts of the Group's reserves and the movements therein for the current and prior years are presented in the consolidated statement of changes in equity.

(i) Contributed surplus

The Group's contributed surplus represents the excess of the nominal value of the shares of the subsidiaries acquired pursuant to the reorganisation in 2009 over the nominal value of the Company's shares issued in exchange therefor.

(ii) Reserve funds

In accordance with the Law of the PRC for Enterprise with Foreign Investments and the articles of association of subsidiaries of the Group established in the PRC, appropriations from net profits, after offsetting accumulated losses brought forward from prior years, should be made to the reserve funds before distributions are made to the owners. The percentage of net profits to be appropriated to the reserve funds should not be less than 10% of the net profits. When the balance of the reserve funds reaches 50% of the paid-up capital, no further appropriations are required to be made. Upon approval obtained from the board of directors, the reserve funds can be used to offset accumulated deficits or to increase the registered capital.

(iii) Other reserves

Other reserves represent: (1) the aggregate of the difference between consideration paid for acquisition of an equity interest in subsidiaries and the carrying value of non-controlling interests, and the difference arising from deemed disposal of equity interests to non-controlling shareholders; and (2) waiver of amounts due to related parties.

(iv) Treasury shares

During the year ended 31 December 2016, the Company repurchased its own ordinary shares of 2,000,000 (2015: 32,000,000) on the Stock Exchange at an aggregate consideration of HK\$1,917,000 equivalent to RMB1,624,000 (2015: HK\$36,280,000 equivalent to RMB29,770,000) and together with the 7,000,000 (2015: 12,100,000) repurchased shares which were held as treasury shares as at 31 December 2015, 9,000,000 (2015: 37,100,000) ordinary shares were then cancelled by the Company. Upon the cancellation of the 9,000,000 (2015: 37,100,000) shares repurchased, the issued share capital of the Company was reduced by the par value of HK\$90,000 equivalent to RMB75,000 (2015: HK\$371,000 equivalent to RMB301,000) and the premium paid on the repurchase of these cancelled shares of HK\$9,193,000 equivalent to RMB7,668,000 (2015: HK\$54,364,000 equivalent to RMB43,732,000), including transaction costs, was deducted from share premium of the Company. As at 31 December 2016, there were no ordinary shares repurchased but not yet cancelled by the Company.

31. Partly-Owned Subsidiary with Material Non-Controlling Interests

Details of the Group's subsidiary that have material non-controlling interests are set out below:

	2016	2015
Percentage of equity interest held by non-controlling interests of Guangdong Victory	49%	49%

	2016 RMB'000	2015 RMB'000
Loss for the year allocated to non-controlling interests of Guangdong Victory	(20,130)	(5,448)
Dividends paid to non-controlling interests of Guangdong Victory	–	–
Accumulated balances of non-controlling interests at the reporting date of Guangdong Victory	71,767	89,553

The following tables illustrate the summarised financial information of the above subsidiary. The amounts disclosed are before any inter-company eliminations:

	2016 RMB'000	2015 RMB'000
Revenue	225	376
Total expenses	(41,295)	(11,494)
Loss for the year	(41,070)	(11,118)
Total comprehensive income for the year	(41,070)	(11,118)
Current assets	5,409	5,101
Non-current assets	189,697	240,567
Current liabilities	(683)	(2,820)
Non-current liabilities	(47,066)	(59,766)
Net cash flows from/(used in) operating activities	(2,025)	407
Net cash flows used in investing activities	(184)	(312)
Net cash flows from financing activities	5,344	–
Net increase in cash and cash equivalents	3,135	95

32. Business Combination

The fair values of the identifiable assets and liabilities of the subsidiaries as at the dates of acquisition were as follows:

	Sanjian Pharmaceutical RMB'000 (note (i))	Nanning Nuyou RMB'000 (note (ii))	Guangdong Victory RMB'000 (note (iii))	Total RMB'000
Property, plant and equipment	9,703	1	1,461	11,165
Prepaid land lease payments	3,694	–	–	3,694
Intangible assets	4,542	–	253,986	258,528
Deferred tax assets	902	–	95	997
Cash and cash equivalents	17,005	1	48	17,054
Trade and bills receivables	6,463	282	9	6,754
Prepayments, deposits and other receivables	12,191	16	4,542	16,749
Inventories	8,008	60	–	8,068
Trade payables	(5,318)	(96)	–	(5,414)
Bank borrowings	(19,000)	–	–	(19,000)
Other payables and accruals	(30,551)	(534)	(2,445)	(33,530)
Tax payable	(62)	(34)	–	(96)
Deferred tax liabilities	(2,767)	–	(63,497)	(66,264)
Non-controlling interests	–	–	(95,158)	(95,158)
Net identifiable assets and liabilities	4,810	(304)	99,041	103,547
Goodwill	–	1,804	47,486	49,290
Contingent consideration – financial asset at fair value through profit or loss	–	–	353	353
	4,810	1,500	146,880	153,190
Satisfied by:				
Cash	4,810	1,500	126,880	133,190
Consideration payable	–	–	20,000	20,000
	4,810	1,500	146,880	153,190

32. Business Combination (Continued)

An analysis of net cash inflow/(outflow) of cash and cash equivalents in respect of the acquisition of the subsidiaries is as follows:

	Sanjian Pharmaceutical RMB'000	Nanning Nuyou RMB'000	Guangdong Victory RMB'000	Total RMB'000
Cash consideration	(4,810)	(1,500)	(126,880)	(133,190)
Cash and bank balances acquired	17,005	1	48	17,054
Net inflow/(outflow) of cash and cash equivalents in respect of the acquisition	12,195	(1,499)	(126,832)	(116,136)
Revenue for the period ended 31 December 2015 since acquisition	15,192	5	376	15,573
Profit/(loss) for the period ended 31 December 2015 since acquisition	(60)	(219)	74	(205)
Transaction costs involved	68	10	263	341

Had the above business combinations taken place at the beginning of the year ended 31 December 2015, the Group's profit for the year ended 31 December 2015 would have been RMB285,012,000 and the Group's revenue would have been RMB1,060,725,000.

32. Business Combination (Continued)

Notes:

(i) Acquisition of Sanjian Pharmaceutical

On 26 January 2015, Wuzhou Shenguan entered into an equity transfer agreement with Mr. Sha Shuming ("Mr. Sha"), the spouse of Ms. Zhou Yaxian, pursuant to which Mr. Sha agreed to sell and Wuzhou Shenguan agreed to purchase the entire equity interest in Sanjian Pharmaceutical at a cash consideration of RMB4,810,000. The acquisition was completed on 16 March 2015 which was made as part of the Group's strategy to diversify and expand the existing businesses of the Group and create a new revenue stream.

Details of the acquisition are set out in the Company's announcement dated 26 January 2015.

(ii) Acquisition of Nanning Nuyou

On 11 May 2015, Shenguan Investment Development, a subsidiary of the Group, contributed capital of RMB5,000,000 to establish a wholly-owned subsidiary, Guangxi Luxianna Biotechnology Co., Ltd. ("Luxianna"), in Nanning, Guangxi. On 21 May 2015, Luxianna entered into an equity transfer agreement with an independent third party, Ms. Wu Zhiling ("Ms. Wu"), pursuant to which Ms. Wu agrees to sell and Luxianna agrees to acquire the entire equity interest in Nanning Nuyou at a cash consideration of RMB1,500,000. The transaction has been completed on 9 July 2015.

(iii) Acquisition of Guangdong Victory

On 20 July 2015, Shenguan Investment Development entered into an equity transfer agreement ("Guangdong Victory Agreement") with Enneford Industrial Limited ("Enneford"), an independent third party incorporated in Hong Kong with limited liability, pursuant to which Shenguan Investment Development agreed to acquire and Enneford agreed to sell 51% equity interests in Guangdong Victory at a cash consideration of RMB146,880,000. The transaction has been completed on 21 August 2015. The acquisition was made as part of the Group's strategy to seek suitable investment opportunities with a view to increasing the Company's shareholders value and broaden its income source alongside with developing its existing business.

Details of the acquisition are set out in the Company's announcement dated 20 July 2015.

33. Contingent Liabilities

At the end of the reporting period, the Group did not have any significant contingent liabilities.

34. Pledge of Assets

Details of the bank borrowings, which are secured by the assets of the Group, are included in notes 23 and 26 to the financial statements.

35. Operating Lease Arrangements

(a) As lessor

The Group leases its investment properties (note 14 to the financial statements) under operating lease arrangements, with leases negotiated for terms of five years. The terms of the leases generally also require the tenant to pay security deposits and provide for periodic rent adjustments according to the then prevailing market conditions.

At the end of reporting period, the Group had total future minimum lease receivables under non-cancellable operating leases falling due as follows:

	2016 RMB'000	2015 RMB'000
Within one year	308	–
In the second to fifth years, inclusive	1,050	–
	1,358	–

(b) As lessee

The Group leases its office and production premises under operating lease arrangements, with leases negotiated for terms ranging for 1 to 10 years.

At the end of reporting period, the Group had total future minimum lease payments under non-cancellable operating leases falling due as follows:

	2016 RMB'000	2015 RMB'000
Within one year	2,966	558
In the second to fifth years, inclusive	10,118	637
More than five years	11,967	–
	25,051	1,195

36. Commitments

In addition to the operating lease commitments detailed in note 35(b) above, the Group had the following capital commitments at the end of the reporting period:

	2016 RMB'000	2015 RMB'000
Contracted, but not provided for:		
Buildings	103,377	109,491
Plant and machinery	11,426	12,046
	114,803	121,537

37. Related Party Disclosures

(a) In addition to those transactions detailed elsewhere in these financial statements, the Group had the following material transactions with related parties during the year:

	<i>Notes</i>	2016 RMB'000	2015 RMB'000
Company controlled by a director of the Company:			
Continuing connected transactions:			
Sales of products	<i>(i)</i>	2,626	2,356
Purchases of cattle hides	<i>(ii)</i>	47,855	6,942
Rent of production premises	<i>(ii)</i>	1,017	–
Administrative support and liaising services	<i>(ii)</i>	48	–
Connected transaction:			
Acquisition of an available-for-sale investment	<i>(iii)</i>	–	31,100
Companies controlled by spouse of a director of the Company:			
Continuing connected transactions:			
Purchases of packing materials	<i>(ii)</i>	14,463	23,577
Spouse of a director of the Company:			
Connected transaction:			
Acquisition of Sanjian Pharmaceutical	<i>(iv)</i>	–	4,810

Notes:

- (i) The sales were made according to the prices and conditions offered to major customers of the Group.
- (ii) These transactions were based on terms mutually agreed between the parties.

37. Related Party Disclosures (Continued)

(a) (continued)

Notes: (continued)

- (iii) On 6 August 2015, the Group entered into a sale and purchase agreement (“the Ferguson Agreement”) with an independent third party, Nanning Zhe Yuan Tang Business Limited (“Nanning Zhe Yuan”), pursuant to which Nanning Zhe Yuan agreed to sell and the Group agreed to purchase a 15% equity interest in Ferguson (Wuhan) Biotechnologies Limited (“Ferguson”) at a cash consideration of RMB31.1 million. On the same date of the Ferguson Agreement, Gobitech Limited, an independent third party and 85% equity shareholder of Ferguson, entered into two separate equity transfer agreements with Guangxi Guan Yu Property Limited (“Guangxi Guan Yu”) and Guangxi Shenguan Investment Limited (“Guangxi Investment”), companies controlled by certain directors of the Company, to transfer as to 20% and 45% of its equity interests in Ferguson to Guangxi Guan Yu and Guangxi Shenguan, respectively. Upon completion of the acquisition on 31 August 2015, the acquired 15% equity interest in Ferguson was accounted for an available-for-sale investment as set out in note 18 to the financial statements.

Details of the acquisition are set out in the Company’s announcement dated 6 August 2015.

- (iv) On 26 January 2015, the Group entered into an equity transfer agreement with Mr. Sha, the spouse of Ms. Zhou Yaxian, pursuant to which Mr. Sha agreed to sell and Wuzhou Shenguan agreed to purchase the entire equity interest in Sanjian Pharmaceutical at a cash consideration of RMB4,810,000. Details of the transaction are set out in note 32(i).

(b) Balances with related parties

Balances with related parties are detailed in note 21 to these financial statements.

(c) Compensation of key management personnel

	2016 RMB'000	2015 RMB'000
Fees	332	316
Salaries, allowances and benefits in kind	10,136	4,187
Discretionary performance-related bonuses	3,000	4,502
Retirement benefit contributions	27	26
Total compensation paid to key management personnel	13,495	9,031

Further details of directors’ emoluments are included in note 8 to these financial statements.

The related party transactions in respect of item (a) above also constitute connected transactions or continuing connected transactions as defined in Chapter 14A of the Listing Rules.

38. Financial Instruments by Category

All financial assets and liabilities of the Group as at 31 December 2016 and 2015, except for an available-for-sale investment which is stated at cost less impairment loss and the put option which is a financial asset at fair value through profit or loss, were loans and receivables, and financial liabilities stated at amortised cost, respectively.

39. Transfer of Financial Assets

Transferred financial assets that are not derecognised in their entirety

At 31 December 2016, the Group endorsed certain bills receivable accepted by banks in Mainland China to certain of its suppliers in order to settle the trade payables due to such suppliers. In the opinion of the directors, the Group has retained the substantial risks and rewards, which include default risks of certain issuing banks after the endorsement, and accordingly, the Group continued to recognise the full carrying amounts of the endorsed bills receivable from such issuing banks (the "Endorsed Bills") and the associated trade payables settled. Subsequent to the endorsement, the Group did not retain any rights on the use of the Endorsed Bills, including the sale, transfer or pledge of the Endorsed Bills to any other third parties. As at 31 December 2016, the aggregate carrying amounts of the Endorsed Bills were RMB30,490,000 (2015: RMB2,978,000).

Transferred financial assets that are derecognised in their entirety

At 31 December 2016, the Group endorsed certain bills receivable accepted by banks in Mainland China to certain of its suppliers in order to settle the trade payables due to such suppliers, which had a maturity of one to six months at the end of the reporting period. In accordance with the Law of Negotiable Instruments in the PRC, the holders of these bills receivables have a right of recourse against the Group if the PRC banks default (the "Continuing Involvement"). These bills receivables were honoured by reputable banks in the PRC rating at AAA by national credit rating agencies. In the opinion of the directors, these banks have good reputation and credit quality, and the risk of default of these bills receivables (the "Derecognised Bills") on maturity is remote, and therefore, the Group has transferred substantially all risks and rewards relating to the Derecognised Bills since after the transfer the Group's exposure to the variability in the amounts of the net cash flows of the transferred asset is not significant. Accordingly, it has derecognised the full carrying amounts of the Derecognised Bills and the associated trade payables. The maximum exposure to loss from the Group's Continuing Involvement in the Derecognised Bills and the undiscounted cash flows to repurchase these Derecognised Bills is equal to their carrying amounts. In the opinion of the directors, the fair values of the Group's Continuing Involvement in the Derecognised Bills are not significant. As at 31 December 2016, the aggregate carrying amount of the Derecognised Bills were RMB1,151,000 (2015: 12,250,000).

During the year ended 31 December 2016, the Group has not recognised any gain or loss on the date of transfer of the Derecognised Bills. No gains or losses were recognised from the Continuing Involvement, both during the year or cumulatively. The endorsement has been made evenly throughout the year.

40. Fair Value and Fair Value Hierarchy of Financial Instruments

Management has assessed that the fair values of cash and cash equivalents, pledged deposits, trade and bills receivables, trade and bills payables, financial assets included in prepayments, deposits and other receivables, financial liabilities included in other payables and accruals, and the current portion of interest-bearing bank borrowings approximate to their carrying amounts largely due to the short term maturities of these instruments.

The Group's finance department headed by the finance controller is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance controller reports directly to the audit committee. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the financial controller. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instrument:

Asset measured at fair value:

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
<i>As at 31 December 2016</i>				
Financial asset at fair value through profit or loss	–	–	18,078	18,078
<i>As at 31 December 2015</i>				
Financial asset at fair value through profit or loss	–	–	353	353

40. Fair Value and Fair Value Hierarchy of Financial Instruments (Continued)

Fair value hierarchy (Continued)

The Group did not have any financial liabilities measured at fair value as at 31 December 2016 and 2015.

During the year, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (2015: Nil).

41. Financial Risk Management Objectives and Policies

The Group's principal financial instruments comprise pledged deposits, cash and cash equivalents, and interest-bearing bank borrowings. The main purpose of these financial instruments is to raise finance for the Group's operations. The Group has various other financial assets and liabilities such as trade and bills receivables and trade and bills payables, which arise directly from its operations.

The main risks arising from the Group's financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk. The directors review and agree policies for managing each of these risks and they are summarised below.

Interest rate risk

Interest rate risk means the risk on the fluctuation of fair value on future cash flows of financial instruments which arose from changes in interest rates. Floating interest rate instruments will result in the Group facing the risk of changes in market interest rates, and fixed interest rate instruments will result in the Group facing fair value interest rate risk.

The Group's income and operating cash flows are substantially independent of changes in market interest rates. The Group has no significant interest-bearing assets. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's long term debt obligations. The Group has not used any interest rate swaps to hedge its exposure to interest rate risk.

At 31 December 2016, it was estimated that if interest rates at those dates had been 100 (2015: 100) basis points higher/lower, with all other variables held constant, there would have been a decrease/increase of RMB435,000 (2015: RMB3,225,000) in the Group's profit before tax and a decrease/increase of RMB435,000 (2015: RMB3,225,000) in the Group's equity for the year ended 31 December 2016 (through the impact on floating rate borrowings).

41. Financial Risk Management Objectives and Policies (continued)

Foreign currency risk

Foreign currency risk means the risk on the fluctuation of fair value or future cash flows of financial instruments which arose from changes in exchange rates.

The Group's businesses are mainly located in the PRC and are mainly transacted and settled in RMB. Accordingly, the directors considered that the Group's foreign currency exchange risk is insignificant. Certain sales and purchases were settled in other currencies including US\$. The Group also had bank borrowings denominated in HK\$ in 2016. The fluctuation of the exchange rates of these currencies against RMB will affect the Group's results of operations.

Substantially all of the Group's turnover and substantially all of the Group's operating expenses are denominated in RMB, which is currently not a freely convertible currency. The PRC Government imposes controls on the convertibility of RMB into foreign currencies and, in certain cases, the remittance of currency out of China. Shortages in the availability of foreign currencies may restrict the ability of the Group's PRC subsidiaries to remit sufficient foreign currencies to pay dividends or other amounts to the Group.

Under existing PRC foreign exchange regulations, payments of current account items, including dividends, trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval from the State Administration for Foreign Exchange by complying with certain procedural requirements. However, approval from appropriate PRC Government authorities is required where RMB is to be converted into foreign currencies and remitted out of China to pay capital account items, such as the repayment of bank loans denominated in foreign currencies.

Currently, the Group's PRC subsidiaries may purchase foreign exchange for settlement of current account transactions, including payment of dividends to the shareholders of the PRC subsidiaries, with the prior approval of the State Administration for Foreign Exchange. The Group's PRC subsidiaries may also retain foreign exchange in their current accounts to satisfy foreign exchange liabilities or to pay dividends. Since foreign exchange transactions on the capital account are still subject to limitations and require approval from the State Administration for Foreign Exchange, this could affect the Group's subsidiaries' ability to obtain the required foreign currency amounts through debt or equity financing, including by means of loans or capital contributions from the Company.

There are limited hedging instruments available in the PRC to reduce the Group's exposure to exchange rate fluctuations between RMB and other currencies. To date, the Group has not entered into any hedging transactions to reduce the Group's exposure to foreign currency risk resulting from trade and bills receivables denominated in US\$ and bank borrowings denominated in HK\$. While the Group may decide to enter into other hedging transactions in the future, the availability and effectiveness of these hedges may be limited and the Group may not be able to hedge the Group's exposure successfully, or at all.

A reasonably possible increase/decrease of 5% in the exchange rate of US\$ against RMB or HK\$ against RMB would have decreased/increased the Group's profit before tax by RMB12,330,000 (2015: RMB4,174,000) and decreased/increased the Group's equity by RMB997,000 (2015: RMB13,751,000) during the year ended 31 December 2016.

41. Financial Risk Management Objectives and Policies (Continued)

Credit risk

The Group trades only with recognised and creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and the Group's exposure to bad debts is not significant.

The credit risk of the Group's other financial assets, which mainly comprise cash and cash equivalents, and other receivables, arises from default of the counterparty, with a maximum exposure equal to the carrying amounts of these instruments.

Since the Group trades only with recognised and creditworthy third parties, there is no requirement for collateral. There are no significant concentrations of credit risk within the Group as the Group's trade and bills receivables are widely dispersed in different customers.

Further quantitative data in respect of the Group's exposure to credit risk arising from trade and bills receivables are disclosed in note 21 to the financial statements.

Liquidity risk

Liquidity risk means the risk that an enterprise may encounter difficulties to obtain adequate finance to repay the debt related to financial instruments. Liquidity risk may arise from the inability to dispose of financial assets promptly, counterparties being unable to repay their contracted debt obligations, the repayment of debts before the maturity dates of debt obligations, or the inability to generate the expected cash flows.

In the management of the liquidity risk, the Group monitors and maintains a level of cash and cash equivalents deemed adequate by the management to finance the Group's operations and mitigate the effects of fluctuations in cash flows. The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of bank loans. In the opinion of the directors of the Company, the Group expects to have adequate sources of funding to finance the Group and manage the liquidity position.

41. Financial Risk Management Objectives and Policies (continued)

Liquidity risk (Continued)

The maturity profile of the Group's financial liabilities as at the end of the reporting period, based on the contractual undiscounted payments, was as follows:

	2016			Total <i>RMB'000</i>
	Within one year or on demand <i>RMB'000</i>	In the second year <i>RMB'000</i>	In the third to fifth years, inclusive <i>RMB'000</i>	
Interest-bearing bank borrowings	271,151	–	–	271,151
Trade payables	65,335	–	–	65,335
Financial liabilities included in other payables and accruals	99,720	–	–	99,720
	436,206	–	–	436,206

	2015			Total <i>RMB'000</i>
	Within one year or on demand <i>RMB'000</i>	In the second year <i>RMB'000</i>	In the third to fifth years, inclusive <i>RMB'000</i>	
Interest-bearing bank borrowings	549,242	–	–	549,242
Trade payables	42,726	–	–	42,726
Financial liabilities included in other payables and accruals	104,726	–	–	104,726
	696,694	–	–	696,694

41. Financial Risk Management Objectives and Policies (Continued)

Capital management

The primary objectives of the Group's capital management are to safeguard the Group's ability to continue as a going concern, to maintain healthy capital ratios in order to support its business and maximise shareholders' value so that it can continue to provide returns for shareholders and benefits for other stakeholders, and to provide an adequate return to shareholders by pricing products and services commensurately with the level of risk.

The Group manages the capital structure and makes adjustments to it in the light of changes in economic conditions. In order to maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made in the objectives, policies or processes for managing capital during the years ended 31 December 2016 and 2015.

The Group monitors capital using a gearing ratio and a debt-to-equity ratio. The gearing ratio is calculated as net debt divided by adjusted capital. Net debt/cash is calculated as total interest-bearing bank borrowings (as shown in the consolidated statement of financial position) less cash and cash equivalents and pledged deposits. Adjusted capital comprises all components of equity attributable to owners of the Company. The Group aims to maintain the gearing ratio at a reasonable level, if any. The debt-to-equity ratio is calculated by dividing the total interest-bearing bank borrowings by the total equity. The gearing ratios and debt-to-equity ratio as at the ends of the reporting periods were as follows:

	2016 RMB'000	2015 RMB'000
Interest-bearing bank borrowings	263,563	544,545
Less: Cash and cash equivalents	(119,016)	(210,784)
Less: Pledged deposits	(456,000)	(354,727)
Net cash	(311,453)	(20,966)
Adjusted capital	2,823,697	2,780,749
Gearing ratio	N/A	N/A
Total equity	2,895,276	2,870,495
Debt-to-equity ratio	9.1%	19.0%

42. Statement of Financial Position of the Company

Information about the statement of financial position of the Company at the end of the reporting period is as follows:

	2016 RMB'000	2015 RMB'000
NON-CURRENT ASSETS		
Investments in subsidiaries	183,956	172,289
CURRENT ASSETS		
Amounts due from subsidiaries	566,746	565,354
Prepayments, deposits and other receivables	85	80
Bank balances	4,518	24,206
Total current assets	571,349	589,640
CURRENT LIABILITIES		
Amounts due to subsidiaries	40,150	37,427
Other payables	450	419
Total current liabilities	40,600	37,846
NET CURRENT ASSETS	530,749	551,794
Net assets	714,705	724,083
EQUITY		
Issued capital	28,060	28,135
Reserves (<i>note</i>)	686,645	695,948
Total equity	714,705	724,083

42. Statement of Financial Position of the Company (Continued)

Note:

A summary of the Company's reserves is as follows:

	Share premium account RMB'000	Treasury shares RMB'000	Contributed surplus RMB'000	Exchange fluctuation reserve RMB'000	Employee share-based compensation reserve RMB'000	Retained profits RMB'000	Total RMB'000
At 1 January 2015	635,828	(20,403)	172,535	(152,829)	5,444	42,863	683,438
Profit for the year	-	-	-	-	-	108,876	108,876
Exchange realignment	-	-	-	41,644	-	-	41,644
Total comprehensive income for the year	-	-	-	41,644	-	108,876	150,520
Share repurchase	-	(29,770)	-	-	-	-	(29,770)
Cancellation of shares repurchased	(43,732)	44,033	-	-	-	-	301
Share option exercised	3,210	-	-	-	(897)	-	2,313
Transfer of share option reserve upon expiry of share option	-	-	-	-	(4,547)	-	(4,547)
Final 2014 dividend	(106,307)	-	-	-	-	-	(106,307)
At 31 December 2015 and 1 January 2016	488,999*	(6,140)*	172,535	(111,185)	-	151,739*	695,948
Profit for the year	-	-	-	-	-	35,451	35,451
Exchange realignment	-	-	-	44,985	-	-	44,985
Total comprehensive income for the year	-	-	-	44,985	-	35,451	80,436
Share repurchase	-	(1,624)	-	-	-	-	(1,624)
Cancellation of shares repurchased	(7,668)	7,764	-	-	-	-	96
Final 2015 dividend	(88,211)	-	-	-	-	-	(88,211)
At 31 December 2016	393,120*	-*	172,535	(66,200)	-	187,190*	686,645

* These reserve accounts comprise the Company's reserves available for distribution amounting to RMB580,310,000 (2015: RMB634,598,000).

The employee share-based compensation reserve comprises the fair value of share options granted which are yet to be exercised, as further explained in the accounting policy for share-based payments in note 2.4 to the financial statements. The amount will either be transferred to the share premium account when the related options are exercised, or be transferred to retained profits should the related options expire or be forfeited after the vesting period.

43. Events after the Reporting Period

On 13 March 2017, the Group entered into an equity transfer agreement with Guangxi Shenguan Investment Limited (“Guangxi Shenguan”), a company controlled by Ms. Zhou Yaxian pursuant to which Guangxi Shenguan agreed to dispose of and the Group agreed to acquire 5% equity interest of Ferguson at a consideration of RMB13,380,000.

On the same date, the Group entered into an capital increase agreement with Guangxi Shenguan, Gobitech Limited, an independent third party, and Guangxi Guan Yu Zhiye Limited, a company controlled by Ms. Zhou Yaxian, pursuant to which the Group agreed to make a capital contribution of RMB17,843,900 to Ferguson by cash.

Upon completion of the above transactions, the equity interest attributable to the Group in Ferguson will increase from 15% to 25%.

Details of the transactions are set out in the Company’s announcement dated 13 March 2017.

44. Approval of the Financial Statements

The financial statements were approved and authorised for issue by the board of directors on 17 March 2017.

FIVE YEAR FINANCIAL SUMMARY

122

The consolidated results and the consolidated assets, liabilities and non-controlling interests of Shenguan Holdings (Group) Limited and its subsidiaries (together the "Group") for the last five financial years are extracted from the published audited financial statements and represented below.

The summary below does not form part of the audited financial statements.

	2016	2015	2014	2013	2012
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Year ended 31 December					
RESULTS					
REVENUE	980,617	1,054,565	1,403,008	1,654,492	1,648,477
Cost of sales	(687,542)	(588,713)	(633,214)	(687,010)	(689,255)
Gross profit	293,075	465,852	769,794	967,482	959,222
Other income and gains, net	88,473	41,016	38,359	72,597	70,326
Selling and distribution expenses	(32,506)	(11,660)	(17,743)	(22,039)	(20,385)
Administrative expenses	(177,898)	(140,372)	(99,663)	(77,860)	(81,201)
Finance costs, net	(15,927)	(17,700)	(14,610)	(6,360)	2,239
PROFIT BEFORE TAX	155,217	337,136	676,137	933,820	930,201
Income tax expense	(21,565)	(51,558)	(128,661)	(162,543)	(182,018)
PROFIT FOR THE YEAR	133,652	285,578	547,476	771,277	748,183
Profit attributable to:					
Owners of the Company	154,163	291,390	547,476	771,277	748,183
Non-controlling interests	(20,511)	(5,812)	–	–	–
	133,652	285,578	547,476	771,277	748,183
As at 31 December					
ASSETS, LIABILITIES AND NON-CONTROLLING INTERESTS					
TOTAL ASSETS	3,503,845	3,694,004	3,698,944	3,185,057	2,882,621
TOTAL LIABILITIES	(608,569)	(823,509)	(1,063,339)	(540,999)	(537,838)
NON-CONTROLLING INTERESTS	(71,579)	(89,746)	–	–	–
	2,823,697	2,780,749	2,635,605	2,644,058	2,344,783